<SEC-DOCUMENT>0001564590-22-031433.txt : 20220912
<SEC-HEADER>0001564590-22-031433.hdr.sgml : 20220912
<ACCEPTANCE-DATETIME>20220912084517
ACCESSION NUMBER:		0001564590-22-031433
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220912
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220912
DATE AS OF CHANGE:		20220912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptive Biotechnologies Corp
		CENTRAL INDEX KEY:			0001478320
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				270907024
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38957
		FILM NUMBER:		221237603

	BUSINESS ADDRESS:	
		STREET 1:		1165 EASTLAKE AVE E
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109
		BUSINESS PHONE:		206-659-0067

	MAIL ADDRESS:	
		STREET 1:		1165 EASTLAKE AVE E
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptive TCR Corp
		DATE OF NAME CHANGE:	20091209
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>adpt-8k_20220912.htm
<DESCRIPTION>8-K FOR FINANCING
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-09-10T00:28:18.6380002+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : f5286ce828ba4b7b9b6c8cfa7e802bff -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:adpt="http://www.adaptivebiotech.com/20220912" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
adpt-8k_20220912.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001478320_20220912_20220912">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0001478320_20220912_20220912">0001478320</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="adpt-20220912.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001478320_20220912_20220912">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-09-12</xbrli:startDate>
					<xbrli:endDate>2022-09-12</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;border-top:Double 2.25pt;padding-top:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001478320_20220912_20220912">8-K</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001478320_20220912_20220912" format="ixt:datemonthdayyearen">September 12, 2022</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0001478320_20220912_20220912">ADAPTIVE BIOTECHNOLOGIES CORPORATION</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001478320_20220912_20220912" format="ixt-sec:stateprovnameen">Washington</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0001478320_20220912_20220912">001-38957</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001478320_20220912_20220912">27-0907024</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityAddressAddressLine1" contextRef="C_0001478320_20220912_20220912">1165 Eastlake Avenue East</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressCityOrTown" contextRef="C_0001478320_20220912_20220912">Seattle</ix:nonNumeric>, <ix:nonNumeric id="F_000010" name="dei:EntityAddressStateOrProvince" contextRef="C_0001478320_20220912_20220912" format="ixt-sec:stateprovnameen">Washington</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;line-height:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityAddressPostalZipCode" contextRef="C_0001478320_20220912_20220912">98109</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;line-height:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric id="F_000012" name="dei:CityAreaCode" contextRef="C_0001478320_20220912_20220912">206</ix:nonNumeric>) <ix:nonNumeric id="F_000013" name="dei:LocalPhoneNumber" contextRef="C_0001478320_20220912_20220912">659-0067</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:WrittenCommunications" contextRef="C_0001478320_20220912_20220912" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:SolicitingMaterial" contextRef="C_0001478320_20220912_20220912" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:PreCommencementTenderOffer" contextRef="C_0001478320_20220912_20220912" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0001478320_20220912_20220912" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:15%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:Security12bTitle" contextRef="C_0001478320_20220912_20220912">Common stock, par value $0.0001 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:15%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:TradingSymbol" contextRef="C_0001478320_20220912_20220912">ADPT</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:SecurityExchangeName" contextRef="C_0001478320_20220912_20220912" format="ixt-sec:exchnameen">The NASDAQ Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000021" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001478320_20220912_20220912" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.01&#160;&#160;&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entry into a Material Definitive Agreement. </p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Interest Purchase Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 12, 2022, Adaptive Biotechnologies Corporation (&#8220;<span style="font-weight:bold;font-style:italic;">Adaptive</span>&#8221;) entered into a Revenue Interest Purchase Agreement (the &#8220;<span style="font-weight:bold;font-style:italic;">Purchase Agreement</span>&#8221;) with OrbiMed Royalty &#38; Credit Opportunities IV, LP (&#8220;<span style="font-weight:bold;font-style:italic;">OrbiMed</span>&#8221;), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the &#8220;<span style="font-weight:bold;font-style:italic;">Purchasers</span>&#8221;). Pursuant to the Purchase Agreement, the Purchasers have agreed to pay $125 million to Adaptive at closing, less certain transaction expenses. Adaptive will also be entitled to receive up to $125 million in subsequent installments as follows: (i) $75 million upon Adaptive&#8217;s request occurring no later than September 12, 2025 (the &#8220;<span style="font-weight:bold;font-style:italic;">Second Payment</span>&#8221;) and (ii) $50 million upon Adaptive&#8217;s request in connection with certain permitted acquisitions occurring no later than September 12, 2025 (the &#8220;<span style="font-weight:bold;font-style:italic;">Third Payment</span>&#8221;), in each case subject to certain funding conditions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Interest Payments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for such payments, the Purchasers will have a right to receive certain revenue interests (the &#8220;<span style="font-weight:bold;font-style:italic;">Revenue Interests</span>&#8221;) from Adaptive based on a percentage (the &#8220;<span style="font-weight:bold;font-style:italic;">Applicable Payment Percentage</span>&#8221;) of all GAAP revenue (the &#8220;<span style="font-weight:bold;font-style:italic;">Revenue Base</span>&#8221;). If only the First Payment has been made, the Applicable Payment Percentage shall be five percent of the quarterly Revenue Base.&#160;&#160;If both the First Payment and Second Payment have been made, the Applicable Payment Percentage shall be eight percent of the quarterly Revenue Base.&#160;&#160;If each of the First, Second and Third Payments have been made, the applicable payment percentage applied to the Revenue Interest shall be ten percent of the quarterly Revenue Base.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:43.52%;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments in respect of the Revenue Interests shall be made quarterly within 45 days following the end of each fiscal quarter (each, a &#8220;<span style="font-weight:bold;font-style:italic;">Revenue Interest Payment</span>&#8221;).&#160;&#160;If OrbiMed has not received Revenue Interest Payments in the aggregate equal to or greater than the sum of its invested capital (the &#8220;<span style="font-weight:bold;font-style:italic;">Cumulative Purchaser Payments</span>&#8221;) on or prior to September 12, 2028, the revenue interest rate shall be increased to a rate which, if applied retroactively to Adaptive&#8217;s cumulative Revenue Base, would have resulted in Revenue Interest Payments equal to the sum of all Cumulative Purchaser Payments.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Return Cap</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OrbiMed will be entitled to 100% of the Revenue Interest Payments until it has received a total cumulative value of 165% of the Cumulative Purchaser Payments (the &#8220;<span style="font-weight:bold;font-style:italic;">Return Cap</span>&#8221;), unless full repayment of the amount of the Return Cap has not been made by September 12, 2032, in which case the Return Cap shall be increased to 175% of the Cumulative Purchaser Payments.&#160;&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Put/Call Options</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the occurrence of a Put Option Event (as defined in the Purchase Agreement), including material divestitures by Adaptive, a change of control, material judgments, or bankruptcy events, Purchasers representing at least a majority of the purchase commitments under the Purchase Agreement shall have the right but not the obligation to require Adaptive to repurchase all of the outstanding Revenue Interests at the applicable price (the &#8220;<span style="font-weight:bold;font-style:italic;">Put/Call Price</span>&#8221;).&#160;&#160;Additionally, at any time following receipt of the First Payment, Adaptive may exercise a call option to repurchase all Revenue Interests at the applicable Put/Call Price.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all Put Option Events other than a change of control or a material divestiture, the Put/Call Price shall be an amount equal to the applicable Return Cap.&#160;&#160;For a change of control or a material divestiture, prior to March 12, 2024, the Put/Call Price shall be an amount equal to 120% of the Cumulative Purchaser Payments less the sum of all Revenue Interest Payments made by Adaptive to the Purchasers prior to such date, between March 12, 2024 and September 12, 2024, the Put/Call Price shall be an amount equal to 125% of the Cumulative Purchaser Payments less the sum of all Revenue Interest Payments made by Adaptive to the Purchasers prior to such date, and after September 12, 2024, the Put/Call Price shall be equal to the applicable Return Cap.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Purchase Agreement contains various representations and warranties, information rights, non-financial covenants, indemnification obligations and other provisions that are customary for a transaction of this nature. The closing of the transaction contemplated by the Purchase Agreement is subject to certain conditions that are customary for a transaction of this nature.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing is a summary only and does not purport to be a complete description of all of the terms and provisions of the Purchase Agreement, and is subject to and qualified by reference to the full text of the Purchase Agreement, which has been filed as Exhibit 10.1 to this Current Report on Form 8-K.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:4pt;">
<td valign="top" style="width:10%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.03&#160;&#160;&#160;&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. </p></td>
</tr>
</table></div>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information set forth under Item 1.01, &#8220;Entry into a Material Definitive Agreement,&#8221; is incorporated herein by reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0.42%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 8.01. Other Events.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 12, 2022, the Company issued a press release announcing the entry into the Purchase Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01 Financial Statements and Exhibits.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="adpt-ex101_62.htm"><span style="text-decoration:underline;">Revenue Interest Purchase Agreement, made and entered into as of September 12, 2022, by and among Adaptive Biotechnologies Corporation, the Purchasers from time to time party hereto, and OrbiMed Royalty &#38; Credit Opportunities IV, LP</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="adpt-ex991_47.htm"><span style="text-decoration:underline;">Press Release dated September 12, 2022</span></a></p>
</td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Adaptive Biotechnologies Corporation</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: September 12, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Tycho Peterson</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tycho Peterson</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>adpt-ex101_62.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
adpt-ex101_62.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.1</p>
<p style="text-align:center;margin-top:150pt;margin-bottom:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REVENUE INTEREST PURCHASE AGREEMENT</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">dated as of September 12, 2022</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">among</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ADAPTIVE BIOTECHNOLOGIES CORPORATION,</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">the Purchasers from time to time party hereto</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ORBIMED ROYALTY &amp; CREDIT OPPORTUNITIES IV, LP,</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">as Purchaser Agent</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">TABLE OF CONTENTS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article I.</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> DEFINITIONS</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428882"><font style="text-transform:none;">5</font></a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 1.01. Definitions.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428883">5</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article II.</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> PURCHASE OF REVENUE INTERESTS; PAYMENTS</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428884"><font style="text-transform:none;">31</font></a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 2.01. Purchase of Revenue Interests.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428885">31</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 2.02. Payments by the Company.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428886">31</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 2.03. Purchaser Payments; Conditions Precedent.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428887">33</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 2.04. Payment Procedure; Currency Conversion; Late Payments.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428888">35</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 2.05. No Assumed Obligations.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428890">36</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article III.</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> REPRESENTATIONS AND WARRANTIES OF THE COMPANY</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428891"><font style="text-transform:none;">36</font></a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.01. Organization.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428892">36</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.02. Authorization.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428893">36</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.03. Governmental Authorization.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428894">37</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.04. Ownership.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428895">37</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.05. Financial Statements; No Material Adverse Effect.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428896">37</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.06. No Undisclosed Liabilities.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428897">38</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.07. Solvency; No Fraudulent Transfer.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428898">38</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.08. Litigation.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428899">38</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.09. Compliance with Laws.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428900">39</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.10. Conflicts; Adverse Agreements.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428901">39</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.11. Intellectual Property.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428902">40</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.12. Regulatory Approvals; Products.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428903">41</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.13. Material Contracts.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428904">44</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.14. Place of Business.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428905">45</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.15. Customers and Suppliers.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428906">45</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.16. Digital Biotechnologies</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428907">45</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.17. Perfection; Subordination.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428908">45</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.18. Insurance.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428909">46</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.19. Tax.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428910">46</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.20. Disclosures.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428911">46</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.21. Investment Company Act.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428913">46</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.22. OFAC; Anti-Terrorism Laws.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428914">46</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.23. Broker&#8217;s Fees.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428915">47</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.24. Data Privacy and Information Security.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428916">47</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article IV.</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428917"><font style="text-transform:none;">48</font></a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 4.01. Organization.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428918">48</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 4.02. Authorization.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428919">49</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 4.03. Broker&#8217;s Fees.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428920">49</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 4.04. Conflicts.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428921">49</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 4.05. Litigation.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428922">49</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 4.06. Financing.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428923">49</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 4.07. Access to Information.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428924">50</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 4.08. Investment.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428926">50</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article V.</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> COVENANTS</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428928"><font style="text-transform:none;">50</font></a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.01. Notices; Access; Information.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428929">50</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.02. Reports.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428930">53</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.03. Compliance with Law; Existence and Maintenance of Properties; Material Contracts; Payment of Obligations.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428931">54</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.04. Confidentiality; Public Announcement.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428932">55</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.05. Security Interest.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428933">56</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.06. Further Assurances; Creation/Acquisition of Subsidiaries; Additional Collateral; Control Agreements.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428934">56</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.07. Put Option; Call Option; Catch Up Payment.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428935">58</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.08. Intellectual Property; Regulatory Approvals.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428937">60</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.09. Use of Proceeds.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428938">61</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.10. Protective Covenants.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428939">61</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.11. Insurance; Landlord Waivers; Control Agreements.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428940">63</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.12. Taxes.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428941">64</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.13. Digital Biotechnologies</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428942">66</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.14. Additional Secured Indebtedness.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428943">66</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 5.15. Supplements to Disclosure Letter.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428945">66</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article VI.</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> TERMINATION</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428947"><font style="text-transform:none;">67</font></a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 6.01. Termination Date.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428948">67</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 6.02. Effect of Termination.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428949">67</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article VII.</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> PURCHASER AGENT</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428950"><font style="text-transform:none;">67</font></a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 7.01. Appointment and Authority.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428951">67</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 7.02. Rights as a Purchaser.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428952">68</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 7.03. Exculpatory Provisions.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428953">68</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 7.04. Reliance by Purchaser Agent.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428954">69</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 7.05. Delegation of Duties.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428955">70</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 7.06. Resignation of Purchaser Agent.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428956">70</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 7.07. Non-Reliance on Purchaser Agent and Other Purchasers.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428957">70</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 7.08. Collateral and Guaranty Matters.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428958">71</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 7.09. Reimbursement by Purchasers.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428959">72</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-transform:uppercase;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article VIII.</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> MISCELLANEOUS</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428960"><font style="text-transform:none;">72</font></a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.01. Limitations on Damages.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428961">72</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.02. Notices.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428962">73</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.03. Successors and Assigns.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428963">74</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.04. Indemnification.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428964">75</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.05. No Implied Representations and Warranties; Survival of Representations and Warranties.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428965">76</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.06. Independent Nature of Relationship.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428966">76</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.07. Entire Agreement.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428967">77</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.08. Amendments; No Waivers.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428968">77</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.09. Interpretation.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428969">77</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.10. Headings and Captions.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428970">78</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.11. Counterparts; Effectiveness; Electronic Signature.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428971">78</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.12. Severability.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428972">78</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.13. Expenses.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428973">78</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.14. Governing Law; Jurisdiction.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428974">79</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.15. Waiver of Jury Trial.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428975">79</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.16. Specific Performance.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a href="#_Toc113428976">79</a></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:-7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibits</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A<font style="margin-left:36pt;">-Form of Notice of Purchaser Payment Request</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REVENUE INTEREST PURCHASE AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This <font style="font-weight:bold;">REVENUE INTEREST PURCHASE AGREEMENT</font> (as amended, supplemented or otherwise modified from time to time, this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) is made and entered into as of September 12, 2022 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;), by and among Adaptive Biotechnologies Corporation, a Washington corporation (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), the Purchasers from time to time party hereto (each, a &#8220;<font style="text-decoration:underline;">Purchaser</font>&#8221; and collectively, the &#8220;<font style="text-decoration:underline;">Purchasers</font>&#8221;) and OrbiMed Royalty &amp; Credit Opportunities IV, LP, as collateral agent and administrative agent for the Purchasers (the &#8220;<font style="text-decoration:underline;">Purchaser Agent</font>&#8221;). </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Company wishes to obtain financing for general corporate purposes, future acquisitions and to pay fees and expenses associated with the foregoing; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Purchasers wish to purchase the Revenue Interests (as hereinafter defined) from the Company, and the Company wishes to sell, assign and transfer the Revenue Interests to the Purchasers, in consideration for the Purchasers&#8217; payment of the Purchaser Payments (as hereinafter defined) all upon and subject to the terms and conditions hereinafter set forth.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW<font style="font-weight:normal;">, </font>THEREFORE<font style="font-weight:normal;">, in consideration of the mutual covenants, agreements, representations and warranties set forth herein, the parties hereto agree as follows:</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc110631203"></a><a name="_Toc113428882"></a><font style="Background-color:#auto;text-decoration:none;">Article I.</font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Toc110631203"></a><a name="_Toc113428882"></a>DEFINITIONS</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur024"></a><a name="_Ref_ContractCompanion_9kb9Ur026"></a><a name="_Toc113428883"></a><font style="Background-color:#auto;text-decoration:none;">Section 1.01.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Definitions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following terms that are defined in the UCC (as hereinafter defined) are used in the definition of &#8220;Collateral&#8221; in this <font style="text-decoration:underline;">Section 1.01</font> of this Agreement as so defined in the UCC (and, in the event any such term is defined differently for purposes of Article 9 of the UCC than for any other purpose or purposes of the UCC, the Article 9 definition shall govern): Account, Chattel Paper, Commercial Tort Claim, Commodity Account, Commodity Intermediary, Deposit Accounts, Documents, Electronic Chattel Paper, Equipment, General Intangibles, Goods, Instruments, Inventory, Investment Property, Letter of Credit Rights, Proceeds, Securities Account, Securities Intermediary and Tangible Chattel Paper.  </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the following, as used herein, shall have the following meanings:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Acquisition</font>&#8221; means (a) any transaction, or any series of related transactions, by which any Person directly or indirectly, by means of a take-over bid, tender offer, amalgamation, merger, purchase of assets or similar transaction having the same effect as any of the foregoing, (i) acquires any business or product or all or substantially all of the assets of any Person engaged in any business or any business, product, business line or product line, division or other unit operation of any Person, (ii) acquires control of securities of a Person engaged in a business representing more than 50% of the ordinary voting power for the election of directors or other governing body if the business affairs of such Person are managed by a board of directors or other governing body or (iii) acquires control of more than 50% of the ownership interest in any Person engaged in any business that is not managed by a board of directors or other governing body and (b) any Product In-License.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Acquisition Cost</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means consideration paid or payable for an Acquisition (including all milestone, maintenance and/or similar payments, research and development spend, earnouts (whether earned or contingent), deferred purchase price and any other contractual commitment, whether fixed or contingent), excluding (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) royalties on sales calculated on an arm&#8217;s-length basis and (ii) future milestones that would not be due and payable if the Company or its Subsidiary exercised a right of contractual termination without penalty at the sole option of the Company or its Subsidiary (for the avoidance of doubt, all milestone, maintenance and/or similar payments actually made will constitute Acquisition Cost).</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Acquisition Costs will be reduced by any proceeds of grants awarded to the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company or any Subsidiary and earmarked for and applied to the payment of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">evelopment costs for such Acquisition</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Additional Secured Indebtedness</font>&#8221; has the meaning set forth in Section 5.14.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Affiliate</font>&#8221; means any Person that Controls, is Controlled by, or is under common Control with another Person. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Agreement</font>&#8221; has the meaning set forth in the first paragraph hereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Applicable Law</font>&#8221; means, with respect to any Person, all laws, rules, regulations and orders of Governmental Authorities applicable to such Person or any of its properties or assets.&nbsp;&nbsp;For avoidance of doubt, the term Applicable Law includes the terms and conditions of any Marketing Authorization or Regulatory Approval.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Applicable Percentage</font>&#8221; means the applicable percentage set forth in the chart below based on the Purchaser Payments that have been made at such time:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:0%;">
<tr>
<td style="width:49.04%;"></td>
<td style="width:26.22%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments </p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applicable Percentage</p></td>
</tr>
<tr style="height:3.5pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Payment</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00%</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second Payment</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.00%</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Payment</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.00%</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">provided</font> that if the Purchasers have not received Revenue Interest Payments under this Agreement in an amount equal to or greater than 100.0% of the Cumulative Purchaser Payments on or prior to September 12, 2028 (the &#8220;<font style="text-decoration:underline;">Revenue Measurement Date</font>&#8221;), the Applicable Percentages for all subsequent Payment Dates after the Revenue Measurement Date shall equal a single, defined rate  equal to (i) 100.0% of the Cumulative Purchaser Payments made on or prior to the Revenue Measurement Date, divided by (ii) the sum of the Revenue Base from the Effective Date through the last day of the fiscal quarter ending immediately prior to Revenue Measurement Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Audited Financial Statements</font>&#8221; has the meaning set forth in the definition of &#8220;Financial Statements&#8221;.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Bankruptcy Event</font>&#8221; means the occurrence of any of the following:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Company or any Subsidiary shall commence any case, proceeding or other action (</font><font style="color:#000000;">i</font><font style="color:#000000;">) under </font><font style="color:#000000;">the </font><font style="color:#000000;">law</font><font style="color:#000000;">s</font><font style="color:#000000;"> of any jurisdiction, domestic or foreign, relating to bankruptcy, insolvency, reorganization, </font><font style="color:#000000;">or similar </font><font style="color:#000000;">relief, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, administration, protection, liquidation or dissolution (other than a solvent winding-up, dissolution or liquidation of a Subsidiary into the Comp</font><font style="color:#000000;">any or a Subsidiary Guarantor)</font><font style="color:#000000;"> or (ii) seeking appointment of a receiver, interim receiver, receiver and manager, trustee, administrator, administrative receiver, custodian or other similar official for it or for all or any portion of its assets, or the Company or any Subsidiary shall make a general assignment for the benefit of its creditors or enter into a composition, assignment or arrangement with any of its creditors (whether by way of a voluntary arrangement, scheme of arrangement, deed of compromise or otherwise);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">there shall be commenced against the Company or any Subsidiary any case, proceeding or other action seeking to adjudicate it bankrupt or insolvent, or seeking dissolution, liquidation, administration, winding up, reorganization, arrangement, adjustment, protection, or seeking the entry of an order for relief or the appointment of a receiver, interim receiver, receiver and manager, trustee, administrator, administrative receiver, custodian or other similar official for the Company or any Subsidiary or for any substantial part of its property, and either (i) such proceeding shall remain undismissed or unstayed for a period of ninety (90) days or any of the actions sought in such proceeding (including, without limitation, the entry of an order for relief against the Company or any Subsidiary or (ii) the appointment of a receiver, interim receiver, receiver and manager, trustee, administrator, administrative receiver, custodian or other similar official for it or for any substantial part of its property) shall occur;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Company or any Subsidiary shall be generally not paying its debts as such debts become due or shall admit in writing its inability to pay its debts generally as such debts become due; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">an affirmative vote by the applicable Board to commence any case, proceeding or other action described in clause (a) above or any other action by the Company or any Subsidiary to otherwise cause, consent to, approve or acquiesce in any of the acts described in clauses (a) through (c) inclusive above.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Board</font>&#8221; means the Board of Directors of the Company or board of directors or similar governing body of any Subsidiary, as applicable.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Business Day</font>&#8221; means any day other than a Saturday, a Sunday, any day which is a legal holiday under the laws of the State of New York, or any day on which banking institutions located in the State of New York are required by law or other governmental action to close.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Call Closing Date</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 5.07(b)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Call Option</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 5.07(b)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Catch Up Payment</font>&#8221; means, as of any date of determination, an amount equal to 100% of the Cumulative Purchaser Payments, minus, the sum of all Revenue Interest Payments made by </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company to the Purchasers prior to such date.</font><font style="font-weight:bold;">&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the avoidance of doubt, the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catch Up</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Payment </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall be calculated as of the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> date the Catch Up Payment is required to be paid.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Catch Up Payment Date</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 5.07(c). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Catch Up Payment Event</font>&#8221; means any one of the following events: </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Company fails to make any Revenue Interest Payments during the Revenue Interest Period when due (other than amounts being disputed by the Company in good faith, so long as all amounts not being so disputed have been paid); provided, that no more than five (5) times during the term of this Agreement, such failure shall not constitute a Catch Up Payment Event if the Company makes such payment within 30 days of the applicable due date; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Company breaches in any respect the covenants and agreements in Section 5.10(a)(i) or Section 5.10(a)(ii) of this Agreement, which such breach, if capable of cure, is not cured within 30 days after the earlier of (x) receipt of written notice of such breach from the Purchaser Agent and (y) Knowledge of the Company of such breach.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Catch Up Payment Option</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 5.07(c)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Challenge Event</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 5.12(d)(ii)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Change in Law</font>&#8221; means the occurrence, after the Effective Date (or, with respect to any successors or assigns of any Purchaser, after the date such Person acquires its interest hereunder, except that, to the extent that the predecessor or assignor of such Person was entitled to additional amounts in accordance with <font style="text-decoration:underline;">&#8206;Section 5.12(d)(ii)</font> immediately before such Person acquires its interest hereunder, and payments to such Person (or by such Person to its Tax Affiliate) are subject to withholding on the date such Person acquires its interest hereunder, such Person shall be entitled to additional amounts in accordance with <font style="text-decoration:underline;">&#8206;Section 5.12(d)(ii)</font> to the same extent as its predecessor or assignor), of any of the following: (a) the adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (c) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority; <font style="text-decoration:underline;">provided</font> that notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a &#8220;Change in Law&#8221;, regardless of the date enacted, adopted or issued.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Change of Control</font>&#8221; means, at any time, the occurrence of any of the following events or circumstances:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the acquisition by any &#8220;person&#8221; or &#8220;group&#8221; (within the meaning of Sections 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) of beneficial ownership of any Equity Interests of the Company, if after such acquisition, such &#8220;person&#8221; or &#8220;group&#8221; would be the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">as amended), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company&#8217;s then outstanding securities entitled to vote generally in the election of directors;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">a merger or consolidation of the Company with any other Person, other than a merger or consolidation of the Company in which the Company is the surviving Person and in which the persons holding more than fifty percent (50%) of the combined voting power of the Company&#8217;s voting securities outstanding immediately prior to such merger or consolidation, continue to hold at least fifty percent (50%) of the combined voting power of the Company&#8217;s voting securities outstanding immediately after such merger or consolidation; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any Transfer of all or substantially all of the assets of the Company and its Subsidiaries on a consolidated basis to a Third Party. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">CLIA</font>&#8221; means the Clinical Laboratory Improvement Amendments of 1988, 42 U.S.C. &#167; 263a et seq. (or any successor thereto), as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">CMS</font>&#8221; means the United States Centers for Medicare and Medicaid Services or any successor agency thereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Code</font>&#8221; means the Internal Revenue Code of 1986, as amended.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Collateral</font>&#8221; means all of the rights, title or interest of the Company or any Subsidiary Guarantor in (i) the Core Assets, (ii) all Accounts, Chattel Paper, Contracts, Commercial Tort Claims, Documents, General Intangibles (including all Intellectual Property), Equipment, Goods, Instruments, Inventory, Investment Property, Payment Intangibles, Letters of Credit and Letter of Credit Rights and Supporting Obligations constituting or relating to Core Assets, (iii) all Pledged Equity and Pledged Investment Property, Deposit Accounts, Securities Accounts, cash or cash equivalents, wherever located, (iv) all books, records, writings, databases, information and other property supporting the foregoing, and (v) any and all Proceeds, products, rents, royalties and profits of or from any and all of the foregoing; <font style="text-decoration:underline;">provided</font> that Collateral shall not include the Excluded Property (as defined in the Guaranty and Security Agreement) or any Excluded Accounts. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Commercialization</font>&#8221; means any and all activities, other than manufacturing, directed to the preparation for sale of, or sale of the Products, including activities related to marketing, promoting, distributing, and importing the Products, and interacting with Regulatory Agencies regarding any of the foregoing.  When used as a verb, &#8220;to <font style="text-decoration:underline;">Commercialize</font>&#8221; and &#8220;<font style="text-decoration:underline;">Commercializing</font>&#8221; means to engage in Commercialization, and &#8220;<font style="text-decoration:underline;">Commercialized</font>&#8221; has a corresponding meaning.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Company</font>&#8221; has the meaning set forth in the first paragraph hereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Company Indemnified Party</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 8.04(b)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Confidential Information</font>&#8221; has the meaning set forth in the Existing CDA.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Consolidated EBITDA</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means, for the Company and its Subsidiaries, for any period, an amount equal to the sum of: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">total net income determined on a consolidated basis in accordance with GAAP for such period; plus </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">solely to the extent deducted in determining <font style="text-decoration:underline;">clause (i)</font> for such period, and without duplication:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">total interest expense (including that portion attributable to capital leases in accordance with GAAP and capitalized interest), premium payments, debt discount, fees, charges and related expenses with respect to all outstanding Indebtedness of the Company and its Subsidiaries determined on a consolidated basis in accordance with GAAP; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">income tax expense determined on a consolidated basis in accordance with GAAP; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(C)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">depreciation and amortization determined on a consolidated basis in accordance with GAAP;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(D)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">non-cash charges relating to stock option awards or other equity compensation; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(E)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">charges, costs and expenses (including charges, expenses and fees paid to the Purchaser Agent and any Purchaser) incurred during such period in connection with (x) the consummation of the transactions contemplated by this Agreement and the other Transaction Documents; and (y) the administration of the Transaction Documents, including any amendment, restatement, amendment and restatement, waiver, supplement or other modification thereto; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">any extraordinary, unusual or non-recurring items determined on a consolidated basis in accordance with GAAP, <font style="text-decoration:underline;">provided</font> that the aggregate amount added back to Consolidated EBITDA pursuant to this clause (F) in any measurement period shall not exceed 10% of Consolidated EBITDA for such measurement period (calculated before giving effect to amounts added back pursuant to this clause (F)); and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(G)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">all other non-cash charges, expenses and costs approved by the Required Purchasers in their sole discretion acting reasonably;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in each case of <font style="text-decoration:underline;">clauses (A)</font> through <font style="text-decoration:underline;">(G)</font>, for such period.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Consolidated Total Debt</font>&#8221; means, as of any date, all Indebtedness of the Company and its Subsidiaries, measured on a consolidated basis as of such date.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Consolidated Total Leverage Ratio</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall mean the ratio of (a)&#160;Consolidated Total Debt to (b)&#160;Consolidated EBITDA for the most recently ended </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Test Period </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for which financial statements are required to have been delivered</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or otherwise made available</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (or for which financial statements are not yet required to be delivered</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or made available</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> but have already been delivered</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or made available</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) pursuant to this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Contracts</font>&#8221; means, collectively, all leases, contracts and agreements to which an Obligor is now or hereafter a party and has, or will have, any rights, privileges, power, liability or contingent liability, including, without limitation, all Licenses, together with any and all extensions, modifications, amendments and renewals of such leases, contracts and agreements.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Control</font>&#8221; means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise; <font style="text-decoration:underline;">provided</font> that with respect to any Intellectual Property, Regulatory Filing or Regulatory Approval, &#8220;Control&#8221; means that the applicable Person owns or has a license to such item or right and has the ability to grant to a party a license, sublicense, or rights of access and use under such item or right without violating the terms or conditions of any agreement or other arrangement between such Person and any Third Party in existence as of the time such party would be required hereunder to grant such license, sublicense, or rights of access and use; <font style="text-decoration:underline;">provided further</font>, that, notwithstanding the foregoing, if a Person undergoes a Change of Control, such Person shall not be deemed, solely by virtue of the Change of Control, to Control any Intellectual Property Right that is owned or controlled by the Third Party acquiring, directly or indirectly, such Person through such Change of Control, or such Third Party&#8217;s Affiliates, either prior to or following such Change of Control.  &#8220;<font style="text-decoration:underline;">Controlling</font>&#8221; and &#8220;<font style="text-decoration:underline;">Controlled</font>&#8221; have meanings correlative thereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Control Agreement</font>&#8221; means, with respect to any deposit account, any securities account, commodity account, securities entitlement or commodity contract, an agreement, in form and substance reasonably satisfactory to the Purchaser Agent, among the Purchaser Agent, the financial institution or other Person at which such account is maintained or with which such entitlement or contract is carried and the Obligor maintaining such account, effective to grant &#8220;control&#8221; (as defined under the relevant Uniform Commercial Code) over such account to the Purchaser Agent.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Core Assets</font>&#8221; means all rights, interest and title of the Company and its Subsidiaries in any proprietary products, services, chemistry, computational biology, algorithms, data, and processes that directly relate to clonoSEQ or relate to or rely upon the immune sequencing platform for sequencing (immunoSEQ), mapping (MIRA), pairing (pairSEQ) and characterizing (TruTCR). For the avoidance of doubt, Core Assets expressly exclude any assets or property of Digital Biotechnologies, Inc. and any of Digital Biotechnologies, Inc.&#8217;s rights, title or interest in any such assets or other property. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Cumulative Purchaser Payments</font>&#8221; means (a) if the Purchasers have made the First Payment, $125,000,000, (b) if the Purchasers have made the First Payment and Second Payment, $200,000,000 and (c) if the Purchasers have made the First Payment, Second Payment and Third Payment, $250,000,000.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Data Processors</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means any </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> service providers, software developers, outsourcers, or others to which </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or its Subsidiaries engage and allow access to Personal Data or IT Assets (including, for clarity, all information and transactions stored or contained </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therein or transmitted thereby)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Development</font>&#8221; means all activities related to discovery, research, development, pre-clinical and other non-clinical testing, test design, analytical and clinical validation, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and validation, quality assurance/quality control, clinical studies, including Manufacturing in support thereof, statistical analysis and report writing, the preparation and submission of Product Approval Applications and regulatory affairs with respect to the foregoing.&nbsp;&nbsp;When used as a verb, &#8220;Develop&#8221; means to engage in Development. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Disclosure Letter</font>&#8221; means the Confidential Disclosure Letter, dated as of the Effective Date, and delivered by the Company to the Purchaser Agent.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Disputes</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 3.11(f)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Disqualified Equity Interests</font>&#8221; means Equity Interests that, by their terms (or by the terms of any security or other Equity Interest into which they are convertible or for which they are exchangeable), or upon the happening of any event or condition, (a) mature (excluding any maturity as the result of an optional redemption by the issuer thereof) or are mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, or are redeemable at the option of the holder thereof, in whole or in part, (b) are convertible into or exchangeable for (i) debt securities or (ii) any Equity Interests referred to in <font style="text-decoration:underline;">clause (a)</font> above, (c) contain any repurchase obligation or (d) provide for required scheduled payments or the payment of cash dividends or distributions; <font style="text-decoration:underline;">provided</font> that if such Equity Interests are issued pursuant to a plan for the benefit of the Company or any Subsidiary or their directors, officers, employees and/or consultants or by any such plan to directors, officers, employees or consultants of the Company or any Subsidiary, such Equity Interests shall not constitute Disqualified Equity Interests solely because they may be required to be repurchased by the Company or any Subsidiary in order to satisfy applicable statutory or regulatory obligations or as a result of such director, officer, employee or consultant&#8217;s termination, death or disability.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Disqualified Person</font>&#8221; has the meaning set forth in the definition of &#8220;Eligible Assignee&#8221;.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Domestic Subsidiary</font>&#8221; means any direct or indirect Subsidiary that is organized under the laws of the United States, any state or commonwealth thereof, or the District of Columbia. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221; has the meaning in the first paragraph hereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Electronic Signature</font>&#8221; means an electronic sound, symbol or process attached to, or associated with, a contract or other record and adopted by a Person with the intent to sign, authenticate or accept such contract or record.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Eligible Assignee</font>&#8221; is (i) a Purchaser, (ii) an Affiliate of a Purchaser or any fund or investment vehicle managed by the Purchaser or an Affiliate of a Purchaser or under common management with a Purchaser and (iii) any Person that has certified to the Purchaser Agent that it </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is a &#8220;qualified institutional buyer&#8221; (as defined in Rule 144A under the Securities Act of 1933, as amended) or an &#8220;accredited investor&#8221; (as defined in Rule 501(a)(1), (2), (3) or (7)) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has certified to the Purchaser Agent that it </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can make all of the Purchaser Payments when due and that has </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assets under management (together with its Affiliates) of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at least</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $150,000,000; </font><font style="text-decoration:underline;">provided</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that, notwithstanding the foregoing, &#8220;Eligible Assignee&#8221; shall not include</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(x</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> any (1)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitor of the Company </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">identified on </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> list delivered to the Purchase</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Agent by the Company </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on or prior to</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Effective Date or (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any other Person </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">designated by </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prior written notice to the Purchase</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Agent by the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Company after the Effective Date </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approved</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in good faith</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the Purchase</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Agent</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (provided that the Purchaser Agent shall not, in good faith, withhold its approval for any competitor of the Company)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(y) any</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Affiliate of any entity under clause (x)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that is identifiable as such by name (or otherwise known to the Purchaser Agent to be an Affiliate)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(z)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> any</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activist hedge fund (any such person, a &#8220;</font><font style="text-decoration:underline;">Disqualified Person</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding t</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he foregoing, in no event will</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any </font><font style="font-style:italic;">bona fide</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> debt fund, investment vehicle, regulated banking entity, non-regulated lending entity or other similar entity</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, in each case</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that is primarily engaged in commercial loans and similar extensions of credit in the ordinary course of business</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be a Disqualified </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Person</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">except to the extent it is </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">explicitly identified</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> under </font><font style="text-decoration:underline;">clause</font><font style="text-decoration:underline;"> (x)</font><font style="text-decoration:underline;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">above</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or falls under </font><font style="text-decoration:underline;">clause (y)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> above</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Environmental Laws</font>&#8221; means any and all federal, state, local, foreign and other applicable statutes, laws, regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of the environment or the release of any materials into the environment, including those related to hazardous substances or wastes, air emissions and discharges to waste or public systems.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Equity Interests</font>&#8221; means any and all shares, interests, participations or other equivalents (however designated) of equity interests of a corporation, any and all equivalent ownership interests in a Person other than a corporation (including, without limitation, partnership interests, membership interests and similar ownership interests), any and all warrants, rights or options to purchase or other arrangements or rights to acquire any of the foregoing, and all other ownership or profit interests in a Person (including partnership, member or trusts interests in such Person), in each case whether voting or non-voting, but excluding any Permitted Convertible Notes.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">ERISA</font>&#8221; means the Employee Retirement Income Security Act of 1974, as amended from time to time.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Excluded Accounts</font>&#8221; means (a) any deposit account solely used for (i) funding payroll or segregating payroll taxes or funding other employee wage or benefit payments, (ii) segregating 401(k) contributions or contributions to an employee stock purchase plan and other health and benefit plans, in each case for payment in accordance with Applicable Laws and (iii) accounts pledged to secure letters of credit and bank guarantees to the extent constituting Permitted Liens under <font style="text-decoration:underline;">clause (n)</font> thereof, (b) any zero balance accounts, (c) withholding tax and fiduciary trust accounts (including trust accounts holding client funds), and (d) any deposit accounts with respect to which the aggregate amount on deposit individually in such account does not exceed $500,000.00. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Excluded Foreign Subsidiary</font>&#8221; means (A) any Foreign Subsidiary that: (i) does not hold any right, title or interest in any Intellectual Property, (ii) does not hold or maintain any material Regulatory Approval, whether now in effect or hereafter issued by any Regulatory Agency, (iii) is </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not a </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to any Material </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, (iv</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">does not, individually or together with all Excluded Foreign Subsidiaries, have </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cash</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cash equivalents </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exceeding $</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000,000</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the aggregate</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at any time, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) as of the last</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">day of the most recent </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iscal</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">q</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uarter</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for which financial statements have been delivered pursuant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </font><font style="text-decoration:underline;">&#8206;</font><font style="text-decoration:underline;">Section 5.02(a)(</font><font style="text-decoration:underline;">i</font><font style="text-decoration:underline;">)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, for the period of four consecutive </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iscal</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">q</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uarters</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> then</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ended, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">together with all other Excluded Foreign Subsidiaries, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contributed </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">less</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> than 5</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(x) Consolidated </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EBITDA </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or (y) consolidated total revenue of the Company and its Subsidiaries </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for such period</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and (vi</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) as of the last</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">day of the most recent </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iscal</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">q</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uarter</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for which financial statements have been delivered pursuant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </font><font style="text-decoration:underline;">&#8206;</font><font style="text-decoration:underline;">Section 5.02(b)(</font><font style="text-decoration:underline;">i</font><font style="text-decoration:underline;">)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </font><font style="text-decoration:underline;">&#8206;</font><font style="text-decoration:underline;">(ii)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, for the period of four consecutive </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iscal</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">q</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uarters</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> then</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ended, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">together with all other Excluded Foreign Subsidiaries, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contributed </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">less</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> than 5</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the consolidated total assets of the Company and its Subsidiaries </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for such period</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Excluded Liabilities</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 2.05</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Existing CDA</font>&#8221; means that certain Confidentiality Agreement, dated as of July 6, 2022, by and between OrbiMed Advisors LLC and the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">FATCA</font>&#8221; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">FCPA</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 3.22(b)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">FDA</font>&#8221; means the United States Food and Drug Administration or any successor federal agency thereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">FFDCA</font>&#8221; means the United States Federal Food, Drug, and Cosmetic Act, as amended from time to time, together with any rules and regulations promulgated thereunder (including all additions, supplements, extensions, and modifications thereto).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Financial Statements</font>&#8221; means (a) the audited consolidated balance sheets of the Company as of December 31, 2021 and 2020 and the related consolidated statements of operations, comprehensive loss, convertible preferred stock and shareholders&#8217; (deficit) equity and cash flows for the years then ended (the &#8220;<font style="text-decoration:underline;">Audited Financial Statements</font>&#8221;), (b) the unaudited balance sheets of the Company as of March 31, 2022 and June 30, 2022 and the related consolidated statements of operations, comprehensive loss, convertible preferred stock and shareholders&#8217; (deficit) equity and cash flows for the three (3) month periods then ended (the &#8220;<font style="text-decoration:underline;">Interim Financial Statements</font>&#8221;) and (c) each financial statement delivered pursuant to <font style="text-decoration:underline;">Section 5.02(a)</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">First Payment</font>&#8221; means $125,000,000, which shall be paid by the Purchasers on the First Purchaser Payment Date in accordance with <font style="text-decoration:underline;">&#8206;Section 2.03(a)(i)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">First Purchaser Payment Date</font>&#8221; means the Effective Date.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Foreign Subsidiary</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means any direct or indirect Subsidiary of the Company that is not a Domestic Subsidiary.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">GAAP</font>&#8221; means generally accepted accounting principles in the United States in effect from time to time.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Governmental Authority</font>&#8221; means any government, court, regulatory or administrative agency or commission, or other governmental authority, agency or instrumentality, whether foreign, federal, state, local or supranational (domestic or foreign), including each Patent Office, the FDA, CMS and similar foreign authorities.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Guarantee</font>&#8221; of or by any Person (the &#8220;guarantor&#8221;) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the &#8220;primary obligor&#8221;) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (b) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof, (c) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation or (d) as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation; <font style="text-decoration:underline;">provided</font> that the term Guarantee shall not include endorsements for collection or deposit in the ordinary course of business.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Guaranty and Security Agreement</font>&#8221; means the Guaranty and Security Agreement between the Company, each Subsidiary Guarantor and the Purchaser Agent dated as of the date hereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Indebtedness</font>&#8221; means with respect to any Person, without duplication: (a) any liability or obligation of such Person (i) for borrowed money or with respect to advances or deposits of any kind, (ii) evidenced by a bond, note, debenture, or similar instrument, (iii) in respect of the deferred purchase price of property or services, including a purchase money obligation given in connection with the acquisition of any businesses, properties or assets of any kind (other than trade or account payables or a current liability arising in the ordinary course of business), (iv) under conditional sale or other title retention agreements relating to property acquired by such Person, (v) upon which interest charges are customarily paid, (vi) contingent or otherwise, in respect of bankers&#8217; acceptances, letters of credit or similar extensions of credit, (vii) in respect of hedging agreements and other derivative contracts (for the net amount owed by such Person thereunder), (viii) for the payment of money relating to any obligations under any finance lease of real or personal property which are required to be recorded as a capitalized lease obligation in accordance with GAAP, (ix) under guaranteed minimum purchase, take or pay or similar performance requirement contracts, (x) the primary purpose or intent of which is to provide assurance to an obligee that the obligation of the obligor thereof will be paid or discharged, or any agreement relating thereto will be complied with, or the holders thereof will be protected (in whole or in part) against loss in respect thereof, including guaranteed minimum sales, purchase or performance requirements, (xi) under this Agreement and (xii) any other obligation or liabilities which are required under GAAP to be shown as a liability on the balance sheet of such Person; (b) any Guarantee by such Person of Indebtedness </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of any other Person; </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) (without duplication) any amendment, supplement, modification, deferral, renewal, extension or refunding of any liability of the types referred to in </font><font style="text-decoration:underline;">clauses (a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">(b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="text-decoration:underline;">(</font><font style="text-decoration:underline;">c</font><font style="text-decoration:underline;">)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> above. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indebtedness of any Person shall include</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, without duplication,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A) all Indebtedness referred to in clauses (a) &#8211; (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) above secured by any Lien on Property owned by such Person, even though such Person has not assumed or become liability for the payment of such Indebtedness and (B) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such Person</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is liable therefor as a result of such Person&#8217;s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Indemnified Amounts</font>&#8221; means any amounts for which an Indemnified Party may seek reimbursement under Section 8.04(a) or (b). </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Indemnified Liabilities</font>&#8221; means any and all liabilities, obligations, losses, assessments, awards, causes of action, damages, penalties, claims, charges, fines, judgments, reasonable and documented costs, expenses and disbursements of any kind or nature whatsoever (including reasonable and documented expenses of investigation and the reasonable and documented fees and disbursements of counsel for Indemnified Parties), whether direct, indirect or consequential, whether based on any federal, state or foreign laws, statutes, rules or regulations (including securities and commercial laws, statutes, rules or regulations), on common law or equitable cause or on contract or otherwise, imposed on, incurred by, or asserted against any such Indemnified Party, in any manner relating to or arising out of this Agreement or the other Transaction Documents or the transactions contemplated hereby or thereby (including any enforcement of any of the Transaction Documents (including any sale of, collection from, or other realization upon any of the Collateral)). </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Indemnified Party</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 8.04(b)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Intellectual Property</font>&#8221; means all intellectual property and other proprietary rights of any kind or nature, in any jurisdiction in the world, whether registered or unregistered and whether registrable or not, protected, created or arising under any law, including any and all rights in: proprietary information; technical data; laboratory notebooks; clinical data; priority rights; trade secrets; know-how; confidential information; inventions (whether patentable or unpatentable and whether or not reduced to practice or claimed in a pending patent application); Patents; registered or unregistered trademarks, trade names, service marks, trade dress, logos, slogans, including all goodwill associated therewith; domain names; registered and unregistered copyrights and all applications thereof and all rights in works of authorship of any type, in all forms or media, designs rights, registered designs, database rights and rights in compilations of data.&nbsp;&nbsp;For the avoidance of doubt, Intellectual Property excludes Personal Data.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Intellectual Property Updates</font>&#8221; means a summary of any new Patents, trademarks or copyrights issued by, or Patent, trademark or copyright applications filed with (including as amended or supplemented) an applicable filing office (e.g., a Patent Office), in each case, constituting Product Intellectual Property (in form sufficient to allow Purchaser Agent to prepare appropriate filings in respect thereof to protect its Liens thereon), together with any material information or developments with respect to the Material Patents.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Intended Tax Treatment</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;">Section 5.12(b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Interim Financial Statements</font>&#8221; has the meaning set forth in the definition of &#8220;Financial Statements&#8221;.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Investment</font>&#8221; means, with respect to any Person, (a) any investment by such Person in any other Person in the form of loans, guarantees, advances or other extensions of credit (excluding accounts receivable arising in the ordinary course of business), or capital contributions, (b) acquisitions of Indebtedness (including, any bonds, notes, debentures or other debt securities), (c) acquisition of Equity Interests or all or substantially all of the assets of any other Person, (d) the purchase or ownership of any futures contract or liability for the purchase or sale of currency or other commodities at a future date in the nature of a futures contract, (e) any payment in respect of (i) the purchase, license or other acquisition of any business, division, product line of any other Person or (ii) any Product In-License or (f) any other investment that are or would be classified as investments on a balance sheet of such Person prepared in accordance with GAAP.&nbsp;&nbsp;The amount of any Investment shall be the original cost of such Investment plus the cost of all additions thereto, without any adjustments for increases or decreases in value, or write-ups, write-downs or write-offs with respect to such Investment. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">IRS</font>&#8221; means United States Internal Revenue Service.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">IRS Withholding Form</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 5.12(b)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">IT Assets</font>&#8221; means the computers and other information technology infrastructure and assets used by the Company or any of the Subsidiaries in the conduct of their business as operated and as proposed to be operated.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Knowledge</font>&#8221; means the actual knowledge, after reasonable due inquiry.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Knowledge of the Company</font>&#8221; means the Knowledge of any Knowledge Person.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Knowledge Person</font>&#8221; means any of the persons listed on <font style="text-decoration:underline;">Schedule 1.01(a)</font> to the Disclosure Letter, and any individual that succeeds such person in the role identified on <font style="text-decoration:underline;">Schedule 1.01(a)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">License</font>&#8221; means any existing or future license, commercialization, co-promotion, collaboration, distribution, marketing or partnering agreement entered into before or during the Revenue Interest Period by the Company or any of its Affiliates that grants a license to a Third Party under any Product Intellectual Property.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Licensees</font>&#8221; means, collectively, the licensees and any sublicensees under any License.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Liens</font>&#8221; means all liens, encumbrances, security interests, mortgages, rights to preferential payments that has the practical effect of creating a security interest or charges of any kind, but excluding any Permitted Licenses.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Manufacture</font>&#8221; and &#8220;<font style="text-decoration:underline;">Manufacturing</font>&#8221; means all activities related to the design, development, validation, performance, production, manufacture, processing, filling, finishing, packaging, labeling, shipping, and holding of any Product, or any intermediate thereof, including, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">without limitation, process </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or protocol</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> development, process </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or protocol</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance, and quality control.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Marketing Authorization</font>&#8221; means, with respect to any Product, the Regulatory Approval required by Applicable Law to distribute, sell, offer, or otherwise commercialize any Product in a country or region, including, to the extent required by Applicable Law for the sale or offering of the Product, all pricing approvals and government reimbursement approvals.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Material Adverse Effect</font>&#8221; means (a) a material adverse effect on the business, operations, or financial condition of the Company and its Subsidiaries, taken as a whole, (b) a material adverse effect on the validity or enforceability of any of the Transaction Documents, (c) a material adverse effect on the ability of the Company or any Obligor to perform any of its material obligations under the Transaction Documents, (d) a material adverse effect on the rights or remedies of the Purchaser Agent or any Purchaser under any of the Transaction Documents, (e) a material adverse effect on the Products, the Product Intellectual Property or the Development, Commercialization or Manufacture of the Products, (f) a material adverse effect on the timing or amount of the Revenue Interest Payments or (g) a material adverse effect on the validity, perfection (except to the extent permitted under the Guaranty and Security Agreement) or first priority of Liens in favor of the Purchaser Agent for the benefit of the Purchasers (except to the extent resulting solely from any actions or inactions on the part of the Purchaser Agent and the Purchasers despite timely receipt of information regarding the Company and its Subsidiaries as required by this Agreement).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Material Breach</font>&#8221; means (a) any failure by the Company or any Subsidiary to make a payment required under this Agreement or any other Transaction Document when due and such failure is not cured within 30 days after the date on which such payment was due, (b) any breach of any covenant under Section 5.10(a)(i) or Section 5.10(a)(ii) of this Agreement (or, solely for purposes of Section 2.03(b)(v)(B), any breach of any covenant under Sections 5.10(a)(i), 5.10(a)(ii), 5.10(a)(iii), 5.10(a)(vi), or 5.10(a)(viii)), and (c) any material breach of any other covenant in this Agreement or any other Transaction Document that is not cured within 30 days after the earlier of (x) receipt of written notice of such breach from the Purchaser Agent and (y) Knowledge of the Company of such breach. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Material Contract</font>&#8221; means: (a) any &#8220;material contract&#8221; (as such term is defined in Item 601(b)(10) of Regulation S-K of the Securities Act of 1933, as amended, other than those agreements and arrangements described in Item 601(b)(10)(iii)) with respect to the Company or its Affiliates that relates to the Development, Manufacture, or Commercialization of any Product; (b) any development agreement, collaboration agreement, marketing agreement, co-promotion agreement, license agreement, option agreement, distribution agreement, partnering agreement or similar agreement with respect to Company or its Affiliates related to the Development, Manufacture, or Commercialization of any Product to the extent the breach, non-performance, absence or termination of which could reasonably be expected to have a Material Adverse Effect; (c) any agreement with respect to the Company or its Affiliates relating to any Material Patent, including any license, option, assignment, or agreement related to control of such Material Patent, in each case, to the extent the breach, non-performance, absence or termination of which could reasonably be expected to have a Material Adverse Effect; (d) any agreement which requires </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consideration or other payments in excess of $</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000,000</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per fiscal year</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; or (e) any agreement evidencing Material Indebtedness</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Material Divestiture</font>&#8221; means a sale, not otherwise deemed a Change of Control, of one or more Core Assets, pursuant to which the Company receives aggregate net proceeds equal to or greater than the then applicable Put/Call Price.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Material Indebtedness</font>&#8221; means any Indebtedness with a principal amount in excess of $10,000,000.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Material Patents</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 3.11(e)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Non-Core Asset</font>&#8221; means any Product or other assets of the Company or its Subsidiaries that is not a Core Asset. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Obligations</font>&#8221; means, without duplication, all obligations of the Company in respect of the Revenue Interests, including all obligations to make Revenue Interest Payments and to pay the Put/Call Price, and all present and future Indebtedness, taxes, liabilities, obligations, covenants, duties, debts, and Indemnified Liabilities owing by the Company to the Purchaser Agent or the Purchasers, arising under or pursuant to the Transaction Documents, including all Reimbursable Expenses. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Obligors</font>&#8221; means the Company and each Subsidiary Guarantor.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">OFAC</font>&#8221; means the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control and any successor thereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Organization Documents</font>&#8221; means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction), (b) with respect to any limited liability company, the certificate or articles of formation or organization and operating agreement, and (c) with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization and any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable Governmental Authority in the jurisdiction of its formation or organization and, if applicable, any certificate or articles of formation or organization of such entity.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Patent</font>&#8221; means any issued national, regional and international patent and any application or invention disclosure therefor (whether pending, expired, lapsed, or abandoned, and including filings made pursuant to the Patent Cooperation Treaty, provisional applications, non-provisional applications, continuations, continuations-in-part, continued prosecution applications, and divisionals), and any patents that issue as a result of those applications or from any application claiming priority to or from any of those applications, and which for the purposes of this Agreement, shall be deemed to include all certificates of invention and applications for certificates of invention, petty patents, and any renewals, restorations, reissues, reexaminations or other post-grant proceedings, extensions revisions, registrations, revalidations, utility models, supplemental protection certificates, patent term extensions, pediatric exclusivity periods and substitutions relating to any of the issued patents and patent applications, in any jurisdiction.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Patent Office</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means the respective patent office, including the United States Patent and Trademark Office, the European Patent </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and any comparable patent office in any other jurisdiction, for any Patents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Payment Date</font>&#8221; means each February 14, May 15, August 14 and November 14, commencing on the first such date to occur following the end of the quarter in which the First Purchaser Payment Date occurs; <font style="text-decoration:underline;">provided</font> that, if any such date shall occur on a day that is not a Business Day, the applicable Payment Date shall be the next Business Day.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Permitted Acquisition</font>&#8221; means any transaction or series of related transactions in the form of Acquisitions, <font style="text-decoration:underline;">provided</font> that:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Company shall have delivered written notice of any Acquisition with aggregate Acquisition Costs in excess of $10,000,000 to the Purchaser Agent, on behalf of the Purchasers, not less than ten (10) Business Days prior to the execution of a definitive agreement for such Acquisition (or such shorter period as may be agreed by the Purchaser Agent in its sole discretion); </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">immediately prior to, and after giving effect thereto, no Material Breach shall have occurred and be continuing, or result therefrom;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">all transactions in connection therewith shall be consummated, in all material respects, in accordance with applicable law;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">no Change of Control shall result from such transaction;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">such Acquisition shall be consensual and, if required, shall have been approved by the target&#8217;s board of directors;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Person whose Equity Interests or business are being acquired shall be engaged in, or the asset acquired shall be used to engage in, or any Product In-License shall be in relation to, the same line of business as the Company or lines of business reasonably incidental or ancillary thereto; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Obligors shall comply with the requirements of </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 5.06</font><font style="color:#000000;"> with respect to the property, assets and businesses acquired in such purchase or other acquisition and with respect to any acquired or newly formed Subsidiaries which are required to become Obligors under the Transaction Documents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Permitted Convertible Notes</font>&#8221; means unsecured Indebtedness of the Company in the form of senior subordinated convertible notes; <font style="text-decoration:underline;">provided</font> that such convertible notes shall (i) permit physical settlement (and cash in lieu of fractional shares) upon conversion (and the Company shall not elect cash or combination settlement upon conversion, or redeem such notes, without the Purchaser Agent&#8217;s prior written consent), (ii) not be guaranteed by any Subsidiary of the Company, (iii) not provide for any scheduled amortization or mandatory prepayment of principal prior to the stated maturity thereof (other than customary payments upon a &#8220;change of control&#8221; or &#8220;fundamental change&#8221; (it being understood that conversion of any such Indebtedness shall not be considered a prepayment)), (iv) contain usual and customary subordination terms for underwritten offerings of senior subordinated convertible notes acceptable to the Purchaser Agent and (v) </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specifically designate this Agreement and all Obligations as &#8220;designated senior indebtedness&#8221; or similar term so that the subordination terms referred to in </font><font style="text-decoration:underline;">clause (iv)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of this definition specifically refer to such notes as being subordinated to the Obligations pursuant to such subordination terms.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Permitted Indebtedness</font>&#8221; means:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness owed to the Purchasers and the Purchaser Agent under this Agreement and the other Transaction Documents;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness existing on the Effective Date and disclosed on </font><font style="text-decoration:underline;color:#000000;">Schedule 5.10(a)(i)</font><font style="color:#000000;"> to the Disclosure Letter and any renewals or refinancing of such Indebtedness in amounts not exceeding the principal amounts thereof (plus unpaid accrued interest and premium thereon and underwriting discounts, fees, commissions and expenses but less any required amortization according to the terms thereof);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness to trade creditors incurred in the ordinary course of business;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">intercompany Indebtedness in the Company or any Subsidiary.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Guarantees of the Company and its Subsidiaries in respect of Indebtedness and other obligations of the Company and any Subsidiary otherwise permitted hereunder;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness incurred by the Company or its Subsidiaries to finance the payment of insurance premiums;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness owed to any Person providing worker&#8217;s compensation, health, disability or other employee benefits or property, casualty or liability insurance to the Company or any Subsidiary incurred in connection with such Person providing such benefits or insurance pursuant to customary reimbursement or indemnification obligations to such Person;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Guarantees (or liabilities as a surety, endorser, accommodation endorser or otherwise) in respect of performance, surety, statutory, appeal or similar obligations incurred in the ordinary course of business but excluding guaranties with respect to any obligations for borrowed money;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness in respect of payment processing services, business credit card programs, and netting services, overdrafts and related liabilities arising from treasury, depositary and cash management services securing maximum amounts;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur057"></a><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness consisting of capitalized lease obligations and purchase money Indebtedness, in each case incurred by the Company or any of its Subsidiaries to finance the acquisition, repair, improvement or construction of fixed or capital assets of such person, </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that (i) the principal amount of such Indebtedness does not exceed the lower of the cost or fair market value of the property so acquired or built or of such repairs or improvements financed with such Indebtedness (each measured at the time of such acquisition, repair, improvement or construction is made) and (ii) such Indebtedness is in an aggregate amount outstanding at any time not to exceed $5,000,000; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness in respect of hedging agreements entered into for </font><font style="font-style:italic;color:#000000;">bona fide</font><font style="color:#000000;"> hedging purposes in the ordinary course and not for speculative purposes;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Permitted Convertible Notes;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness in respect of letters of credit in an amount not to exceed at any time $5,000,000; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(n)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness under guaranteed minimum purchase, take or pay or similar performance requirement contracts in an amount not to exceed at any time $10,000,000;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(o)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness set forth in </font><font style="text-decoration:underline;color:#000000;">Schedule 1.01(b)</font><font style="color:#000000;"> to the Disclosure Letter;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(p)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">other Indebtedness not otherwise permitted under </font><font style="text-decoration:underline;color:#000000;">clauses (a)</font><font style="color:#000000;"> through </font><font style="text-decoration:underline;color:#000000;">(o)</font><font style="color:#000000;"> in an aggregate outstanding principal amount not to exceed at any time $10,000,000; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(q)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">secured Indebtedness of the Company and its Subsidiaries so long as, on a pro forma basis, the Consolidated Total Leverage Ratio is no more than 3.00 to 1.00; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that (i) no Put Option Event or Material Breach, nor any event that with the giving of notice or the passage of time would constitute a Put Option Event or Material Breach, shall have occurred and be continuing and (ii) such Indebtedness is subject to an intercreditor agreement in form and substance reasonably satisfactory to the Purchaser Agent; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(r)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness approved in advance in writing by the Required Purchasers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Permitted Licenses</font>&#8221; means any in-license of Intellectual Property and any out-license of Intellectual Property, in each case so long as (i) the license constitutes an arms-length transaction and (ii) the license occurs in the Company&#8217;s ordinary course of business; <font style="text-decoration:underline;">provided</font> that the Company shall not be permitted to exclusively, even as to the Company, out-license any Intellectual Property unless such out-license is (x) for specific fields and (y) does not materially restrict the Company&#8217;s business, taken as a whole.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Permitted Liens</font>&#8221; means:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens in favor of the Purchaser Agent or the Purchasers created by or otherwise existing under or in connection with the Transaction Documents;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens in existence as of the date hereof and set forth on </font><font style="text-decoration:underline;color:#000000;">Schedule 5.10(a)(ii)</font><font style="color:#000000;"> to the Disclosure Letter;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens imposed by mandatory provisions of law regarding landlords, carriers, warehousemen, bailees, mechanics and materialmen incurred in the ordinary course of business so long for sums that are being contested in good faith by appropriate proceedings;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens (other than those imposed by ERISA) incurred in the ordinary course of business in connection with worker&#8217;s compensation, unemployment insurance or other forms of governmental insurance or benefits, insurance, surety bonds, or other obligations of a like nature or to secure the performance of letters of credit, banker&#8217;s acceptances, bids, tenders, statutory </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">obligations, leases and contracts (other than for borrowed money) entered into in the ordinary course of </font><font style="color:#000000;">business;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens for Taxes that are not delinquent or remain payable without any penalty or that are being contested in good faith and with due diligence by appropriate proceedings and for which adequate reserves have been established in accordance with GAAP;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">(i) banker&#8217;s Liens for collection or rights of set off or similar rights and remedies as to deposit accounts or other funds maintained with depositary institutions; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that such deposit accounts or funds are not established or deposited for the purpose of providing collateral for any Indebtedness and are not subject to restrictions on access by the Company or any Subsidiary in excess of those required by applicable banking regulations; and (ii) customary Liens incurred in the ordinary course of business to secure obligations in respect of payment processing services, business credit card programs, and netting services, overdrafts and related liabilities arising from treasury, depositary and cash management services securing maximum amounts not to exceed $5,000,000 at any time outstanding; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens on insurance policies, premiums and proceeds thereof, or other deposits, to secure insurance premium financings with respect to unearned premiums and other liabilities to insurance carriers;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens securing Indebtedness permitted under </font><font style="text-decoration:underline;color:#000000;">clause &#8206;(j)</font><font style="color:#000000;"> of the definition of Permitted Indebtedness; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that (i) such Liens exist prior to the acquisition of, or attach substantially simultaneous with, or within twenty (20) days after the, acquisition, lease, repair, improvement or construction of, such property financed or leased by such Indebtedness and (ii) such Liens do not extend to any property of the Company or any Subsidiary other than the property (and proceeds thereof) acquired, leased or built, or the improvements or repairs, financed by such Indebtedness;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens on specific items of inventory or other goods (and the proceeds thereof) of the Company securing such Person&#8217;s obligations in respect of bankers&#8217; acceptances issued or created for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into in the ordinary course of business;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods in the ordinary course of business;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any interest or title of a lessor or licensor under any lease, sublease, license or sublicense entered into by the Company or any Subsidiary entered into in the ordinary course of its business;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur156"></a><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">servitudes, easements, rights of way, restrictions and other similar encumbrances on real property imposed by law and encumbrances consisting of restrictions, easements, restrictions on the use of property or minor imperfections in title thereto, in each case not </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">interfering in any material respect with the </font><font style="color:#000000;">ordinary conduct of </font><font style="color:#000000;">business of the Company or its </font><font style="color:#000000;">Subsidiaries</font><font style="color:#000000;">;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(n)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens on cash collateral securing (i) hedging agreements entered into for </font><font style="font-style:italic;color:#000000;">bona fide</font><font style="color:#000000;"> hedging purposes in the ordinary course of business and not for speculative purposes and (ii) Indebtedness permitted under </font><font style="text-decoration:underline;color:#000000;">clause (m)</font><font style="color:#000000;"> of the definition of Permitted Indebtedness;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(o)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens on deposits or other amounts held in escrow to secure payments (contingent or otherwise) payable by the Company with respect to (i) the settlement, satisfaction, compromise or resolution or judgments, litigation, arbitration or other disputes and (ii) any commercial contracts for manufacturing, production and other service arrangements entered into in the ordinary course of business; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(p)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens securing Indebtedness under </font><font style="text-decoration:underline;color:#000000;">clauses (m)</font><font style="color:#000000;"> or </font><font style="text-decoration:underline;color:#000000;">(p)</font><font style="color:#000000;"> of the definition of Permitted Indebtedness; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(q)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens securing Indebtedness under </font><font style="text-decoration:underline;color:#000000;">clause (q)</font><font style="color:#000000;"> of the definition of Permitted Indebtedness;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(r)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">judgment liens, </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that the applicable Obligor shall have removed such judgement lien within one hundred eighty (180) days during which execution shall be effectively stayed, or no action shall have been legally taken by the lien holder to attach or levy upon any assets of any Obligor to enforce any such judgment;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(s)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens created under, or arising from the filing of, financing statements in respect of operating leases to the extent such operating leases are otherwise permitted under this Agreement; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(t)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens approved in advance in writing by the Required Purchasers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Person</font>&#8221; means an individual, corporation, partnership, limited liability company, joint venture, association, trust or other entity or organization, but not including a government or political subdivision or any agency or instrumentality of such government or political subdivision.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Personal Data</font>&#8221; means any information that is considered personally identifiable information or personal data under Applicable Law. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">PHSA</font>&#8221; means the U.S. Public Health Service Act (or any successor thereto), as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto).&nbsp;&nbsp;For avoidance of doubt, the term PHSA includes the CLIA, and their implementing regulations. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Pledged Equity</font>&#8221; has the meaning set forth in the Guaranty and Security Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Pledged Investment Property</font>&#8221; has the meaning set forth in the Guaranty and Security Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Prime Rate</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means, for any day, the per annum rate of interest in effect for such day quoted by the Wall Street Journal as the &#8220;prime rate&#8221;.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Pro Rata Portion</font>&#8221; means, with respect to any Purchaser, the sum of the unfunded Purchaser Commitment of such Purchaser and Purchaser Payments made by such Purchaser divided by the sum of all unfunded Purchaser Commitments and all Purchasers Payments made by the Purchasers.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref309990986"></a>&#8220;<font style="text-decoration:underline;">Product</font>&#8221; means any product, service or tool that constitutes or utilizes a Core Asset, including a testing service, developed, licensed, marketed, sold, distributed, offered or otherwise commercialized by the Company or its Subsidiaries (excluding Digital Biotechnologies, Inc.), including any such product or service in development or which may be developed.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Product Approval Application</font>&#8221; means any application for Marketing Authorization for any Product including, without limitation, any NDA, BLA, 510(k), de novo request, PMA, or EUA as those terms are defined by the FDA, and any comparable foreign equivalents.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Product Assets</font>&#8221; means (a) all Product Intellectual Property, (b) each Material Contract related to Products, (c) all Regulatory Approvals related to Products, (d) all inventory of Products and any raw materials and work-in-process relating thereto, (e) all accounts receivables and payment intangibles arising out of sales of any Product or licenses of any Product Intellectual Property, (f) all other assets primarily related to the Development, Manufacture or Commercialization of any Product and that are owned by, licensed to, or otherwise Controlled by the Company or any Subsidiary, (g) any other rights, title and interest in and to assets that are owned, or in the case of Intellectual Property Controlled by the Company, or any Subsidiary that are reasonably necessary for the Development, Commercialization, Manufacture, formulation, use, or sale of any Products, (h) all books and records of the Company that at any time evidence or contain information relating to any of the foregoing or are otherwise necessary or helpful in the collection or realization thereof and (i) all proceeds and products of any of the foregoing; provided, however, that (x) cash and cash equivalents, other than any such proceeds and products, and (y) any rights, title, or interests in or to assets or other property owned or, in the case of Intellectual Property, Controlled by Digital Biotechnologies, Inc., in each case, shall not be deemed &#8220;Product Assets&#8221;.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Product In-License</font>&#8221; means any in-license of Intellectual Property by the Company or any of its Subsidiaries to Develop, Manufacture or Commercialize a drug or pharmaceutical product, other than a non-exclusive license under which the Company is not granted any right to Develop, Commercialize or Manufacture a pharmaceutical product, therapeutic, medical device or diagnostic.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Product Intellectual Property</font>&#8221; means all Intellectual Property that is necessary for, or otherwise material to, the Development, Commercialization, and/or Manufacture of any Product, and that is owned, licensed or otherwise Controlled by any Obligor, including, without limitation, the Intellectual Property identified in <font style="text-decoration:underline;">Schedule 3.11(a)</font> to the Disclosure Letter. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Purchaser</font>&#8221; has the meaning set forth in the first paragraph hereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Purchaser Agent</font>&#8221; has the meaning set forth in the first paragraph hereof.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Purchaser Agent Representative</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;">&#8206;</font><font style="text-decoration:underline;">Section 5.01(c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Purchaser Commitment</font>&#8221; means, with respect to any Purchaser, the commitment of such Purchaser to purchase the Revenue Interests and pay the Purchaser Payments in an aggregate amount equal to the amount set forth opposite such Purchaser&#8217;s name on <font style="text-decoration:underline;">Schedule 1.01(c)</font> to this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Purchaser Indemnified Party</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 8.04(a)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Purchaser Payments</font>&#8221; means each of the First Payment, the Second Payment and the Third Payment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Put Option</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 5.07(a)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Put Option Closing Date</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 5.07(a)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Put Option Event</font>&#8221; means any one of the following events:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any Bankruptcy Event; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">one or more final and unappealable judgments, orders or awards (or any settlement of any claim that, if breached, would result in a final and unappealable judgment, order or award) for the payment of money to a Third Party (expressly excluding the Purchasers, Purchaser Agent and their respective Affiliates) exceeding $10,000,000 in the aggregate shall be rendered against any Obligor and remain unsatisfied after such payment of money becomes due and (i) enforcement proceedings shall have been commenced by any creditor upon any such judgment, order, award or settlement after all appeals have been exhausted or lapsed or (ii) there shall be a period of thirty (30) consecutive days after entry thereof during which a stay of enforcement of any such judgment, order, award or settlement, by reason of a pending appeal or otherwise, shall not be in effect; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">however</font><font style="color:#000000;">, that any such judgment, order, award or settlement shall not give rise to a Put Option Event if and for so long as (A) the amount of such judgment, order, award or settlement is covered by a valid and binding policy of insurance between the defendant and the insurer covering payment thereof in an amount that reduces the payment obligation to less than $10,000,000, and (B) such insurer has been notified, and has not disputed the claim made for payment, of the amount of such judgment, order, award or settlement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any Change of Control pursuant to which the Company or its equityholders receives aggregate net proceeds equal to or greater than the then applicable Put/Call Price; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any Material Divestiture.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Put/Call Price</font>&#8221; means, as of any date of determination: <font style="font-weight:bold;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">in case of an exercise of (i) the Put Option by the Required Purchasers or (ii) the Call Option by the Company, in each case other than in connection with a Change of Control or a Material Divestiture, an amount equal to the then applicable Return Cap;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">in case of an exercise of (</font><font style="color:#000000;">i</font><font style="color:#000000;">) the Put Option by the Required Purchasers or (ii) the Call Option by the Company</font><font style="color:#000000;">, in each case in connection with a </font><font style="color:#000000;">Change of Control</font><font style="color:#000000;"> or a Material Divestiture </font><font style="color:#000000;">occurring on or before the </font><font style="color:#000000;">18 month</font><font style="color:#000000;"> anniversary of the Effective Date, an amount equal to 120.0% of the Cumulative Purchaser Payments; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">in case of an exercise of (i) the Put Option by the Required Purchasers or (ii) the Call Option by the Company, in each case in connection with a Change of Control or a Material Divestiture occurring after the 18 month anniversary of the Effective Date but on or before the 24 month anniversary of the Effective Date, an amount equal to 125.0% of the Cumulative Purchaser Payments; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">in case of an exercise of (i) the Put Option by the Required Purchasers or (ii) the Call Option by the Company, in each case in connection with a Change of Control or a Material Divestiture occurring after the 24 month anniversary of the Effective Date, an amount equal to the then applicable Return Cap,  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">minus, in each case, the sum of all Revenue Interest Payments made by the Company to the Purchasers prior to such date; <font style="text-decoration:underline;">provided</font> that the Put/Call Price shall not be less than zero.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the avoidance of doubt, the Put/Call Price shall be calculated as of the date the Put/Call Price is required to be paid.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Qualified Equity Interests</font>&#8221; of any Person means Equity Interests of such Person that are not Disqualified Equity Interests.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Regulatory Agency</font>&#8221; means any Governmental Authority that has authority over the approval, use, control, safety, licensing, permitting, efficacy, reliability, operation, Manufacturing, testing, marketing, distribution, sale, offering, performance, or other Development and Commercialization activities relating to any Product, including the FDA, CMS, and any comparable state or foreign Governmental Authority other Governmental Authority with responsibility for the approval of the marketing and sale of pharmaceuticals or other regulation of pharmaceuticals.&nbsp;&nbsp;For avoidance of doubt, the term Regulatory Agency includes approved accrediting bodies under CLIA.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Regulatory Approval</font>&#8221; means all approvals (including, without limitation, where applicable, Drug Product Approval Applications, pricing and reimbursement approval, labeling approval and schedule classifications), licenses, registrations, listings, clearances, certificates, permits or authorizations (including, without limitation, pre- and post-approval Marketing Authorizations) of any Governmental Authority necessary for the testing, distribution, offering, manufacture, use, storage, import, export, transport, offer for sale, or sale, or other Development or Commercialization activities of each Product, together with all amendments, supplements and updates thereto and all benefits arising therefrom, including any orphan drug or regulatory exclusivities or other non-patent exclusivities or priority review vouchers. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Regulatory Filings</font>&#8221; means all applications, filings, dossiers and the like submitted to a Regulatory Agency for the purpose of obtaining Regulatory Approval from that Regulatory Agency.  Regulatory Filings shall include, but not be limited to, all Product Approval Applications.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Reimbursable Expenses</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means all</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonable and customary </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs and expenses (including reasonable attorneys&#8217; fees and expenses, as well as appraisal fees, consulting fees, advisory fees, fees incurred on account of lien searches, inspection fees and filing fees) incurred as a result of</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or arising from or relating to</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or in connection with</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> preparing, amending, executing,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> negotiating, administering, defending and enforcing </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Transaction Documents</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or otherwise incurred by the Purchaser Agent and/or the Purchasers in connection with the Transaction Documents</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Required Purchasers</font>&#8221; means the Purchasers whose aggregate Pro Rata Portions exceed 50%.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Restricted Payments</font>&#8221; means (a) any dividend or other distribution, direct or indirect, on account of any shares (or equivalent) of any class of Equity Interests of any Person or any of its Subsidiaries, now or hereafter outstanding, (b) any redemption, retirement, sinking fund or similar payment, purchase or other acquisition for value, direct or indirect, of (i) any shares (or equivalent) of any class of Equity Interests of any Person or any of its Subsidiaries, now or hereafter outstanding or (ii) any call option on any shares (or equivalent) of any class of Equity Interests or any Person or any of its Subsidiaries (irrespective of whether such call option can be cash, net share or physically settled), and (c) any payment made to retire, or to obtain the surrender of, any outstanding warrants, options or other rights to acquire shares of any class of Equity Interests of any Person or any of its Subsidiaries, now or hereafter outstanding.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Return Cap</font>&#8221; means, as of any date of determination, (i) an amount equal to 165.0% of the Cumulative Purchaser Payments or (ii) if the Purchasers have not received the amount set forth in <font style="text-decoration:underline;">clause (i)</font> on or before the ten-year anniversary of the Effective Date, an amount equal to 175.0% of the Cumulative Purchaser Payments.  For the avoidance of doubt: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:0%;">
<tr>
<td style="width:33.29%;"></td>
<td style="width:33.3%;"></td>
<td style="width:33.3%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Cumulative Purchaser Payments</font></p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Return Cap (on or prior to the 10<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> anniversary of the Effective Date)</font></p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Return Cap (after 10<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> anniversary of Effective Date)</font></p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$125,000,000</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$206,250,000</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$218,750,000</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$200,000,000</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$330,000,000</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$350,000,000</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$250,000,000</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$412,500,000</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$437,500,000</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Revenue Base</font>&#8221; means, as of any date of determination, the amount of world-wide net revenues of the Company and its Subsidiaries (excluding Digital Biotechnologies, Inc. if it is not a Subsidiary Guarantor) on all net sales, royalty payments, milestone payments, license payments, and other forms of consideration made to the Company or its Subsidiaries, calculated in accordance with GAAP, during the fiscal quarter ending on such date of determination.  The Revenue Base shall be determined in a manner consistent with the methodologies, practices and procedures used in developing the Company&#8217;s audited financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Revenue Interest Payments</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means, with respect to each </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fiscal </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quarter during the Revenue Interest Period, payments to the Purchasers in respect of the Revenue Interests calculated by multiplying </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Applicable Percentage by </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) the Revenue Base</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for such fiscal quarter</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (or</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, in the case of the first fiscal quarter, the period commencing on the Effective Date and ending on the last day of t</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he fiscal quarter in which the Effective Date occurs)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Revenue Interest Period</font>&#8221; means the period from the Effective Date through and including the date on which the Purchasers have received Revenue Interest Payments and, if applicable, any Catch Up Payment, which in the aggregate are equal to the Return Cap, unless earlier terminated upon (i) the Purchasers&#8217; exercise, or deemed automatic exercise, of the Put Option in accordance with <font style="text-decoration:underline;">&#8206;Section 5.07(a)</font> or (ii) the Company&#8217;s exercise of the Call Option in accordance with <font style="text-decoration:underline;">&#8206;Section 5.07(b)</font>, in each case upon the indefeasible payment of the Put/Call Price.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Revenue Interests</font>&#8221; means all of the right, title and interest of the Company and its Subsidiaries in and to that portion of the Revenue Base equal to the Revenue Interest Payments for each calendar quarter (or portion thereof) during the Revenue Interest Period.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">ROFN Notice</font>&#8221; has the meaning set forth in Section 5.14.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">ROFN Proposal</font>&#8221; has the meaning set forth in Section 5.14.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Safety Notices</font>&#8221; means any recalls, field notifications, market withdrawals, warnings, &#8220;dear doctor&#8221; letters, investigator notices, safety alerts or other notices of action issued or instigated by the Company, any Subsidiary or any Governmental Authority relating to an alleged lack of safety or regulatory compliance of the Products.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Sanctions</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 3.22(a)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">SEC</font>&#8221; means the Securities and Exchange Commission.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Second Payment</font>&#8221; means $75,000,000, which shall be paid by the Purchasers on the Second Purchaser Payment Date in accordance with <font style="text-decoration:underline;">&#8206;Section 2.03(a)(ii)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Second Purchaser Payment Date</font>&#8221; means the date specified in the applicable notice sent to the Purchaser Agent pursuant to <font style="text-decoration:underline;">Section 2.03(b)(vi)(B)</font> with regards to the Second Payment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Subsidiary</font>&#8221; means with respect to any Person (i) any corporation of which the outstanding Equity Interests having at least a majority of votes entitled to be cast in the election of directors under ordinary circumstances is at the time owned, directly or indirectly, by such Person or (ii) any other Person of which at least a majority voting interest under ordinary circumstances is at the time, directly or indirectly, owned by such Person.  Unless the context otherwise requires, &#8220;Subsidiary&#8221; refers to a direct or indirect Subsidiary of the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Subsidiary Guarantor</font>&#8221; means any Subsidiary of the Company that is a guarantor of the Obligations under the Guaranty and Security Agreement (or under another guaranty agreement in form and substance satisfactory to the Purchaser Agent) and has granted to the Purchaser Agent, on behalf of the Purchasers, a Lien upon and security interest in its right, title and interest in, to and under the Collateral pursuant to the Guaranty and Security Agreement; <font style="text-decoration:underline;">provided</font> that no </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Excluded Foreign Subsidiary shall be or be required to be a Subsidiary Guarantor for so long as such Subsidiary remains an Excluded Foreign Subsidiary. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Tax</font>&#8221; or &#8220;<font style="text-decoration:underline;">Taxes</font>&#8221; means any federal, state, local or foreign tax, levy, impost, duty, assessment, fee, deduction or withholding or other charge, including all excise, sales, use, value added, transfer, stamp, documentary, filing, recordation and other fees imposed by any taxing authority (and interest, fines, penalties and additions related thereto).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Tax Affiliate</font>&#8221; means any Affiliate of a Purchaser that is capable of providing an IRS Withholding Form to the Company on the Effective Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Tax Return</font>&#8221; means any report, return, form (including elections, declarations, statements, amendments, claims for refund, schedules, information returns or attachments thereto) or other information supplied or required to be supplied to a Governmental Authority with respect to Taxes.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Term</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 6.01</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Test Period</font>&#8221; in effect at any time means the most recent period of four consecutive fiscal quarters of the Company ended on or prior to such time (taken as one accounting period) in respect of which financial statements for each fiscal quarter or fiscal year in such period have been or are required to be delivered pursuant to <font style="text-decoration:underline;">&#8206;Section 5.02(a)(i)</font> or <font style="text-decoration:underline;">&#8206;Section 5.02(a)(ii)</font>; <font style="text-decoration:underline;">provided</font><font style="font-style:italic;"> </font>that, prior to the first date that financial statements have been or are required to be delivered pursuant to <font style="text-decoration:underline;">&#8206;Section 5.02(a)(i)</font> or <font style="text-decoration:underline;">&#8206;Section 5.02(a)(ii)</font>, the Test Period in effect shall be the period of four consecutive fiscal quarters of the Company ended June 30, 2022.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Third Party</font>&#8221; means any Person other than the Purchaser Agent, any Purchaser, the Company or any of their respective Subsidiaries or Affiliates.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Third Party Claim</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">&#8206;Section 8.04(a)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Third Payment</font>&#8221; means $50,000,000, which shall be paid by the Purchasers on the Third Purchaser Payment Date in accordance with <font style="text-decoration:underline;">&#8206;Section 2.03(a)(iii)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Third Purchaser Payment Date</font>&#8221; means the date specified in the applicable notice sent to the Purchaser Agent pursuant to <font style="text-decoration:underline;">Section 2.03(b)(vi)(B)</font> with regards to the Third Payment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Transaction Documents</font>&#8221; means, collectively, this Agreement, the Guaranty and Security Agreement, the Disclosure Letter, each intellectual property security agreement, the Control Agreements and any related ancillary documents or agreements delivered or executed, as applicable, in connection with the foregoing.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Transfer</font>&#8221; means the sale, conveyance, transfer, license, sublicense, lease or other disposition of any property, including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">UCC</font>&#8221; means the Uniform Commercial Code (or any similar or equivalent legislation) as in effect in any applicable jurisdiction.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">UCC Financing Statements</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means the UCC-1 financing statements, in form and substance reasonably satisfactory to the Purchaser Agent</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the Company</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, that shall be filed by the Purchaser Agent at or promptly following the Effective Date, as well as any additional UCC-1 financing statements or amendments thereto as reasonably requested from time to time</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and reasonably satisfactory to the Purchaser Agent and the Company</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, to perfect the Purchaser Agent&#8217;s security interest in the Collateral.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">United States</font>&#8221; means the United States of America.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Withholding Action</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 5.12(d)(iv)</font>.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc110631204"></a><a name="_Toc113428884"></a><font style="Background-color:#auto;text-decoration:none;">Article II.</font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Toc110631204"></a><a name="_Toc113428884"></a>PURCHASE OF REVENUE INTERESTS; PAYMENTS</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428885"></a><font style="Background-color:#auto;text-decoration:none;">Section 2.01.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Purchase of Revenue Interests.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon the terms and subject to the conditions set forth in this Agreement, the Company agrees to sell, assign and transfer to each Purchaser, and each Purchaser agrees to purchase and accept from the Company, free and clear of all Liens, such Purchaser&#8217;s Pro Rata Portion of the Revenue Interests.  The Purchasers&#8217; interest in the Revenue Interests shall vest immediately upon the Company&#8217;s receipt of payment of the First Payment pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 2.03(a)(i)</font><font style="color:#000000;">, subject to the termination provisions of </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 6.01</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company hereby consents to the Purchaser Agent recording and filing the UCC Financing Statements and other financing statements in the appropriate filing offices under the UCC (and continuation statements with respect to such financing statements when applicable) and any other notices of security or notices of charge meeting the requirements of Applicable Law in such manner and in such jurisdictions as are necessary or appropriate to perfect the assignment to the Purchasers of the Revenue Interests and the Liens in the Collateral granted to the Purchaser Agent under the Guaranty and Security Agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428886"></a><font style="Background-color:#auto;text-decoration:none;">Section 2.02.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Payments by the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Payments in Respect of the Revenue Interests</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In consideration of the Purchaser Payments made by the Purchasers, the Purchasers shall be entitled to receive, and the Company shall pay to the Purchasers, on the applicable Payment Dates, the Revenue Interest Payments during the Revenue Interest Period, upon the exercise (or deemed exercise) by the respective party of the Call Option or the Put Option, as the case may be, the Put/Call Price in respect thereof, and upon the exercise of the Purchasers of the Catch Up Payment Option, the Catch Up Payment in respect thereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">With respect to each calendar quarter, commencing with first Payment Date, the Company shall pay to the Purchasers, the Revenue Interest Payment for such calendar quarter on the applicable Payment Date.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For clarity, any increase in the Applicable Percentage</font><font style="color:#000000;"> in connection with the payment of the </font><font style="color:#000000;">Second Payment </font><font style="color:#000000;">shall be applied only on and after the Second</font><font style="color:#000000;"> Purchaser</font><font style="color:#000000;"> Payment</font><font style="color:#000000;"> Date</font><font style="color:#000000;"> </font><font style="color:#000000;">and </font><font style="color:#000000;">any increase</font><font style="color:#000000;"> in the Applicable Percentage</font><font style="color:#000000;"> in connection with the payment of the Third Payment shall be applied only </font><font style="color:#000000;">on and after</font><font style="color:#000000;"> </font><font style="color:#000000;">the </font><font style="color:#000000;">Third</font><font style="color:#000000;"> Purchaser</font><font style="color:#000000;"> Payment</font><font style="color:#000000;"> Date</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur0AE"></a><a name="_Ref_ContractCompanion_9kb9Ur0AG"></a><a name="_Ref_ContractCompanion_9kb9Ur0AI"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Reimbursable Expenses</font><font style="color:#000000;">.  The Company shall pay to the Purchaser Agent all Reimbursable Expenses (including reasonable attorneys&#8217; fees and expenses for documentation and negotiation of this Agreement) incurred through and after the Effective Date, promptly, but not earlier than thirty (30) days following the Company&#8217;s receipt of an invoice related thereto from the Purchaser Agent.  It is the intention of the parties hereto that the Company shall pay Reimbursable Expenses to the Purchaser Agent; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that, at the discretion of the Purchasers and upon prior written notice to the Company, Reimbursable Expenses may be deducted from the Purchaser Payments to the extent such Reimbursable Expenses are invoiced at least ten (10) Business Days prior to the date of such Purchaser Payment (or, in the case of the First Payment, at least one (1) Business Day prior to the date of the First Payment). Notwithstanding the foregoing, the Purchasers and the Purchaser Agent acknowledge and agree that (i) the Company provided an expense deposit in an amount of $75,000 in connection that the execution of that certain Summary of Terms by and between the Company and OrbiMed Advisors, LLC and (ii) such expense deposit shall first be applied to any Reimbursable Expenses before the Company is obligated to make payment to the Purchaser Agent of any Reimbursable Expenses or any Purchaser is entitled to deduct any amounts from the Purchaser Payments.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Payment Procedure; Currency Conversion; Late Payments</font><font style="color:#000000;">.  Any payments to be made by the Company to the Purchasers hereunder or under any other Transaction Document shall be made in United States dollars by wire transfer of immediately available funds.  All Revenue Interest Payments and other payments by the Company (other than payments in respect of Reimbursable Expenses and indemnification obligations pursuant to </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 8.04</font><font style="color:#000000;">) shall be made to each Purchaser in accordance with its Pro Rata Portion.  If any currency conversion shall be required in connection with the calculation of amounts payable hereunder, such conversion shall be made using the average of the buying and selling rates on the last five (5) Business Days of the calendar quarter to which such amounts pertain, as published by The Wall Street Journal, Internet Edition at www.wsj.com. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All Revenue Interests and any other Obligations required to be paid to the Purchasers on each Payment Date but not paid when due (other than good faith underpayments) shall bear interest at a rate of the Prime Rate plus three percent (3.00%) per annum (calculated on the basis of a three hundred sixty (360) day year and actual days elapsed) from the due date until paid in full or, if less, the maximum interest rate permitted by Applicable Law.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428887"></a><font style="Background-color:#auto;text-decoration:none;">Section 2.03.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Purchaser Payments; Conditions Precedent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk113637595"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Purchaser Payments</font><font style="color:#000000;">.  In each case subject to the applicable conditions precedent in </font><font style="text-decoration:underline;color:#000000;">clause (b)</font><font style="color:#000000;">, which may be waived by the Required Purchasers in their sole discretion, and, with respect to the Second Payment and Third Payment, subject to each Purchaser&#8217;s rights under </font><font style="text-decoration:underline;color:#000000;">Section 5.15</font><font style="color:#000000;"> to choose not to fund its Pro Rata Portion of such Second Payment or Third Payment if the Company amends or supplements the Disclosure Letter (other than (i) any supplement or amendment of Schedule 3.13 (Material Contracts)</font><font style="color:#FF0000;font-family:F3;"> </font><font style="color:#000000;">or (ii) any other supplement or amendment to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">the Disclosure Letter</font><font style="color:#000000;"><a name="_Hlk113637595"></a> </font><font style="color:#000000;">(except for any supplement or amendment related to </font><font style="text-decoration:underline;color:#000000;">Section 3.07</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">Section 3.16</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">Section 3.21</font><font style="color:#000000;">, or </font><font style="text-decoration:underline;color:#000000;">Section 3.22</font><font style="color:#000000;">)</font><font style="color:#000000;">, </font><font style="color:#000000;"> so long as the information or event underlying such other</font><font style="color:#000000;"> </font><font style="color:#000000;">supplement or amendment does not relate to an event or circumstance which would reasonably</font><font style="color:#000000;"> </font><font style="color:#000000;">be expected to give rise to a Material Adverse Effect</font><font style="color:#000000;">)</font><font style="color:#000000;">,</font><font style="color:#000000;"> </font><font style="color:#000000;">in connection with its certification as to the satisfaction of the conditions in </font><font style="text-decoration:underline;color:#000000;">Section 2.03(b)(v)(A)</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">(B)</font><font style="text-decoration:underline;color:#000000;">)</font><font style="color:#000000;">:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur04A"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">On the First Purchaser Payment Date, each Purchaser shall pay to the Company, and the Company shall accept, such Purchaser&#8217;s Pro Rata Portion of the First Payment (less any then unpaid Reimbursable Expenses to the extent deducted pursuant to </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 2.02(b)</font><font style="color:#000000;">) by wire transfer of immediately available funds.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur07D"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">On the Second Purchaser Payment Date, at the Company&#8217;s option, each Purchaser shall pay to the Company, and the Company shall accept, such Purchaser&#8217;s Pro Rata Portion of the Second Payment (less any then unpaid Reimbursable Expenses to the extent deducted pursuant to </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 2.02(b)</font><font style="color:#000000;">) by wire transfer of immediately available funds.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur08G"></a><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">On the Third Purchaser Payment Date, at the Company&#8217;s option, each Purchaser shall pay to the Company, and the Company shall accept, such Purchaser&#8217;s Pro Rata Portion of the Third Payment (less any then unpaid Reimbursable Expenses to the extent deducted pursuant to </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 2.02(b)</font><font style="color:#000000;">) by wire transfer of immediately available funds.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur08I"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Conditions Precedent</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Conditions Precedent to the Effective Date and the First Payment</font><font style="color:#000000;">.  The Company and each other Obligor, as applicable, shall have delivered to the Purchaser Agent:</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(A)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">this Agreement, duly executed by the Company;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(B)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Guaranty and Security Agreement, duly executed by each Obligor;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(C)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">UCC-1 financing statements in proper form for filing against each Obligor;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(D)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">a short-form security agreement in respect of the Product Intellectual Property;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(E)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">a completed Perfection Certificate, duly executed by the Company;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(F)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">certificates or other evidence of insurance in effect as required by Section 5.11(a); </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(G)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">one or more legal opinions of counsel to each Obligor, in each case in form and substance reasonably satisfactory to the Purchaser Agent;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(H)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> a secretary&#8217;s certificate executed by an officer of each Obligor attaching certified Organization Documents, certificates of good standing and incumbency certificates of each Obligor and resolutions of the governing body of each Obligor </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">authorizing such Obligor to enter into the Transaction Documents and perform the transactions contemplated </font><font style="color:#000000;">thereby;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(I)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">all consents required (if any) by the Obligors under any Material Contracts, Applicable Law, the Organization Documents of the Obligors and Governmental Authorities; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(J)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">copies of all Material Contracts and all amendments of such Material Contracts as of and through the Effective Date; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(K)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">an officer&#8217;s certificate, certifying as to the conditions in </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 2.03(b)(v)(A)</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">(B)</font><font style="color:#000000;">; and</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(L)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">a Notice of Purchaser Payment Request in substantially the form attached hereto as </font><font style="text-decoration:underline;color:#000000;">Exhibit A</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Conditions Precedent to the Second Payment</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(A)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The First Payment shall have occurred;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(B)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall have delivered to the Purchaser Agent an officer&#8217;s certificate certifying as to the conditions in </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 2.03(b)(v)(A)</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">(B)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Conditions Precedent to the Third Payment</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(A)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The First Payment shall have occurred;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(B)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Second Payment shall have occurred; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(C)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall have delivered to the Purchaser Agent, an officer&#8217;s certificate certifying as to the conditions in </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 2.03(b)(v)(A)</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">(B)</font><font style="color:#000000;">; and </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(D)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall have delivered to the Purchaser Agent evidence reasonably satisfactory to the Purchaser Agent that one or more Permitted Acquisitions shall be consummated substantially concurrently with the making of the Third Payment using all of the proceeds from the Third Payment to fund such Permitted Acquisition, and all documents required to be delivered to the Purchaser Agent pursuant to the definition of &#8220;Permitted Acquisition&#8221;. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">[Reserved]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Conditions Precedent to each Purchaser Payment</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur0AK"></a><a name="_Ref_ContractCompanion_9kb9Ur123"></a><a name="_Ref_ContractCompanion_9kb9Ur125"></a><font style="Background-color:#auto;text-decoration:none;">(A)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The representations and warranties in </font><font style="text-decoration:underline;color:#000000;">Article III</font><font style="color:#000000;"> hereof, and in any other Transaction Document shall be true, accurate and complete in all material respects on the date of the applicable payment; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">however</font><font style="color:#000000;">, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">further</font><font style="color:#000000;">, that those representations and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">warranties expressly referring to a specific date shall</font><font style="color:#000000;"> only</font><font style="color:#000000;"> be</font><font style="color:#000000;"> required to be</font><font style="color:#000000;"> true, accurate and complete in all material respects as of such date;</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(B)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">(i) No Put Option Event shall have occurred and be continuing, (ii) no Catch Up Payment Event shall have occurred and be continuing and (iii) no Material Breach shall have occurred and be continuing; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(C)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the extent not deducted from the applicable Purchaser Payment, payment of the Reimbursable Expenses then due as specified in Section 2.02(b) (to the extent invoiced at least one (1) Business Day prior to the First Payment and at least ten (10) Business Days prior to each of the Second Payment and Third Payment); and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur127"></a><font style="Background-color:#auto;text-decoration:none;">(D)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">With respect to the Second Payment and Third Payment, the Company shall have provided to the Purchaser Agent at least fifteen (15) Business Days (or such shorter period as agreed in writing by Purchaser Agent) advance written notice of the Second Purchaser Payment Date or Third Purchaser Payment Date, as applicable, in substantially the form attached hereto as Exhibit A.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding anything to the contrary herein, each Purchaser Commitment shall terminate:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to the extent funded,</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">upon the occurrence of a Bankruptcy Event, </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">upon the exercise of the Put Option or Catch Up Payment Option by the Purchasers or the Call Option by the Company, and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">in any event, no later than (A) with respect to the First Payment, the First Purchaser Payment Date, (B) with respect to the Second Payment, September 12, 2025 and (C) with respect to the Third Payment, September 12, 2025.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For the avoidance of doubt, each of the conditions precedent in </font><font style="text-decoration:underline;color:#000000;">Section 2.03</font><font style="color:#000000;"> may be waived by the Required Purchasers in their sole discretion.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428888"></a><font style="Background-color:#auto;text-decoration:none;">Section 2.04.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Payment Procedure; Currency Conversion; Late Payments.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc112589796"></a><a name="_Toc113347294"></a><a name="_Toc113428889"></a>Any payments to be made by or on behalf of a Purchaser to the Company hereunder or under any other Transaction Document shall be made in United States dollars by wire transfer of immediately available funds.&nbsp;&nbsp;If any currency conversion shall be required in connection with the calculation of amounts payable hereunder, such conversion shall be made using the average of the buying and selling rates on the last five (5) Business Days of the calendar quarter to which such amounts pertain, as published by The Wall Street Journal, Internet Edition at www.wsj.com.&nbsp;&nbsp;All Purchaser Payments and any other payments required to be paid to the Company but not paid when due shall bear interest at a rate of the Prime Rate plus three percent (3.00%) per annum (calculated on the basis of a three hundred sixty (360) day year and actual days elapsed) from the due date until paid in full or, if less, the maximum interest rate permitted by Applicable Law.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428890"></a><font style="Background-color:#auto;text-decoration:none;">Section 2.05.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Assumed Obligations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding any provision in this Agreement or any other writing to the contrary, the Purchasers are acquiring only the Revenue Interests and are not assuming any liability or obligation of the Company or any of its Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter, whether under any Transaction Document or otherwise.  All such liabilities and obligations shall be retained by and remain obligations and liabilities of the Company or its Affiliates (the &#8220;<font style="text-decoration:underline;">Excluded Liabilities</font>&#8221;).</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc110631205"></a><a name="_Toc113428891"></a><font style="Background-color:#auto;text-decoration:none;">Article III.</font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Toc110631205"></a><a name="_Toc113428891"></a>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as set forth in the correspondingly numbered Schedule of the Disclosure Letter, the Company hereby represents and warrants to the Purchaser Agent and the Purchasers, as of the Effective Date, the First Purchaser Payment Date, the Second Purchaser Payment Date and the Third Purchaser Payment Date, as applicable, the following: </p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428892"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.01.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Organization.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Obligor is a corporation or limited liability company, as applicable, duly incorporated or formed, as applicable, validly existing and in good standing under the laws of its respective jurisdiction of formation and has all corporate or limited liability company powers and all licenses, authorizations, consents and approvals required to carry on its respective business as now conducted and as proposed to be conducted in connection with the transactions contemplated by the Transaction Documents.  Each Obligor is duly qualified to do business as a foreign corporation or foreign limited liability company, as applicable, and is in good standing in every jurisdiction in which the failure to do so would be reasonably expected to have a Material Adverse Effect.  As of the Effective Date, the Subsidiaries of the Company are listed on <font style="text-decoration:underline;">Schedule 3.01</font> to the Disclosure Letter.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428893"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.02.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Authorization.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Obligor has all necessary power and authority to enter into, execute and deliver the Transaction Documents to which it is a party and to perform all of the obligations to be performed by it hereunder and thereunder and to consummate the transactions contemplated hereunder and thereunder.  Each Transaction Document has been duly authorized, executed and delivered by each Obligor party thereto, and each Transaction Document constitutes the valid and binding obligation of each Obligor party thereto, enforceable against such Obligor in accordance with their respective terms, subject, as to enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights generally or general equitable principles.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428894"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.03.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Governmental Authorization.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The execution and delivery by each Obligor of the Transaction Documents to which it is a party, and the performance by such Obligor of its obligations thereunder, does not require any notice to, action or consent by, or filing with, any Governmental Authority, except for the filing of the UCC Financing Statements and any filings with the SEC. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428895"></a><font style="text-decoration:none;Background-color:#auto;">Section 3.04.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Ownership.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the Knowledge of the Company, the Company owns or holds a valid license granting all necessary rights to all of (i) the Product Intellectual Property and (ii) the Regulatory Filings. The Company owns or holds a valid license granting all necessary rights to all of the Regulatory Approvals related to each Product free and clear of all Liens (other than Permitted Liens).</font><font style="font-weight:bold;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company, immediately prior to the assignment of the Revenue Interests, owns, and is the sole holder of, all the Revenue Interests and all Collateral, free and clear of any and all Liens (other than Permitted Liens).  Except as permitted pursuant to this Agreement, no Obligor has Transferred or granted any Lien in respect of or agreed to Transfer or grant any Lien in respect of, any portion of the Revenue Interests or the Collateral.  Except for the sale of the Revenue Interests pursuant hereto, no Person other than the Company or its Subsidiaries has any right to receive any payments in respect of the Revenue Base.  The Company has the full right to sell, transfer, convey and assign to the Purchasers all of the Company&#8217;s rights, title and interests in and to the Revenue Interests to the Purchasers pursuant to this Agreement without any requirement to obtain the consent of any Person, except such consents as are obtained at or prior to the Effective Date or otherwise waived by the Purchasers.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428896"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.05.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Financial Statements; No Material Adverse Effect.</font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Audited Financial Statements (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, and (ii) fairly present in all material respects the consolidated financial condition of the Company and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Interim Financial Statements (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, and (ii) fairly present in all material respects the consolidated financial condition of the Company and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby, subject, in the case of </font><font style="text-decoration:underline;color:#000000;">clauses (i)</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">(ii)</font><font style="color:#000000;">, to the absence of footnotes and to normal year-end audit adjustments.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">From December 31, 2021 to and including the Effective Date, there has been no Transfer by the Company or any Subsidiary, voluntary or involuntary, of any material part of the business or property of the Company or any Subsidiary, and no purchase or other acquisition by any of them of any business or property (including any Equity Interests of any other Person) material to the Company or any Subsidiary, in each case, which is not reflected in the foregoing financial statements or in the notes thereto and has not otherwise been disclosed in writing to the Purchasers on or prior to the Effective Date. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font>The financial statements delivered pursuant to Section 5.02(a) (i) have been prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, and (ii) present fairly in all material respects the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated financial condition</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> results of operations of the Company and its Subsidiaries as of the dates thereof and for the periods covered thereby</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject, in the case of </font><font style="text-decoration:underline;">clauses (</font><font style="text-decoration:underline;">i</font><font style="text-decoration:underline;">)</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="text-decoration:underline;">(ii)</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, to the absence of footnotes and to normal year-end audit adjustments</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Since December 31, 2021, there has been no event or circumstance, either individually or in the aggregate, that has had or could reasonably be expected to have a Material Adverse Effect.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428897"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.06.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Undisclosed Liabilities.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except for those liabilities (a) identified in the Financial Statements (including the notes thereto) and/or in any filing made by the Company with the SEC or incurred in the ordinary course of business since the date of the most recent Financial Statements; (b) consisting of Permitted Indebtedness; or (c) in connection with the Obligations under the Transaction Documents, there are no material liabilities of the Company or its Subsidiaries, of any kind whatsoever, whether accrued, contingent, absolute, determined or determinable, that would be required to be reported in a filing by the Company with the SEC.<font style="font-weight:bold;"> </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428898"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.07.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Solvency; No Fraudulent Transfer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and the Subsidiaries, taken as a whole, are not insolvent as defined in any statute of the United States Bankruptcy Code or in the fraudulent conveyance or fraudulent transfer statutes of the State of Washington.&nbsp;&nbsp;Assuming consummation of the transactions contemplated by the Transaction Documents, (a) the present fair saleable value of the Company&#8217;s and the Subsidiaries&#8217; assets is greater than the total amount of liabilities of the Company and the Subsidiaries as such liabilities mature, (b) the Company and the Subsidiaries, taken as a whole, do not have unreasonably small capital with which to engage in its business, and (c) the Company and the Subsidiaries, taken as a whole, have not incurred, nor do they have present plans to incur, debts or liabilities beyond their ability to pay such debts or liabilities as they become absolute and matured.  No transfer of property was or is being made by any Obligor and no obligation was or is being incurred by any Obligor in connection with the transactions contemplated by this Agreement or the other Transaction Documents with the intent to hinder, delay, or defraud either present or future creditors of such Obligor.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur145"></a><a name="_Toc113428899"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.08.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Litigation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no (a) action, suit, arbitration proceeding, claim, investigation or other proceeding (whether administrative, judicial or otherwise) pending or, to the Knowledge of the Company, threatened against the Company or any Subsidiary or (b) any governmental inquiry pending or, to the Knowledge of the Company, threatened against the Company or any Subsidiary, which in each case with respect to <font style="text-decoration:underline;">clauses (a)</font> and <font style="text-decoration:underline;">(b)</font> above, (x) as of the Effective Date, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect or (y) at any time after the Effective Date, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. </p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428900"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.09.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Compliance with Laws.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither the Company nor any Subsidiary (a) is in violation of, has in the past five (5) years violated, or, to the Knowledge of the Company, is under investigation with respect to, or (b) has been threatened to be charged with or been given notice of any violation of any law, rule, ordinance or regulation of, or any judgment, order, writ, decree, permit or license entered by any Governmental Authority applicable to, the Company or any of its Subsidiaries, the Revenue Interests or any Product or any other Collateral, in each case which could reasonably be expected to have a Material Adverse Effect.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428901"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Conflicts; Adverse Agreements.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither the execution and delivery of any of this Agreement or the other Transaction Documents to which any Obligor is a party nor the performance or consummation of the transactions contemplated hereby or thereby will: (a) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any provisions of: (i) any law, rule, ordinance or regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which the Company or any Subsidiary or any of their respective assets or properties may be subject or bound; or (ii) any contract, agreement, commitment or instrument to which the Company or any Subsidiary is a party or by which the Company or its Subsidiary or any of their respective assets or properties is bound or committed; (b) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respect, any provisions of the articles or certificate of incorporation or bylaws (or other organizational or constitutional documents) of the Company or any Subsidiary; (c) except for the filing of the UCC Financing Statements, any other notices of security or notices of charge required hereunder and filings with the United States Patent and Trademark Office or the United States Copyright Office, or any filings with the SEC, require any notification to, filing with, or consent of, any Person or Governmental Authority, except such consents that are obtained at or prior to the Effective Date; (d) give rise to any right of termination, cancellation or acceleration of any right or obligation of the Company, any Subsidiary or any other Person or to a loss of any material benefit relating to the Revenue Interests; or (e) other than pursuant to this Agreement or any other Transaction Document, result in the creation or imposition of any Lien on (i) the assets or properties of the Company or any Subsidiaries or (ii) the Revenue Interests or any Collateral except, in the case of the foregoing <font style="text-decoration:underline;">clauses (a)</font> or <font style="text-decoration:underline;">(c)</font>, as would not, individually or in the aggregate, have a Material Adverse Effect.  No Obligor or any of its Subsidiaries is a party to any contractual obligation or subject to any restriction or limitation in any Organization Document or any judgment, order, regulation, ruling or other requirement of a court or other Governmental Authority, which (either individually or in the aggregate) could reasonably be expected (either individually or in the aggregate) to have, a Material Adverse Effect. </p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428902"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.11.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Intellectual Property.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Schedule 3.11(a)</font><font style="color:#000000;"> to the Disclosure Letter sets forth, as of the Effective Date, an accurate, true and complete list of all (i) issued Patents and pending Patent applications, (ii) trade names, registered trademarks, registered service marks, and applications for trademark registration or service mark registration, (iii) registered copyrights and applications for copyright registration, and (iv) domain name registrations and websites, in each case of clauses (i) through (iv), that constitute Product Intellectual Property. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as disclosed therein, the Product Intellectual Property listed on </font><font style="text-decoration:underline;color:#000000;">Schedule 3.11(a)</font><font style="color:#000000;"> to the Disclosure Letter is subsisting, </font><font style="color:#000000;">and, to the Knowledge of the Company, </font><font style="color:#000000;">enforceable,</font><font style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font><font style="color:#000000;">and has not lapsed, expired, been </font><font style="color:#000000;">cancelled</font><font style="color:#000000;"> or become abandoned, except in the ordinary course of business or where such lapse or abandonment would not reasonably be likely to result in a Material Adverse Effect.&nbsp;&nbsp;To the Knowledge of the Company, except as disclosed therein, each issued Patent and registered trademark listed on </font><font style="text-decoration:underline;color:#000000;">Schedule 3.11(a)</font><font style="color:#000000;"> to the Disclosure Letter is valid</font><font style="color:#000000;"> and enforceable</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as would not reasonably be likely to result in a Material Adverse Effect, all current and former employees and contractors of the Company and each Affiliate who have created or developed (or contributed to the creation or development of) Product Intellectual Property for the Company or an Affiliate have executed binding, and, to the Knowledge of the Company, valid and enforceable written agreements assigning to the Company or the applicable Affiliate, all of their rights, title, and interest in and to such Product Intellectual Property to the extent such rights, title, and interest did not automatically vest in the Company or such Affiliate by operation of law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except for Product Intellectual Property licensed to or owned by any Obligor and set forth on </font><font style="text-decoration:underline;color:#000000;">Schedule 3.11(a)</font><font style="color:#000000;"> to the Disclosure Letter, to the Knowledge of the Company, no other Intellectual Property is necessary to Manufacture or Commercialize the Products.&nbsp;&nbsp;To the Knowledge of the Company, the Manufacture or Commercialization of the Products does not infringe, misappropriate or otherwise violate any Patents or other Intellectual Property that is owned or controlled by a Third Party.&nbsp;&nbsp;During the six-year period prior to the Effective Date, none of the Company or any of its Affiliates has received written notice or, to the Knowledge of the Company, any other communication, from any Third Party alleging that the Development, Manufacture or Commercialization of the Products infringes or misappropriates any Intellectual Property of such Third Party. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the Knowledge of the Company, there are no unpaid maintenance, annuity or renewal fees currently overdue for any of the Patents that cover compositions of matter, formulation, method of use, method of manufacture and/or processes for the Products, and that are Controlled by the Company (&#8220;</font><font style="text-decoration:underline;color:#000000;">Material Patents</font><font style="color:#000000;">&#8221;). To the Knowledge of the Company, there are no unpaid maintenance, annuity or renewal fees currently overdue for any Product Intellectual Property listed on </font><font style="text-decoration:underline;color:#000000;">Schedule 3.11(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">There is no, and there has not been, in the past five (5) years, any pending, decided or settled opposition, interference proceeding, reexamination proceeding, cancellation proceeding, injunction, lawsuit, declaratory judgment, administrative post-grant review proceeding, other administrative or judicial proceeding, hearing, investigation, complaint, arbitration, mediation, International Trade Commission investigation, decree, or any other filed claim (collectively referred to hereinafter as &#8220;</font><font style="text-decoration:underline;color:#000000;">Disputes</font><font style="color:#000000;">&#8221;) related to any of the Product Intellectual Property or Material Patents nor has any such Dispute been threatened in writing challenging the legality, validity, enforceability or ownership of any Product Intellectual Property or Material Patents.&nbsp;&nbsp;There are no Disputes by any Person or Third Party against the Company or its Affiliates, and the Company has not received any written notice or claim of any such Dispute as pertaining to the Products.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">There are no Disputes pending or threatened in writing that have been brought by the Company or any of its Affiliates against any Person or Third Party alleging infringement of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">any </font><font style="color:#000000;">Product Intellectual Property or Material Patents</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">To the</font><font style="color:#000000;"> Knowledge of the Company, no Person or Third Party is committing any act of i</font><font style="color:#000000;">nfringement of any</font><font style="color:#000000;"> Product Intellectual Property or Material Patent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company and its Affiliates have taken commercially reasonable measures and precautions to protect and maintain (i) the confidentiality of all trade secrets with respect to any Product that it owns or exclusively licenses and (ii) the value of all Intellectual Property related to any Product, except where such failure to take action would not reasonably be expected to have a Material Adverse Effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as would not reasonably be likely to result in a Material Adverse Effect, to the Knowledge of the Company, all current and former employees and contractors of the Company and each Affiliate and all other Persons with access to any confidential, non-public information comprising or included in the Intellectual Property related to any Product is subject to a legally binding, and, to the Knowledge of the Company, valid and enforceable written non-disclosure or other confidentiality agreement requiring such employee, contractor, or other Person to maintain the confidentiality of such information and to use such information only for the benefit of the Company or such Affiliate, as applicable.&nbsp;&nbsp;To the Knowledge of the Company, no material trade secret of the Company or its Affiliates with respect to any Product has been published or disclosed to any Person except pursuant to such a written agreement requiring such Person to keep such trade secret confidential, except where such disclosure would not reasonably be expected to have a Material Adverse Effect. </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428903"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.12.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Regulatory Approvals; Products.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company and its Affiliates have made available to the Purchaser Agent any written reports or other written communications received from a Governmental Authority that would indicate that any Regulatory Agency (A) is likely to revise or revoke any current Regulatory Approval granted by any Regulatory Agency with respect to any Product or may not accept for review or grant Regulatory Approval for any Product or (B) is likely to pursue any material compliance and/or enforcement actions against the Company.&nbsp;&nbsp;To the Knowledge of the Company there are no other facts or circumstances that could reasonably be expected to (i) indicate that any of the events specified in the immediately preceding </font><font style="text-decoration:underline;color:#000000;">clauses (A)</font><font style="color:#000000;"> or </font><font style="text-decoration:underline;color:#000000;">(B)</font><font style="color:#000000;"> may occur or (ii) cause the Company or any of its Subsidiaries to voluntarily revise, withdraw or not apply for any Regulatory Approval.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company and its Subsidiaries possess all Regulatory Approvals necessary or required to conduct the business relating to the Products, including to conduct any ongoing clinical trials relating to the Products, and neither the Company nor its Subsidiaries has received any notice of proceedings relating to, and there are no facts or circumstances to the Knowledge of the Company that could reasonably be expected to lead to, the revocation, suspension, termination or modification of any such Regulatory Approvals.&nbsp;&nbsp;All applications, notifications, submissions, information, claims, reports and statistics and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a Regulatory Approval from the FDA or other Regulatory Agency relating to the Company or any Subsidiary, their business operations and Products, when submitted to the FDA or other Regulatory Agency were true, complete and correct in all material respects as of the date of submission or any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">necessary or required updates, changes, corrections or modifications to such applications, submissions, information and data have been submitted to the FDA or other Regulatory Agency.&nbsp;&nbsp;</font><font style="color:#000000;">To</font><font style="color:#000000;"> the Knowledge of the Company, </font><font style="color:#000000;">none of the officers, directors, </font><font style="color:#000000;">employees or Affiliates of the Company or any Subsidiary or any agent or consultant has (</font><font style="color:#000000;">i</font><font style="color:#000000;">) made an untrue statement of material fact or fraudulent statement to any Regulatory Agency or failed to disclose a material fact required to be disclosed to a Regulatory Agency</font><font style="color:#000000;"> in matters relating to the Company</font><font style="color:#000000;">; or (ii) committed an act, made a statement, or failed to make a statement that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,&#8221; set forth in 56 Fed. Reg. 46191 (September 10, 1991). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company and its Affiliates are in compliance with, and have, for the past five (5) years complied with, all applicable federal, state, local and foreign laws, rules, regulations, standards, orders and decrees governing its business, including the FFDCA, the PHSA, CLIA, similar foreign provisions, and all regulations promulgated by each Regulatory Agency, the failure of compliance with which could reasonably be expected to result in a Material Adverse Effect; the Company and its Affiliates have not received any notice citing action or inaction by any of them that would constitute any non-compliance with any applicable federal, state, local and foreign laws, rules, regulations, or standards, which could reasonably be expected to result in a Material Adverse Effect; and to the Knowledge of the Company, no prospective change in any applicable federal, state, local or foreign laws, rules, regulations or standards has been adopted which, when made effective, could reasonably be expected to result in a Material Adverse Effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Any clinical test that is offered by the Company or any of its Affiliates and is not approved or cleared by FDA has been designed, developed, validated, used, and performed solely within the Company&#8217;s single laboratory certified under CLIA to perform high-complexity testing, and to Company&#8217;s Knowledge, such tests are provided only upon the order of a lawful prescription by a licensed healthcare provider. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All preclinical and clinical trials conducted by or on behalf of the Company or its Affiliates relating to each Product were conducted in all material respects in compliance with Applicable Law, including without limitation, good clinical practices (as that term is defined by the FDA and/or relevant international standards) and, in all material respects, in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards.&nbsp;&nbsp;The descriptions and the results of such trials provided to the Purchaser Agent are accurate in all material respects.&nbsp;&nbsp;Neither the Company nor its Affiliates has received any notices or correspondence from any Regulatory Agency, comparable authority, or institutional review board or ethics committee requiring the termination, suspension, or clinical hold of any clinical trials conducted by or on behalf of the Company or its Affiliates with respect to any Product. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Neither the Company nor any of its Affiliates have received any written notices from, (i) any Governmental Authority or (ii) any pricing and reimbursement representative of any Person, in each case exercising authority with respect to pricing and reimbursement for the Products, that have resulted in any non-coverage decision in respect of, or material reduction in the expected pricing of, any Product.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the Knowledge of the Company, a</font><font style="color:#000000;">ll Manufacturing conducted by or on behalf of the Company and its Affiliates relating to the Products have been and are being conducted in material compliance with, as applicable, CLIA and the current good manufacturing practices set forth in 21 C.F.R. Parts 210, 211 and 820.&nbsp;&nbsp;Without limiting the generality of the foregoing, with respect to any Product being tested or Manufactured by the Company and its Subsidiaries, as of the Effective Date, neither the Company nor any Subsidiary has received any written notice from any applicable Governmental Authority, including the FDA, that such Governmental Authority is currently conducting an investigation or review of (</font><font style="color:#000000;">i</font><font style="color:#000000;">) the Company and its Subsidiaries&#8217; (or any third party contractors therefor) manufacturing facilities and processes for Manufacturing such Product or the marketing and sales of such Product, in each case which have identified any material deficiencies or violations of Applicable Laws or the permits related to the Manufacture, marketing and/or sales of such Product that could reasonably be expected to result in a Material Adverse Effect, or (ii) any such Regulatory Approval that could be reasonably expected to result in a revocation or withdrawal of such Regulatory Approval, nor has any such Governmental Authority issued any order or recommendation stating that the development, testing, manufacturing, marketing or sales of such Product by the Company and its Subsidiaries should cease or that such Product should be withdrawn from the marketplace.&nbsp;&nbsp;To the Knowledge of the Company, neither the Company nor any Subsidiary of the Company has experienced any significant failures in the manufacturing of any Product for commercial sale that has had or could reasonably be expected to have, if such failure occurred again, a Material Adverse Effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Neither the Company, its Affiliates nor their respective officers, nor, to the Knowledge of the Company their employees or agents, has been convicted of any crime or engaged in any conduct for which (i) debarment is mandated by 21 U.S.C. &#167; 335a(a) or authorized by 21 U.S.C. &#167; 335a(b); or (ii) exclusion is required pursuant to 42 U.S.C. &#167; 1320a-7b and related regulations, nor is any such debarment or exclusion threatened or pending.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Neither the Company nor any Subsidiary has received (x) from the FDA a Warning Letter, Form FDA-483, &#8220;Untitled Letter,&#8221; or similar written correspondence or notice alleging violations of laws and regulations enforced by the FDA, or (y) any written notice from any Governmental Authority alleging violations of any requirements pertaining to CLIA, in each case including any comparable written correspondence from any other Governmental Authority with regard to any Product or the Manufacture, processing, packaging, Development, Commercialization, or holding thereof, the subject of which communication is unresolved and if determined adversely to the Company or such Subsidiary could reasonably be expected to have a Material Adverse Effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">There have been no Safety Notices, (i) to the Knowledge of the Company, there are no unresolved material product complaints with respect to the Products which could reasonably be expected to have a Material Adverse Effect, and (ii) to the Knowledge of the Company, there are no facts that would be reasonably likely to result in (A) a material Safety Notice with respect to the Products, (B) a material change in the labeling of any of the Products or (C) a termination or suspension of marketing of any Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company and its Affiliates are in material compliance with all applicable federal, state and local laws and regulations regarding the privacy and security of health information and electronic transactions, including, to the extent applicable, the Health Insurance </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Portability and Accountability Act (HIPAA), and has implemented adequate policies, procedures and training designed to assure continued compliance and to detect non-compliance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All of the Products that exist as of the Effective Date are listed on </font><font style="text-decoration:underline;color:#000000;">Schedule 3.12(l)</font><font style="color:#000000;"> to the Disclosure Letter.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company and its Affiliates are in material compliance with (i) all applicable federal, state, and local laws pertaining to health care fraud and abuse, including without limitation the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 </font><font style="font-style:italic;color:#000000;">et seq.</font><font style="color:#000000;">), the federal sunshine and open payments law (42 U.S.C. &#167; 1320a-7h), the federal health care program exclusion provisions (42 U.S.C. &#167; 1320a-7), the Civil Monetary Penalties Act (42 U.S.C. &#167; 1320a-7a), and all rules and regulations promulgated under any of the foregoing; (ii) applicable laws governing health care programs of any Governmental Authority and drug price reporting requirements; and (iii) the federal Medicare and Medicaid statutes (Title XVIII and Title XIX of the Social Security Act) and all rules and regulations promulgated thereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(n)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company has made available to the Purchasers all Regulatory Approvals and all material correspondence with Governmental Authorities (including the FDA), as requested by Purchasers, with respect to such Regulatory Approvals and the potential requirement for additional Regulatory Approvals, with respect to the Products and all requested documents related to the Products in each case in the possession and control of the Company or its Subsidiaries.&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428904"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.13.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Material Contracts.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Schedule 3.13</font> to the Disclosure Letter sets forth a true and complete list of all Material Contracts, including any amendments or modifications thereto.  The Company has made available to Purchasers correct and complete copies of all Material Contracts.  Neither the Company nor its Subsidiaries is in breach of any Material Contract or in default under any Material Contract which breach or default, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect.  There is no event or circumstance that with notice or lapse of time, or both, would reasonably be expected to (a) constitute a material breach or default by the Company and/or its Subsidiaries or, to the Knowledge of the Company, any other party under any Material Contract, (b) give any Person the right to receive or require a rebate, chargeback, penalty or change in delivery schedule under any Material Contract, (c) give any Person the right to accelerate the maturity or performance of any Material Contract or (d) give any Person the right to cancel, terminate or materially modify any Material Contract (excluding any termination for convenience right expressly set forth in such Material Contract).  To the Knowledge of the Company, nothing has occurred and no condition exists that would permit any other party thereto to terminate any Material Contract (excluding any termination for convenience right expressly set forth in such Material Contract).  Schedule 3.13 to the Disclosure Letter identifies each Material Contract that contains an express termination for convenience right.&nbsp;&nbsp;Neither the Company nor its Affiliates has received any written notice or, to the Knowledge of the Company, any threat (in writing) of termination of any such Material Contract.  To the Knowledge of the Company, no other party to a Material Contract is in breach of or in default under such Material Contract which breach or default, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect.  All Material Contracts are valid and binding on the Company and its Affiliates and, to the Knowledge of the Company, on each other party thereto, and are in full force and effect. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428905"></a><font style="text-decoration:none;Background-color:#auto;">Section 3.14.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Place of Business.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s principal place of business, chief executive office and each office where each of the Company and its Subsidiaries keeps its records regarding the Collateral are, as of the Effective Date, each set forth on <font style="text-decoration:underline;">Schedule 3.14</font> to the Disclosure Letter.  None of the Company (or any predecessor by merger or otherwise) and its Subsidiaries has, within the five (5) year period preceding the date hereof, had a name that differs from its name as of the date hereof.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428906"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.15.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Customers and Suppliers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There exists no actual or, to the Knowledge of the Company, threatened (in writing) termination, cancellation or limitation of, or modification to or change in, the business relationship between (i) any Obligor, on the one hand, and any customer or any group thereof, on the other hand, or (ii) any Obligor, on the one hand, and any supplier or any group thereof, on the other hand, in either case, which, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428907"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.16.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Digital Biotechnologies.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;Digital Biotechnologies, Inc. does not own any Core Asset (without giving effect to the last sentence of the definition of &#8220;Core Asset&#8221;).&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428908"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.17.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Perfection; Subordination.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Transaction Documents create valid security interests in, and Liens on, the Collateral purported to be covered thereby, which security interests and Liens will be, upon the timely and proper filings, deliveries, notations and other actions contemplated in the Transaction Documents perfected security interests and Liens (to the extent that such security interests and Liens can be perfected by such filings, deliveries, notations and other actions).  The claims and rights of the Purchaser Agent and the Purchasers created by any Transaction Document are not, and shall not be, subordinated to any creditor of any Obligor or any other Person. The Liens created pursuant to the Transaction Documents will have first ranking priority and will not be subject to any prior ranking or <font style="font-style:italic;">pari passu</font> ranking Lien other than as permitted by this Agreement (it being understood that Permitted Liens may have a superior priority under applicable law to Purchaser Agent&#8217;s and each Purchaser&#8217;s Liens under the Transaction Documents).</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428909"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.18.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Insurance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are in full force and effect insurance policies maintained by reputable insurance companies in accordance with standards customary for companies of a comparable condition and size similarly situated in the same industry as the Company, with coverage of the Company and each of its Subsidiaries in amounts customary for companies of comparable size and condition similarly situated in the same industry as, including product liability insurance, directors and officers insurance and insurance against litigation liability, subject only to such exclusions and deductible items as are usual and customary in insurance policies of such type.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428910"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.19.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tax.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of the Company and its Subsidiaries has timely filed all income and other material Tax Returns and has paid when due all Taxes shown to be due thereon.  There are no Liens in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respect of Taxes applicable to the Company or any of its Subsidiaries except Permitted Liens. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no tax assessment proposed in writing against the Company and its Subsidiaries for a material amount of Taxes that is not being actively contested in good faith and by appropriate proceedings and for which reserves or other appropriate provisions, if any, as are required in conformity with GAAP have been made or provided</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therefor.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428911"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.20.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Disclosures.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc112589819"></a><a name="_Toc113347317"></a><a name="_Toc113428912"></a>All written information heretofore furnished to the Purchaser Agent or any Purchaser by or on behalf of the Company for purposes of or in connection with any Transaction Document or any transaction contemplated hereby, after giving effect to all supplements thereto made prior to the Effective Date, the First Purchaser Payment Date, the Second Purchaser Payment Date or Third Purchaser Payment Date, as applicable, is or will be, taken as a whole, true, correct and complete in all material respects and the Company has not omitted to state a material fact necessary in order to make such information, taken as a whole, not misleading in light of the circumstances under which they were furnished; provided that (i) projections, estimates and other forward looking information are based on estimates believed by management to be reasonable on the date as of which such information is stated or certified and that such projections, estimates and other forward looking statements are subject to contingencies and do not constitute a representation or warrant that such projections, estimates, or other forward looking statements will be realized or attained, (ii) uncertainty is inherent in any such projections, estimates or other forward looking statements, and (iii) projections as to future events or conditions are not to be viewed as facts.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428913"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.21.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Investment Company Act.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither the Company nor any of its Subsidiaries is an &#8220;investment company&#8221; or a company &#8220;controlled&#8221; by an &#8220;investment company,&#8221; within the meaning of the Investment Company Act of 1940. </p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428914"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.22.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">OFAC; Anti-Terrorism Laws.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur079"></a><a name="_Ref_ContractCompanion_9kb9Ur07B"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">None of the Company, any Subsidiary of the Company or, to the Knowledge of the Company, any Affiliate of the Company is a Person that is, or is owned or controlled by persons that are (i) the subject of any sanctions administered or enforced by the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control, the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty&#8217;s Treasury or other relevant sanctions authority (collectively, &#8220;</font><font style="text-decoration:underline;color:#000000;">Sanctions</font><font style="color:#000000;">&#8221;) or (ii) located, organized or resident in a country or territory that is the subject of Sanctions (including, currently, the Crimea region of Ukraine, the so-called Donetsk People&#8217;s Republic, the so-called Luhansk People&#8217;s Republic, Cuba, Iran, North Korea and Syria).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur046"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each of the Company, its Subsidiaries and, to the Knowledge of the Company, their respective directors, officers, employees and agents are in compliance with all applicable Sanctions and the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#8220;</font><font style="text-decoration:underline;color:#000000;">FCPA</font><font style="color:#000000;">&#8221;) and any other applicable anti-corruption law, in all material respects.  The Company and its Subsidiaries have instituted and maintain policies and procedures designed </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">to endure continued compliance with applicable Sanctions, the FCPA and any other applicable anti-corruption law.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428915"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.23.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Broker&#8217;s Fees.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and its Subsidiaries have not taken any action that would entitle any Person to any commission or broker&#8217;s fee in connection with this Agreement.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428916"></a><font style="Background-color:#auto;text-decoration:none;">Section 3.24.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Data Privacy and Information Security.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company and its Subsidiaries maintain industry appropriate data security policies, processes, and controls and an industry appropriate privacy program, all of which comply with the requirements of Applicable Law in all material respects.&nbsp;&nbsp;None of the Company&#8217;s or any Subsidiary&#8217;s privacy statements or disclosures have been in the past five (5) years or are misleading or deceptive in any material respect, and the contemplated transactions to be consummated hereunder as of the Effective Date or on the First Purchaser Payment Date, the Second Purchaser Payment Date or the Third Purchaser Payment Date will not violate any privacy statements of the Company, other consumer-facing disclosures of the Company or, to the Knowledge of the Company any Applicable Laws, in each case in any material respect.&nbsp;&nbsp;There is not currently pending and there has not been in the past five (5) years any action, proceeding, suit or claim against the Company or its Subsidiaries with respect to privacy or data security, and, to the Knowledge of the Company, none of the Company or any Subsidiary nor any Product Assets have experienced in the past five (5) years any material security breach in which an unauthorized party accessed or acquired Personal Data, IT Assets or Confidential Information.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company and its Subsidiaries have contractually obligated all material Data Processors that process Personal Data on behalf of the Company or any of its Subsidiaries to commercially reasonable contractual terms relating to the protection and use of Personal Data and IT Assets, including without limitation obligations to comply with applicable Privacy Laws.&nbsp;&nbsp;The Company and its Subsidiaries have taken reasonable measures to ensure that all Data Processors have complied with their contractual obligations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The IT Assets are sufficient and operate and perform as is necessary to conduct the business of the Company and the Subsidiaries as currently conducted and as currently proposed to be conducted by the Company and the Subsidiaries.&nbsp;&nbsp;To the Knowledge of the Company, neither the IT Assets nor any Core Assets contain any &#8220;virus,&#8221; &#8220;spyware,&#8221; &#8220;malware,&#8221; &#8220;worm,&#8221; &#8220;Trojan horse&#8221; (as such terms are commonly understood in the software industry), disabling codes or instructions, or other similar code or software routines or components that are designed or intended to delete, destroy, disable, interfere with, perform unauthorized modifications to, or provide unauthorized access to any data, files, software, system, network, or other device.&nbsp;&nbsp;The Company and its Subsidiaries have established, implemented and tested backup and disaster recovery policies, procedures and systems consistent with generally accepted industry standards (given the nature and size of the business of the Company and its Subsidiaries), and sufficient to reasonably maintain the operation of the business of the Company and the Subsidiaries as currently conducted and as currently proposed to be conducted by the Company and the Subsidiaries.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company</font><font style="color:#000000;"> and</font><font style="color:#000000;"> its Subsidiaries have implemented and maintained reasonable and appropriate organizational, physical, administrative and technical measures consistent with the industry in which the Company operates</font><font style="color:#000000;"> and </font><font style="color:#000000;">with </font><font style="color:#000000;">the </font><font style="color:#000000;">nature and size of the business of the Company and its Subsidiaries </font><font style="color:#000000;">to protect the operation, confidentiality, integrity, and security of all Confidential Information, Personal Data and IT Assets (including, for clarity, all information and transactions stored or contained therein or transmitted thereby) against unauthorized access, acquisition, interruption, alteration, modification, or use.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company and its Subsidiaries have taken or caused to be taken all commercially reasonable precautions consistent with the nature and size of the business of the Company and its Subsidiaries to ensure that all IT Assets (i)&#160;are free from any defect, bug, virus or programming, design or documentation error or corruption or other material defect, and (ii)&#160;are fully functional and operate and run in a commercially reasonable and efficient business manner.&nbsp;&nbsp;None of the IT Assets have malfunctioned or failed or have experienced any breakdowns or continued substandard performance in the past 24 months that has caused material disruption or material interruption in the Company&#8217;s or any Subsidiary&#8217;s use thereof or to the business of the Company and the Subsidiaries.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc111294623"></a><a name="_Toc110631206"></a><a name="_Toc113428917"></a><font style="Background-color:#auto;text-decoration:none;">Article IV.</font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Toc110631206"></a><a name="_Toc113428917"></a>REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Purchaser and the Purchaser Agent represent and warrant to the Company, as of the Effective Date, the First Purchaser Payment Date, the Second Purchaser Payment Date and the Third Purchaser Payment Date, as applicable, the following:</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428918"></a><font style="Background-color:#auto;text-decoration:none;">Section 4.01.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Organization.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such Purchaser is a duly organized, validly existing and in good standing under the laws of its jurisdiction of organization and has all organizational power and all licenses, authorizations, consents and approvals required to carry on its business as now conducted and as proposed to be conducted in connection with the transactions contemplated by the Transaction Documents.&nbsp;&nbsp;Such Purchaser is duly qualified to do business and is in good standing in every jurisdiction in which the failure to do so would be reasonably expected to have a material adverse effect on such Purchaser&#8217;s performance of its obligations hereunder.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428919"></a><font style="Background-color:#auto;text-decoration:none;">Section 4.02.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Authorization.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such Purchaser has all necessary power and authority to enter into, execute and deliver the Transaction Documents and to perform all of the obligations to be performed by it hereunder and thereunder and to consummate the transactions contemplated hereunder and thereunder.  The Transaction Documents have been duly authorized, executed and delivered by such Purchaser and each Transaction Document constitutes the valid and binding obligation of such Purchaser, enforceable against such Purchaser in accordance with their respective terms, subject, as to enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights generally or general equitable principles.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428920"></a><font style="Background-color:#auto;text-decoration:none;">Section 4.03.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Broker&#8217;s Fees.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such Purchaser has not taken any action that would entitle any Person to any commission or broker&#8217;s fee in connection with the transactions contemplated by the Transaction Documents.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428921"></a><font style="Background-color:#auto;text-decoration:none;">Section 4.04.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Conflicts.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither the execution and delivery of this Agreement or any other Transaction Document to which such Purchaser is a party nor the performance or consummation of the transactions contemplated hereby or thereby will: (a) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any provisions of: (i) any law, rule or regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which such Purchaser or any of its assets or properties may be subject or bound; or (ii) any material contract, agreement, commitment or instrument to which such Purchaser is a party or by which such Purchaser or any of its assets or properties is bound or committed; (b) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, any provisions of the organizational or constitutional documents of such Purchaser; or (c) require any notification to, filing with, or consent of, any Person or Governmental Authority, except, in the case of the foregoing <font style="text-decoration:underline;">clauses (a)</font> or <font style="text-decoration:underline;">(c)</font>, as would not, individually or in the aggregate, have a material adverse effect on the ability of such Purchaser to perform any of its obligations under the Transaction Documents.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428922"></a><font style="Background-color:#auto;text-decoration:none;">Section 4.05.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Litigation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no (a) action, suit, arbitration proceeding, claim, investigation or other proceeding (whether administrative, judicial or otherwise) pending or, to the knowledge of such Purchaser, threatened against such Purchaser or (b) any governmental inquiry pending or, to the knowledge of such Purchaser, threatened against such Purchaser, which in each case with respect to <font style="text-decoration:underline;">clauses (a)</font> and <font style="text-decoration:underline;">(b)</font> above, individually or in the aggregate, would reasonably be expected to have a material adverse effect on the ability of such Purchaser to perform any of its obligations under the Transaction Documents. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428923"></a><font style="Background-color:#auto;text-decoration:none;">Section 4.06.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Financing. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such Purchaser has sufficient cash on hand to pay its Pro Rata Portion of the Purchaser Payments. Such Purchaser acknowledges that its obligations under the Transaction Documents are not contingent on obtaining financing.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428924"></a><font style="Background-color:#auto;text-decoration:none;">Section 4.07.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Access to Information.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc112589832"></a><a name="_Toc113347330"></a><a name="_Toc113428925"></a>Such Purchaser acknowledges that it has had the opportunity to review documents and information relating to the assets and business of the Company and its Subsidiaries provided to it, to review the Company&#8217;s public filings with the Securities and Exchange Commission, to request documents and ask such questions of, and to receive answers from, representatives of the Company concerning the assets of the Company and the Subsidiaries and the Company&#8217;s and the Subsidiaries&#8217; business, in each case, as it deemed necessary to make an informed decision to enter into this Agreement and the Transaction Documents.&nbsp;&nbsp;Such Purchaser has such knowledge, sophistication and experience in financial and business matters that it is capable of evaluating the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">risks and merits of entering into the transaction</font><font style="font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> contemplated by this </font><font style="font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</font><font style="font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> and the Transaction Documents</font><font style="font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428926"></a><font style="Background-color:#auto;text-decoration:none;">Section 4.08.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Investment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc112589834"></a><a name="_Toc113347332"></a><a name="_Toc113428927"></a>Such Purchaser is making this acquisition &#8220;solely for the purpose of investment,&#8221; as that term is defined under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules promulgated thereunder (including but not limited to 16 C.F.R. &#167; 801.1(i)(1)); in particular, such Purchaser (including all of its subsidiaries and Affiliates) has no intention of participating in the formulation, determination, or direction of the basic business decisions of the Company and the Subsidiaries.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc110631207"></a><a name="_Toc113428928"></a><font style="Background-color:#auto;text-decoration:none;">Article V.</font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Toc110631207"></a><a name="_Toc113428928"></a>COVENANTS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From the date hereof through and including the end of the Revenue Interest Period, the following covenants shall apply:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428929"></a><a name="_Ref_ContractCompanion_9kb9Ur134"></a><a name="_Ref_ContractCompanion_9kb9Ur136"></a><a name="_Ref_ContractCompanion_9kb9Ur138"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.01.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notices; Access; Information.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notices</font><font style="color:#000000;">.  The Company shall provide the written notice to the Purchaser Agent and the Purchasers of the following events:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Promptly (and in any event within five (5) Business Days) upon Knowledge of the Company thereof, the occurrence of any Put Option Event, any Catch Up Payment Event, and any breach or default by the Company or any Subsidiary of any covenant, agreement or other provisions of this Agreement or any other Transaction Document. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Promptly (and in any event within five (5) Business Days) upon the Knowledge of the Company thereof, the occurrence of any Material Adverse Effect or any event which would reasonably be expected to have a Material Adverse Effect;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Together with the quarterly financial statements delivered pursuant to </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 5.02(a)(i)</font><font style="color:#000000;"> to the extent such information is required to be reported to the SEC, (A) notice of entry into any new Material Contract or amendment to any Material Contract and including a copy of such Material Contract or amendment to Material Contract and, unless the Company has already publicly disclosed such information, setting forth the material terms of such Material Contract or amendment with a description of its likely impact on the Company and its Subsidiaries&#8217; business or financial condition or (B) notice of any default or event of default under, or any termination (other than expiration in accordance with its terms) of, any Material Contract, in each case either (x) occurring during the relevant fiscal quarter for which financial statements are being delivered to the extent such information is required to be reported to the SEC or (y) occurring during the relevant bi-annual period to the extent such information is not required to be filed with the SEC; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within five (5) Business Days upon Knowledge of the Company thereof to the extent required to be reported to the SEC or otherwise, on a bi-annual basis, any litigation or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">proceedings to which the </font><font style="color:#000000;">Company</font><font style="color:#000000;"> or any </font><font style="color:#000000;">Subsidiary</font><font style="color:#000000;"> is a party </font><font style="color:#000000;">of the type and materiality described in </font><font style="text-decoration:underline;color:#000000;">&#8206;</font><font style="text-decoration:underline;color:#000000;">Section 3.08</font><font style="color:#000000;"> or any material adverse </font><font style="color:#000000;">development</font><font style="color:#000000;"> in any litigation or proceeding described on </font><font style="text-decoration:underline;color:#000000;">Schedule 3.08</font><font style="color:#000000;"> to the Disclosure Letter</font><font style="color:#000000;">;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">On a bi-annual basis, any inspection by any Regulatory Agency of any facility owned or operated by the Company or its Subsidiaries. Company shall provide Purchaser with general updates of any material developments relating to any such inspection.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(vi)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within ten (10) Business Days of the Knowledge of the Company thereof to the extent required to be reported to the SEC and otherwise on a bi-annual basis, any actionable and material infringement by any Third Party of any Product Intellectual Property and any actionable and material infringement by any Product of any Third Party Intellectual Property;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(vii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within ten (10) Business Days of the occurrence thereof to the extent required to be reported to the SEC and otherwise on a bi-annual basis, the Company&#8217;s receipt of any material Regulatory Approval of any Product;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(viii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within ten (10) Business Days of the receipt to the extent required to be reported to the SEC and otherwise on a bi-annual basis, any material written communication from any Governmental Authority, including the FDA (excluding any comment letter from the SEC);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ix)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Not less than ten (10) Business Days prior thereto, any change in, or amendment or alteration of, any Obligor&#8217;s legal name, form of legal entity or jurisdiction of organization;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(x)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the extent permitted by Applicable Law, within ten (10) Business Days following receipt by the Company of any material written notice, claim or demand challenging the legality, validity, enforceability or ownership of any of the Product Intellectual Property or pursuant to which any Third Party commences or threatens (in writing) any action, suit or other proceeding against the Company and relating to the Product to the extent required to be reported to the SEC or otherwise, on a bi-annual basis, the Company shall (i) inform the Purchasers in writing of such receipt and (ii) furnish the Purchasers with a written summary describing in reasonable detail the contents thereof; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(xi)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Not less than ten (10) Business Days prior thereto, the execution of the definitive agreement for, and the consummation of, any Permitted Acquisition with Acquisition Costs in excess of $10,000,000; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(xii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Such other financial and other information as any Purchaser or the Purchaser Agent may, from time to time, reasonably request. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything to the contrary, the Company may provide to the Purchaser Agent and the Purchasers all notices and information required by <font style="text-decoration:underline;">Section&#160;5.01(a)</font> by publicly filing or furnishing such information to the SEC or otherwise making such information publicly available (e.g., a press release), in which event the Company shall be deemed to have satisfied its applicable notice obligations hereunder; <font style="text-decoration:underline;">provided</font> that the Company shall also promptly notify the Purchaser Agent of any public filing containing (x) quarterly financial statements required Section 5.02(a)(i), </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(y) annual financial statements required under Section 5.02(a)(ii) and (z) information regarding the occurrence of a Put Option Event, a Catch-Up Payment Event or a Material Breach. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything set forth above to the contrary, at any time following the Effective Date, any Purchaser may, by providing prompt written notice to the Company, instruct the Company that if any notice or report required to be furnished pursuant to this <font style="text-decoration:underline;">Section 5.01</font> or <font style="text-decoration:underline;">Section 5.02</font> contains material non-public information (any such notice, an &#8220;<font style="text-decoration:underline;">MNPI Notice</font>&#8221;), the Company shall notify the Purchaser Agent (or such other person as specified by Purchaser Agent in writing in from time to time) that the Company desires to deliver to the Purchaser Agent and Purchasers an MNPI Notice (the Company may exclude any information it deems necessary to ensure compliance with applicable securities laws).  Within five (5) Business Days of receipt of such notification, the Purchaser Agent or a Purchaser may either (i) refuse the delivery of such MNPI Notice, in which case Company&#8217;s obligations under <font style="text-decoration:underline;">Section 5.01</font> or <font style="text-decoration:underline;">Section 5.02</font>, as applicable, with respect to such MNPI Notice shall be deemed satisfied as to the Purchaser Agent or such Purchaser, as applicable, or (ii) direct the delivery of such MNPI Notice to the Purchaser Agent pursuant to procedures acceptable to the Purchaser Agent (which may be designed to comply with the internal procedures of the Purchaser Agent regarding the use of material non-public information); provided that, Purchaser Agent shall be deemed to have elected option (i) if option (ii) is not elected within such five (5) Business Day period.&nbsp;&nbsp;If the Purchaser Agent elects option (ii) above, the Company shall promptly deliver to the Purchaser Agent or such Purchaser the information subject to such MNPI Notice.  The Company shall not have any liability under this Agreement or any other Transaction Document as a result of the possession or use by Purchaser or Purchaser Agent of material non-public information delivered to it in compliance with this Agreement. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Maintenance of Books and Records</font><font style="color:#000000;">.  The Company shall keep and maintain, and cause its Affiliates to keep and maintain, at all times full and accurate books of account and records adequate to correctly reflect all payments paid and/or payable with respect to the Revenue Interests.  Such records shall be kept and maintained for a minimum of seven (7) years from the end of the calendar year to which they pertain.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur059"></a><a name="_Ref_ContractCompanion_9kb9Ur05B"></a><a name="_Ref_ContractCompanion_9kb9Ur05D"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Inspection Rights</font><font style="color:#000000;">.  The Purchaser Agent shall have the right, not more than once a year to designate a Third Party independent public accounting firm (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Purchaser Agent Representative</font><font style="color:#000000;">&#8221;) to visit the Company&#8217;s and its Subsidiaries&#8217; offices and properties where the Company and its Subsidiaries keep and maintain their books and records relating or pertaining to the Revenue Base or the Revenue Interests and the Collateral for purposes of conducting an audit of such books and records, and to inspect and audit such books and records, during normal business hours, and, upon ten (10) Business Days&#8217; prior written notice given by the Purchaser Agent to the Company, the Company will provide such Purchaser Agent Representative reasonable access to such books and records, and shall permit the Purchaser Agent Representative to discuss the matters relating or pertaining to the Revenue Interests and any Collateral with officers of the Company; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="font-style:italic;color:#000000;"> </font><font style="color:#000000;">that (i) the Purchaser Agent may not exercise this right more than one time during any year, (ii) the same period may not be audited more than once, and (iii) any audit conducted pursuant to this Agreement shall be at the Purchaser&#8217;s expense, except, in the event the audit reveals a shortfall in any Revenue Interest Payment in excess of five percent (5%) and the Company agrees with the underlying calculations evidencing such shortfall, the Company shall bear the reasonable expenses of the audit.&nbsp;&nbsp;Notwithstanding the foregoing, after the occurrence and during the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">continuance of a </font><font style="color:#000000;">Material Breach</font><font style="color:#000000;">, the </font><font style="color:#000000;">Purchaser Agent</font><font style="color:#000000;"> shall have the right, as often, at such times and with </font><font style="color:#000000;">ten (10) Business Days&#8217; </font><font style="color:#000000;">prior</font><font style="color:#000000;"> written</font><font style="color:#000000;"> notice, as the </font><font style="color:#000000;">Purchaser Agent</font><font style="color:#000000;"> shall determi</font><font style="color:#000000;">ne, in its reasonable discretion</font><font style="color:#000000;">, to have the </font><font style="color:#000000;">Purchaser Agent Representative</font><font style="color:#000000;"> review the relevant documents and records of the </font><font style="color:#000000;">Company</font><font style="color:#000000;"> and its </font><font style="color:#000000;">Subsidiaries</font><font style="color:#000000;">. </font><font style="color:#000000;">The Company shall consider in good faith any reasonable request </font><font style="color:#000000;">by the Purchaser Agent that the Company conduct an audit of a Licensee (to the extent such audit is permitted under the applicable agreement with such Licensee)</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">In the event that</font><font style="color:#000000;"> the Company conducts such audit, the Company shall, to the extent permitted by the applicable agreement with such Licensee, provide a </font><font style="color:#000000;">general summary regarding the results of such audit.&nbsp;&nbsp;The Purchaser Agent acknowledges and agrees that any such report shall be treated as Confidential Information of the Company</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Purchaser Meetings</font><font style="color:#000000;">.  During the Revenue Interest Period, the Purchasers shall be entitled to a quarterly update call or meeting (in person, via teleconference or videoconference or at a location mutually agreed upon by the Purchaser Agent and the Company) to discuss the reports delivered by the Company pursuant to </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 5.02(a)</font><font style="color:#000000;">, the progress of sales and product development and marketing efforts made by the Company and such other matters that the Purchasers reasonably request.&nbsp;&nbsp;Notwithstanding the foregoing, after the occurrence and during the continuance of a Put Option Event or a Material Breach, the Required Purchasers shall have the right, as often, at such times and with five (5) Business Days prior written notice, as the Required Purchasers shall determine, in their reasonable discretion, to have such update meetings or inspect any records and operations of the Company and its Affiliates.  </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur13A"></a><a name="_Ref_ContractCompanion_9kb9Ur13C"></a><a name="_Toc113428930"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.02.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Reports.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref112278878"></a><a name="_Ref_ContractCompanion_9kb9Ur17C"></a><a name="_Ref_ContractCompanion_9kb9Ur17E"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Periodic Reports</font><font style="color:#000000;">.  The Company shall deliver or make available (including via publicly available SEC filings) to the Purchaser Agent the following financial statements: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref112278757"></a><a name="_Ref_ContractCompanion_9kb9Ur015"></a><a name="_Ref_ContractCompanion_9kb9Ur017"></a><a name="_Ref_ContractCompanion_9kb9Ur129"></a><a name="_Ref_ContractCompanion_9kb9Ur12B"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">no later than forty-five (45) days after the last day of each fiscal quarter, (A) a Company-prepared unaudited balance sheet as of such quarter end and the related consolidated statements of operations, comprehensive income or loss, shareholders&#8217; equity and cash flows for the three (3) month period then ended certified by the chief financial officer of the Company, and (B) a statement of the Revenue Base for the period ending on the last day of such fiscal quarter and the calculation of the amount of Revenue Interest Payment due with respect to such fiscal quarter; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur019"></a><a name="_Ref_ContractCompanion_9kb9Ur01B"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">no later than ninety (90) days after the last day of each fiscal year, audited consolidated balance sheets of the Company as of such year end and the related consolidated statements of operations, comprehensive income or loss, shareholders&#8217; equity and cash flows for the year then ended, prepared under GAAP, consistently applied, together with an unqualified opinion on the financial statements from Ernst &amp; Young LLP or other independent certified public accounting firm acceptable to the Purchaser Agent in its reasonable discretion (it being understood that any firm of recognized national standing is acceptable);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">as soon as practicable, and in any event not later than sixty (60) days after the commencement of each fiscal year of the Company, beginning with the fiscal year commencing January 1, 2023, an annual business plan and budget of the Company and its Subsidiaries for the then current fiscal year;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">promptly after the furnishing thereof, copies of any material statement or report furnished to any holder of debt securities of the </font><font style="color:#000000;">Company</font><font style="color:#000000;"> or any </font><font style="color:#000000;">Subsidiary</font><font style="color:#000000;"> pursuant to the </font><font style="color:#000000;">terms</font><font style="color:#000000;"> of any indenture, loan or credit or similar </font><font style="color:#000000;">agreement</font><font style="color:#000000;">;</font><font style="color:#000000;"> and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">promptly, and in any event, within ten (10) Business Days after receipt thereof by the Company or any Subsidiary thereof, (A) copies of each notice or other correspondence received from the SEC (or comparable agency in any applicable non-U.S. jurisdiction) concerning any material inquiry or investigation of the Company or any Obligor by such agency regarding financial or other operational results of the Company or any Obligor and (B) copies of any material written correspondence or any other material written communication from the FDA or any other regulatory body.  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur048"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Updates</font><font style="color:#000000;">.  Concurrently with the delivery of financial statements pursuant to Section 5.02(a) above, the Company shall produce and deliver to the Purchaser Agent:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur17G"></a><a name="_Ref_ContractCompanion_9kb9Ur189"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the insurance binder or other evidence of insurance for any insurance coverage of the Company or any Subsidiary that was renewed, replaced or modified during the fiscal quarter covered by such financial statements; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur18B"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">an Intellectual Property Update.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428931"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.03.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Compliance with Law; Existence and Maintenance of Properties; Material Contracts; Payment of Obligations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall, and shall cause its Subsidiaries to, (i) comply with all material federal, state, local and foreign laws, regulations and orders applicable to the Company or any Subsidiary or any of their respective assets, including all Environmental Laws, (ii) obtain and maintain any and all material licenses, permits, franchises, governmental authorizations, Intellectual Property or other rights necessary for the ownership of its properties and the advantageous conduct of its business and as may be required from time to time by Applicable Law and (iii) maintain each material Regulatory Approval necessary for the Development, Manufacture, and/or Commercialization of the Products, except in the case of (i) or (ii) where the failure to do so, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall, and shall cause its Subsidiaries to, maintain and preserve in full force and effect its legal existence, its good standing under the laws of the jurisdiction of its incorporation or formation, as the case may be, and its qualification to do business in every other jurisdiction where the nature of its business or its properties makes such qualification necessary (except where the failure to be so qualified or licensed would not reasonably be expected to have a Material Adverse Effect); </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that this </font><font style="text-decoration:underline;color:#000000;">Section 5.03(b)</font><font style="color:#000000;"> shall not restrict (i) mergers among Obligors (provided if the Company is party to such a merger it shall be the surviving Person), (ii) mergers among non-Obligor Subsidiaries, (iii) mergers of non-Obligors into Obligors (provided if an Obligor is party to such a merger it shall be the surviving Person) and (iv) Transfers permitted by </font><font style="text-decoration:underline;color:#000000;">Section 5.10(a)(vi)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each of the Company and its Subsidiaries shall pay and discharge (i) prior to the date on which penalties attach thereto, all federal and state and other material Taxes imposed upon </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by the Company or its Subsidiaries, (ii) as the same shall become due and payable, all lawful claims which, if unpaid, would by law become a Lien upon its property (other than Permitted Liens), and (iii) prior to the date on which such Indebtedness shall become delinquent or in default, all </font><font style="color:#000000;">Material Indebtedness</font><font style="color:#000000;">, but subject to any subordination provisions contained in any instrument or agreement evidencing such Indebtedness.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur18F"></a><a name="_Toc113428932"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.04.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Confidentiality; Public Announcement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk112242070"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The terms and conditions set forth in Sections 1, 2, 3 and 4, and the first sentence of Section 5 of the Existing CDA are hereby incorporated by reference; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, however, that (i) references therein to &#8220;OrbiMed&#8221; shall be deemed to refer to the Purchaser Agent and any Purchaser under this Agreement, (ii) references therein to the &#8220;Permitted Purpose&#8221; shall be deemed to refer to any use of the Confidential Information as is reasonably necessary to perform any party&#8217;s obligations or exercise such party&#8217;s rights under this Agreement or any Transaction Document, and (iii) the Purchasers and the Purchaser Agent shall also be permitted to disclose any Confidential Information to potential and actual assignees of any of the Purchaser Agent&#8217;s or Purchaser&#8217;s rights hereunder and potential and actual investors in, or lenders to, such Purchaser Agent or Purchaser (including in the foregoing cases, such Person&#8217;s employees, advisors or consultants), so long as each such Person referred to in this clause (iii) shall be subject to obligations of confidentiality and non-use no less stringent than those contained in this Agreement and the Existing CDA. Each party shall treat any and all Confidential Information (as defined in the Existing CDA) that it receives from the other party in connection with this Agreement in accordance with the terms of the Existing CDA as incorporated pursuant to this </font><font style="text-decoration:underline;color:#000000;">Section 5.04(a)</font><font style="color:#000000;">. The terms of this </font><font style="text-decoration:underline;color:#000000;">Section 5.04(a)</font><font style="color:#000000;">, including the provisions of the Existing CDA incorporated herein, shall continue through the Term and for a period of three (3) years thereafter.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as required by law or the rules and regulations of any securities exchange or trading system or the FDA or any Governmental Authority with similar regulatory authority (which such disclosure shall be governed by the terms of the Existing CDA), or except with the prior written consent of the other party (which consent shall not be unreasonably withheld), no party shall issue any press release or make any other public disclosure with respect to the transactions contemplated by this Agreement or any other Transaction Document; provided, however, that the Company and the Purchaser Agent shall jointly prepare a press release for dissemination promptly following the Effective Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The rights to review, consult with or consent, as applicable and as set forth in </font><font style="text-decoration:underline;color:#000000;">Section 5.04(b)</font><font style="color:#000000;">, with respect to any disclosures shall only apply for the first time that specific information is to be disclosed, and shall not apply to the subsequent disclosure of substantially similar information that has previously been disclosed unless there have been material changes in the disclosure since the date of the previous disclosure.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428933"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.05.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Security Interest.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the Revenue Interest Period, and at all times until the Obligations are paid and performed in full (other than contingent indemnity obligations for which no claim has been made), </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">each Obligor shall grant in favor of the Purchaser Agent, for the benefit of the Purchasers, a valid, continuing, first perfected lien on and security interest in the Collateral described in the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guaranty and Security Agreement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur04E"></a><a name="_Toc113428934"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.06.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Further Assurances; Creation/Acquisition of Subsidiaries; Additional Collateral; Control Agreements.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Without limiting the obligations of the Company in the Guaranty and Security Agreement or in the other Transaction Documents, the Company hereby agrees to take such action and execute, acknowledge and deliver, and cause each of its Subsidiaries (other than Digital Biotechnologies, Inc. or any Excluded Foreign Subsidiary) to take such action and execute, acknowledge and deliver, at its sole cost and expense, such agreements, instruments or other documents as the Purchaser Agent may reasonably request from time to time in order (i) establish and maintain the validity and effectiveness of any of the Transaction Documents and carry out the purposes of this Agreement and the Transaction Documents, (ii) to subject to valid and perfected first priority Liens any of the Collateral or any other property of any Obligor and its Subsidiaries (other than Excluded Foreign Subsidiaries so long as such Subsidiaries remain Excluded Foreign Subsidiaries) intended to be Collateral hereunder free and clear of Liens (other than Permitted Liens) and to assign the Revenue Interests to the Purchasers, (iii) to establish and maintain validity, perfection and priority of the Liens intended to be created thereby (including, without limitation, making all filings and registrations) and the assignment of the Revenue Interests to the Purchasers under the Guaranty and Security Agreement, and (iv) to better assure, convey, grant, assign, transfer and confirm unto each Purchaser the rights granted to it under this Agreement or any other Transaction Document.  In furtherance of the foregoing, to the maximum extent permitted by Applicable Law, the Company authorizes the Purchaser Agent to file the UCC Financing Statements in the appropriate filing offices and any continuation statement or amendment with respect thereto without the signature of such Obligor.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company and the Purchasers shall cooperate and provide assistance as reasonably requested by the other party hereto (except as otherwise set forth herein), at the expense of such other party hereto in connection with any litigation, arbitration, investigation or other proceeding (whether threatened, existing, initiated or contemplated prior to, on or after the date hereof) to which the other party hereto, any of its Affiliates or controlling persons or any of their respective officers, directors, equityholders, controlling persons, managers, agents or employees is or may become a party or is or may become otherwise directly or indirectly affected or as to which any such Persons have a direct or indirect interest, in each case relating to any Transaction Document, the transactions contemplated herein or therein or the Revenue Interests but in all cases excluding any litigation brought by the Company or its Affiliates against the Purchaser or brought by the Purchaser (for itself or on behalf of any Indemnified Party) against the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event the Company or any of its Subsidiaries creates or acquires any Subsidiary (other than an Excluded Foreign Subsidiary), the Company shall provide written notice to the Purchaser Agent of the creation or acquisition of such new Subsidiary within ten (10) Business Days after such creation or acquisition occurs, and, if such Subsidiary holds or will hold any Collateral, promptly (and in any event no later than earlier of any Transfer of such assets to such Subsidiary and thirty (30) days after the creation or acquisition thereof), take all such action as may be reasonably required by the Purchaser Agent or any Purchaser to cause such Subsidiary </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">to become a Subsidiary Guarantor hereunder</font><font style="color:#000000;"> if required under the Transaction Documents</font><font style="color:#000000;">, including without limitation by executing and delivering </font><font style="color:#000000;">the</font><font style="color:#000000;"> Guaranty </font><font style="color:#000000;">and Security Agreement </font><font style="color:#000000;">(or a joinder thereto)</font><font style="color:#000000;"> and delivering such proof of corporate action, incumbency of officers, opinions of counsel and other documents as </font><font style="color:#000000;">reasonably </font><font style="color:#000000;">requested by the Purchaser Agent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">With respect to any Collateral acquired after the Effective Date by any Obligor that is not already subject to the Lien created by any of the Transaction Documents or specifically excluded from the requirement to be subject to such Lien in the Transaction Documents, the Company shall promptly (and in any event within thirty (30) days after the acquisition thereof) (i) execute and deliver to the Purchaser Agent such amendments or supplements to the relevant Transaction Documents or such other documents as the Purchaser Agent shall deem reasonably necessary to grant for its benefit, a Lien on such property subject to no Liens other than Permitted Liens, and (ii) take all actions necessary or reasonably advisable to cause such Lien to be duly perfected in accordance with all applicable requirements of Applicable Law, including the filing of UCC Financing Statements in such jurisdictions as may be reasonably requested by the Purchaser Agent.  The Company shall, and shall cause each other Obligor to, otherwise take such actions and execute and/or deliver to the Purchaser Agent such documents as the Purchaser Agent shall reasonably require to confirm the validity, perfection and priority of the Lien of the Guaranty and Security Agreement on such after-acquired properties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall not, and shall not permit any other Obligor to, maintain or establish any bank accounts other than the bank accounts set forth on </font><font style="text-decoration:underline;color:#000000;">Schedule 5.06(d)</font><font style="color:#000000;"> to the Disclosure Letter (which bank accounts constitute all of the deposit accounts, securities accounts or other similar accounts maintained by the Obligors on the Effective Date), unless (i) Purchaser Agent is provided at least ten (10) Business Days&#8217; prior written notice and (ii) Purchaser Agent, such Obligor and the bank or other financial institution at which the account is to be opened or maintained enter into a Control Agreement regarding such bank account within sixty (60) days following the opening of such new bank account; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that the foregoing requirement to deliver a Control Agreement shall not apply to any Excluded Account, whether now existing or opened hereafter; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">further</font><font style="color:#000000;">, that in the event that any Excluded Account ceases to be an Excluded Account it shall be subject to the requirement to deliver a Control Agreement as if such account was opened on the day it ceased to be an Excluded Account.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur18H"></a><a name="_Toc113428935"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.07.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Put Option; Call Option; Catch Up Payment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur05F"></a><a name="_Ref_ContractCompanion_9kb9Ur068"></a><a name="_Ref_ContractCompanion_9kb9Ur06A"></a><a name="_Ref_ContractCompanion_9kb9Ur06C"></a><a name="_Ref_ContractCompanion_9kb9Ur06E"></a><a name="_Ref_ContractCompanion_9kb9Ur06G"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Put Option</font><font style="color:#000000;">.  Upon the occurrence of a Put Option Event, the Required Purchasers shall have the right, but not the obligation (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Put Option</font><font style="color:#000000;">&#8221;), to require the Company to repurchase from all of the Purchasers all, but not less than all, of the Revenue Interests at the Put/Call Price.&nbsp;&nbsp;For clarity, the Required Purchasers&#8217; exercise of the Put Option shall be binding upon all of the Purchasers.  In addition, upon the occurrence of a Put Option Event, the Purchaser Agent may, and at the direction of the Required Purchasers shall, terminate the Purchaser Commitments.  In the event that the Required Purchasers elect to exercise the Put Option, the Required Purchasers shall, or shall direct the Purchaser Agent to, deliver written notice to the Company specifying the closing date which date shall be no earlier than sixty (60) days after the Company&#8217;s receipt of notice (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Put Option Closing Date</font><font style="color:#000000;">&#8221;).  On the Put Option Closing Date, the Company shall repurchase from the Purchasers the Revenue Interests at the Put/Call Price in cash, the payment of which shall be made by wire transfer of immediately available funds to the account designated by the Purchasers.  </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Notwithstanding anything to the contrary contained herein, immediately upon the occurrence of a Bankruptcy Event, each Purchaser shall be deemed to have automatically and simultaneously elected to terminate the Purchaser Commitments and have the Company repurchase from such Purchaser the Revenue Interests for the Put/Call Price in cash and the Purchaser Commitments shall immediately terminate and the Put/Call Price shall be immediately due and payable without any further action or notice by any party. </font><font style="color:#000000;"> </font><font style="color:#000000;">For the avoidance of doubt, </font><font style="color:#000000;">the Required Purchasers&#8217;</font><font style="color:#000000;"> election not to exercise the Put Option with respect to a given Put Option Event will not preclude </font><font style="color:#000000;">the Required </font><font style="color:#000000;">Purchaser</font><font style="color:#000000;">s</font><font style="color:#000000;"> from exercising the Put Option with respect to a continuing or subsequent Put Option Event.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur028"></a><a name="_Ref_ContractCompanion_9kb9Ur035"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Call Option</font><font style="color:#000000;">.  At any time after the First Purchaser Payment Date, the Company shall have the right, but not the obligation (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Call Option</font><font style="color:#000000;">&#8221;), exercisable upon up to ninety (90) days&#8217; written notice to the Purchasers, to repurchase, all, but not less than all, of the Revenue Interests from the Purchasers at a repurchase price equal to the Put/Call Price; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that such written notice delivered by the Company may state that such notice is conditioned upon the effectiveness of other credit facilities or the receipt of the proceeds from the issuance of other Indebtedness, or the occurrence of some other financing or acquisition, in which case such notice may be revoked by the Company (by notice to the Purchaser Agent prior to the specified effective date of the Call Option) if such condition is not satisfied.  In order to exercise the Call Option, the Company shall deliver written notice to the Purchaser Agent and Purchasers of its election to so repurchase the Revenue Interests not less than ten (10) days prior to the proposed closing date (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Call Closing Date</font><font style="color:#000000;">&#8221;).  Upon delivery of such notice all Purchaser Commitments shall terminate and on the Call Closing Date, the Company shall repurchase from the Purchasers the Revenue Interests at the Put/Call Price, the payment of which shall be made by wire transfer of immediately available funds to the account designated by the Purchasers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Catch Up Payment</font><font style="color:#000000;">.&nbsp;&nbsp;Upon the occurrence of a Catch Up Payment Event, the Required Purchasers shall have the right, but not the obligation (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Catch Up Payment Option</font><font style="color:#000000;">&#8221;), to require the Company to make the Catch Up Payment to the Purchaser Agent, for the account of the Purchasers.&nbsp;&nbsp;For clarity, the Required Purchasers&#8217; exercise of the Catch Up Payment Option shall be binding upon all of the Purchasers. In the event that the Required Purchasers elect to exercise the Catch Up Payment Option, the Required Purchasers shall, or shall direct the Purchaser Agent to, deliver written notice to the Company specifying the closing date which date shall be no earlier than sixty (60) days after the Company&#8217;s receipt of such notice (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Catch Up Payment Date</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;On the Catch Up Payment Date, the Company shall make the Catch Up Payment to the Purchaser Agent, for the account of the Purchasers, in cash, by wire transfer of immediately available funds to the account designated by the Purchaser Agent. For the avoidance of doubt, the Required Purchasers&#8217; election not to exercise the Catch Up Payment Option with respect to a given Catch Up Payment Event will not preclude the Required Purchasers from exercising the Catch Up Payment Option with respect to a continuing or subsequent Catch Up Payment Event.&nbsp;&nbsp;The rights of the Purchasers under this </font><font style="text-decoration:underline;color:#000000;">Section 5.07(c)</font><font style="color:#000000;"> are in addition to any rights or remedies of the Purchasers hereunder, including under </font><font style="text-decoration:underline;color:#000000;">Section 8.04</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Purchaser Remedies</font><font style="color:#000000;">.  Upon (x) the exercise of the Put Option, unless payment of the Put/Call Price has been made when due or (y) the exercise of the Catch Up Payment Option, unless payment of the Catch Up Payment has been made when due, in each case the Purchaser Agent and the Purchasers may exercise all rights and remedies available to the Purchaser Agent </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">and the Purchasers as a creditor hereunder and under the other Transaction Documents and Applicable Law (which exercise may be determined in its sole discretion and which such exercise shall not constitute an election of remedies), including enforcement of the Liens created thereby. </font><font style="color:#000000;"> </font><font style="color:#000000;">For the avoidance of doubt the Put/Call Price shall be due and payable (in the case of an exercise of the Put Option or Call Option, as set forth in this </font><font style="text-decoration:underline;color:#000000;">&#8206;</font><font style="text-decoration:underline;color:#000000;">Section 5.07</font><font style="color:#000000;">) at any time the Put Option or the Call Option is exercised or the Obligations are otherwise accelerated </font><font style="color:#000000;">for any reason, whether due to acceleration pursuant to the terms of this Agreement, by operation or law or otherwise </font><font style="color:#000000;">(including </font><font style="color:#000000;">where bankruptcy filings or the exercise of any bankruptcy right or power, whether in any plan of reorganization or otherwise, results or would result in a payment, discharge, modification or other treatment of the Revenue Interests that would otherwise evade, avoid, or otherwise disappoint the expectations of the Purchasers in receiving the full benefit of their bargained-for Put/Call Price</font><font style="color:#000000;">)</font><font style="color:#000000;">.</font><font style="color:#000000;"> </font><font style="color:#000000;"> The Company and the Purchasers acknowledge and agree that none of the Put/Call Price shall constitute unmatured interest</font><font style="color:#000000;">, whether</font><font style="color:#000000;"> under </font><font style="color:#000000;">Section 502(b)(2) </font><font style="color:#000000;">of the United States Bankruptcy Code, but instead</font><font style="color:#000000;"> </font><font style="color:#000000;">shall constitute the liquidated damages sustained by the Purchasers as a result of the acceleration or prepayment of the Obligations and</font><font style="color:#000000;"> is reasonably calculated </font><font style="color:#000000;">under the circumstances currently existing </font><font style="color:#000000;">to ensure that the Purchasers receive the benefit of their bargain under the terms of this Agreement. </font><font style="color:#000000;"> </font><font style="color:#000000;">The Company acknowledges and agrees that the Purchasers shall be entitled to recover the full amount of the Put/Call Price </font><font style="color:#000000;">in each and every circumstance such amount is due pursuant to or in connection with this Agreement</font><font style="color:#000000;">, so that the Purchasers shall receive the benefit of their bargain hereunder and otherwise receive full recovery as agreed under every possible circumstance, and, to the fullest extent permitted by maximum law, the Company hereby waives any defense to payment, whether such defense may be based in public policy, ambiguity, or otherwise. </font><font style="color:#000000;"> </font><font style="color:#000000;">The Company further acknowledges and agrees, and, to the fullest extent permitted by maximum law, waives any argument to the contrary, that payment of such amounts does not constitute a penalty or an otherwise unenforceable or invalid obligation. </font><font style="color:#000000;"> </font><font style="color:#000000;">The Company expressly agrees tha</font><font style="color:#000000;">t (</font><font style="color:#000000;">i</font><font style="color:#000000;">) payment of any Put/Call P</font><font style="color:#000000;">rice </font><font style="color:#000000;">and any </font><font style="color:#000000;">Catch Up Payment </font><font style="color:#000000;">is</font><font style="color:#000000;"> reasonable and is the</font><font style="color:#000000;"> product of an arm&#8217;s-length transaction between sophisticated business people, ably represented by counsel,</font><font style="color:#000000;"> (ii) payment of any Put/Call Price </font><font style="color:#000000;">and any </font><font style="color:#000000;">Catch Up Payment </font><font style="color:#000000;">shall be payable notwithstanding the then prevailing market rates at the time payment is made, (iii) there has been a course of conduct between the P</font><font style="color:#000000;">urchasers and the Company giving specific consideration in this transaction for such agreement </font><font style="color:#000000;">to pay the Put/Call Price</font><font style="color:#000000;"> </font><font style="color:#000000;">and </font><font style="color:#000000;">any Catch Up Payment</font><font style="color:#000000;">, (iv) the Company shall be estopped hereafter from claiming differently than as agreed to in thi</font><font style="color:#000000;">s </font><font style="text-decoration:underline;color:#000000;">&#8206;</font><font style="text-decoration:underline;color:#000000;">Section 5.07</font><font style="color:#000000;">, (v) the Company&#8217;s agreement </font><font style="color:#000000;">to pay any Put/Call Price</font><font style="color:#000000;"> </font><font style="color:#000000;">and </font><font style="color:#000000;">any </font><font style="color:#000000;">Catch Up Payment </font><font style="color:#000000;">is a material inducement to the Purchasers to fund the Purchase </font><font style="color:#000000;">Payments</font><font style="color:#000000;">, and</font><font style="color:#000000;"> (vi) the Put/Call Price</font><font style="color:#000000;"> represent</font><font style="color:#000000;">s</font><font style="color:#000000;"> a good faith, reasonable estimate and calculation of the lost profits, losses or other damages of the Purchasers and that it would be impractical and extremely difficult to ascertain the actual amount of damages to the Purchasers or profits lost by the Purchasers as a result of such event.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">Any damages that the Purchasers may suffer or incur resulting from or arising in connection with any breach hereof or thereof by the Company shall constitute secured </font><font style="color:#000000;">O</font><font style="color:#000000;">bligations owing to the Purchasers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Rights Not Exclusive</font><font style="color:#000000;">.  The rights provided for herein are cumulative and are not exclusive of any other rights, powers, privileges or remedies provided by this Agreement or Applicable Law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Obligations of Purchaser Agent</font><font style="color:#000000;">.  In connection with the consummation of a repurchase of the Revenue Interests pursuant to the Put Option or the Call Option, the Purchaser </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Agent agrees that it will</font><font style="color:#000000;">, at the cost and expense of the Company, </font><font style="color:#000000;">concurrently with receipt by each Purchaser of payment in full of its Pro Rata Portion of the Put/Call Price (</font><font style="color:#000000;">i</font><font style="color:#000000;">) execute and deliver to the Company such UCC termination statements and other documents as may be necessary to release the Purchaser Agent&#8217;s Lien on the Collateral and otherwise give effect to such repurchase and (ii) take such other actions or provide such other assistance as may be necessary to give effect to such repurchase.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428937"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.08.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Intellectual Property; Regulatory Approvals.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall, at its sole expense, either directly or by causing any Subsidiary or Licensee (subject to all restrictions and limitations contained in any applicable license agreement) to do so, use commercially reasonable efforts (including taking legal action to specifically enforce the applicable terms of any License) to prepare, execute, deliver and file any and all agreements, documents or instruments which are necessary to diligently maintain the Material Patents.&nbsp;&nbsp;The Company shall use commercially reasonable efforts to diligently prosecute all patent applications corresponding to the Material Patents with the intent to protect the Products, where the Company has the right to control such prosecution and subject to the Company&#8217;s disclaimer and abandonment right pursuant to the last sentence of this Section 5.08(a).&nbsp;&nbsp;The Company shall use commercially reasonable efforts to diligently defend or assert all Product Intellectual Property against infringement or interference by any other Persons, and against any claims of invalidity or unenforceability (including, without limitation, by bringing any legal action for infringement or defending any claim of invalidity or action of a Third Party for declaratory judgment of non-infringement or non-enforceability), except where the Company does not have the right, contractually or otherwise, to take such actions or where the failure to do so would not reasonably be expected to result in a Material Adverse Effect.&nbsp;&nbsp;The Company shall not disclaim or abandon, or fail to take any action necessary to prevent the disclaimer or abandonment of, the Material Patents, except in the ordinary course of business or where the failure to do so would not reasonably be expected to result in a Material Adverse Effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall directly, or through a Subsidiary or Licensee (subject to all restrictions and limitations contained in any applicable license agreement), take all actions and prepare, execute, deliver and file all agreements, documents or instruments to secure and maintain, all required Regulatory Approvals held or proposed to be held by the Company or a Subsidiary, except where the failure to do so would not reasonably be expected to result in a Material Adverse Effect.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Neither the Company nor any of its Subsidiaries shall enter into any License (other than agreements described in the definition of Permitted Licenses).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428938"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.09.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Use of Proceeds.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company shall (i) use the proceeds of the First Payment and the Second Payment for general corporate and working capital purposes and to pay fees and expenses in connection with this Agreement and (ii) use the proceeds of the Third Payment for Permitted Acquisitions completed after the Effective Date and fees and expenses in connection with such Permitted Acquisitions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428939"></a><font style="text-decoration:none;Background-color:#auto;">Section 5.10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Protective Covenants.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Neither the Company nor any of its Subsidiaries shall, without the prior written consent of the Purchaser Agent:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">create, incur, assume or suffer to exist any Indebtedness, except for Permitted Indebtedness;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">create, incur, assume or suffer to exist any Lien upon any property or assets of any kind (real or personal, tangible or intangible) of the Company and its Subsidiaries, or agree to do or suffer to exist any of the foregoing, except for Permitted Liens;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">declare or make, directly or indirectly, any Restricted Payment, except that:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(A)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">each Subsidiary may make Restricted Payments to any Obligor;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(B)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Company and each Subsidiary may declare and make dividend payments or other distributions payable solely in the Qualified Equity Interests of such Person;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(C)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Company may make Restricted Payments to current or former employees, officers or directors in connection with employee stock plans, employee stock option agreements, performance stock unit award agreements, retention stock unit award agreements and non-incentive stock-option agreements (including with respect to any withholding of a portion of such Qualified Equity Interests in connection therewith to cover withholding tax obligations in respect of such issuance); and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(D)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Company and any Subsidiary may make other Restricted Payments in an amount not to exceed $5,000,000 in any fiscal year; </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">[Reserved];</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">amend, modify or change its Organization Documents in a manner materially adverse to the rights or remedies of the Purchaser Agent or the Purchasers under the Transaction Documents;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(vi)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Transfer any Collateral, other than:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(A)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the use of cash and cash equivalents, the disposition of inventory and the disposition of obsolete, worn-out or surplus equipment, in each case in the ordinary course of business;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(B)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the incurrence of Permitted Liens;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(C)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the entry into Permitted Licenses;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(D)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">a Transfer to the Company or any other Obligor;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(E)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">leases or subleases of real property in the ordinary course of business;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(F)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the sale or discount without recourse of accounts receivable arising in the ordinary course of business in connection with the compromise or collection thereof; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(G)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the abandonment, cancellation, non-renewal or discontinuance of use or maintenance of immaterial Intellectual Property (or rights relating thereto) that the Company reasonably determines in good faith, and, in respect of immaterial Intellectual Property related to any Core Asset, after reasonable consultation with the Purchaser Agent only where the Company reasonably determines that such abandonment, cancellation, non-renewal or discontinuance of use or maintenance would not reasonably be expected to have a Material Adverse Effect, is desirable in the conduct of its business; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(H)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Transfers of Non-Core Assets. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(vii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">change its fiscal year end (other than, in the case of any Subsidiary, to conform to the Company&#8217;s fiscal year end); </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(viii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">make any Investment in Digital Biotechnologies, Inc. after the Effective Date in an amount exceeding $20,000,000 in the aggregate at any time, unless Digital Biotechnologies, Inc. becomes a Subsidiary Guarantor and its assets become part of the Collateral. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall not take any action or engage in any transaction (or series of actions or transactions), whether by reorganization, Transfer of assets, merger, dissolution, amendment of organizational documents or otherwise, the primary purpose of which is to evade, avoid or seek to avoid the performance or observance of the covenants, agreements or obligations of the Company under the Transaction Documents.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428940"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.11.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Insurance; Landlord Waivers; Control Agreements.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall maintain the current insurance policies with its current insurance companies or comparable policies with comparable insurance companies consistent with industry standards. The Company will furnish to the Purchaser Agent certificates evidencing all such insurance policies required to be maintained pursuant to this Section and, subject to clause (b) below, endorsements naming the Purchaser Agent, for the benefit of itself and the Purchasers, as lender loss payee (in the case of property/casualty insurance and business interruption insurance) and additional insured (in the case of liability insurance), as applicable, and providing that no cancellation or modification as to the scope of coverage of the policies will be made without providing at least 30 days prior written thereof to the Purchaser Agent. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within ninety (90) days following the Effective Date (or such later date as may be reasonably agreed to by the Purchaser Agent), the Company shall furnish to the Purchaser Agent the insurance endorsements required under </font><font style="text-decoration:underline;color:#000000;">Section 5.11(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within ninety (90) days following the Effective Date (or such later date as may be reasonably agreed to by the Purchaser Agent), the Company shall use reasonable best efforts to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">provide to the Purchaser Agent a landlord waiver and collateral access agreement </font><font style="color:#000000;">with regard to</font><font style="color:#000000;"> each of the Company&#8217;s locations set forth in the Perfection Certificate.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within ninety (90) days following the Effective Date (or such later date as may be reasonably agreed to by the Purchaser Agent), the Company shall use reasonable best efforts to provide to the Purchaser Agent Control Agreements, duly executed by the financial institution or other Person at which such account is maintained or with which such entitlement or contract is carried and the Obligor maintaining such account, in respect of each of the deposit accounts and securities accounts of the Company and the Subsidiary Guarantors (other than Excluded Accounts).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc110989612"></a><a name="_Toc113428941"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.12.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Taxes.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Tax Returns</font><font style="color:#000000;">.&nbsp;&nbsp;The Company shall timely file (taking into account all extensions of due dates) all income and all other material Tax Returns required to be filed by it and will pay all Taxes shown as due thereon.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Intended Tax Treatment</font><font style="color:#000000;">.&nbsp;&nbsp;The Purchasers and the Company agree that (i) the transactions contemplated by this Agreement are intended to constitute and shall be treated by the parties as a debt instrument for U.S. federal and applicable state and local income tax purposes, and (ii) the yield on such debt instrument shall be determined assuming that the Revenue Interest Period will end when the Purchasers have received the Return Cap (and, as applicable, that the Put/Call Price will be determined pursuant to </font><font style="text-decoration:underline;color:#000000;">clause (d)</font><font style="color:#000000;"> of the definition thereof) (</font><font style="text-decoration:underline;color:#000000;">clauses (i) and (ii)</font><font style="color:#000000;">, the &#8220;</font><font style="text-decoration:underline;color:#000000;">Intended Tax Treatment</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;None of the Purchasers or the Company shall take any Tax position inconsistent with the foregoing unless otherwise required by a determination within the meaning of Section 1313(a) of the Code.&nbsp;&nbsp;UPON WRITTEN REQUEST BY A PURCHASER TO THE COMPANY&#8217;S CHIEF FINANCIAL OFFICER, THE COMPANY WILL PROMPTLY MAKE AVAILABLE TO SUCH PURCHASER THE ISSUE PRICE, THE AMOUNT OF ORIGINAL ISSUE DISCOUNT, THE ISSUE DATE, THE YIELD TO MATURITY OF SUCH DEBT INSTRUMENT, THE COMPARABLE YIELD AND PROJECTED PAYMENT SCHEDULE. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur19A"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">IRS Withholding Form</font><font style="color:#000000;">.&nbsp;&nbsp;On or prior to the Effective Date, each Purchaser (or, if Purchaser is a disregarded entity, its sole owner) shall deliver to the Company, a duly completed and valid IRS Form W-9 certifying that such Purchaser is a United States person, as such term is defined in Section 7701(a)(30) of the Code, that is exempt from U.S. federal backup withholding (the &#8220;</font><font style="text-decoration:underline;color:#000000;">IRS Withholding Form</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur158"></a><a name="_Ref_ContractCompanion_9kb9Ur15A"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Withholding</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Provided</font><font style="color:#000000;"> that each Purchaser satisfies its obligation to deliver the IRS Withholding Form to the Company pursuant to paragraph &#8206;(c) of this </font><font style="text-decoration:underline;color:#000000;">Section 5.12</font><font style="color:#000000;">, the parties hereto acknowledge and agree that all amounts payable hereunder shall be paid without deduction or withholding for any U.S. federal income Taxes pursuant to any Applicable Law in effect on the Effective Date.&nbsp;&nbsp;If any Purchaser does not deliver to the Company the IRS Withholding Form described in paragraph &#8206;(c) of this </font><font style="text-decoration:underline;color:#000000;">Section 5.12</font><font style="color:#000000;">, except as and to the extent set forth in </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 5.12(d)(ii)</font><font style="color:#000000;">, such Purchaser will indemnify and hold the Company harmless </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">against any Taxes that are determined to have been required to be withheld pursuant to a determination within the meaning of </font><font style="color:#000000;">Section 1313(a)</font><font style="color:#000000;"> of the Code, but that, in accordance with the Intended Tax Treatment, were not withheld in respect of any payment made pursuant to this Agreement.&nbsp;&nbsp;Upon the occurrence of an event described in the last sentence of </font><font style="text-decoration:underline;color:#000000;">&#8206;</font><font style="text-decoration:underline;color:#000000;">Section 5.12(d)(ii)</font><font style="color:#000000;">, if the Purchaser determines in good faith that a reasonable basis exists for contesting any such Taxes required to be withheld by the Company, the Company shall use commercially reasonable efforts to cooperate with such Purchaser in challenging such Tax at the Purchaser&#8217;s expense, if so requested by the Purchaser.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur02A"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event of a Change in Law and in the absence of a Challenge Event, to the extent any amount of Tax is required to be withheld in respect of a payment made pursuant to this Agreement, including by a Purchaser to its Tax Affiliate (other than in respect of (i) Taxes imposed on or measured by net income (however denominated), franchise Taxes and branch profits Taxes, in each case imposed as a result of such Purchaser&#8217;s (or, if applicable, its Tax Affiliate&#8217;s) being organized under the laws of, having its principal office or lending office in, or otherwise having a present or former connection with (other than solely as a result of the transactions contemplated by this Agreement), the jurisdiction (or any political subdivision thereof) imposing such Tax, and (ii) withholding Taxes imposed under FATCA), the sum payable by the Company to such Purchaser shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section), such Purchaser and, as applicable, its Tax Affiliate receive an amount equal to what they would have received had no such deduction or withholding been made.&nbsp;&nbsp;For the avoidance of doubt, and notwithstanding anything to the contrary in the Agreement, (i) a challenge by a taxing authority to the Intended Tax Treatment based on the application of any Applicable Law in effect on the Effective Date to facts existing on the Effective Date, or (ii) a public pronouncement made or regulation promulgated by a taxing authority (or any other administrative decision or court decision) interpreting any Applicable Law in effect on the Effective Date as it would apply to facts existing on the Effective Date in a manner directly contrary to the Intended Tax Treatment (a determination within the meaning of Section 1313(a) of the Code with respect to an event described in </font><font style="text-decoration:underline;color:#000000;">clause (i)</font><font style="color:#000000;">, and an event described in </font><font style="text-decoration:underline;color:#000000;">clause (ii)</font><font style="color:#000000;">, each a &#8220;</font><font style="text-decoration:underline;color:#000000;">Challenge Event</font><font style="color:#000000;">&#8221;), shall not be a Change in Law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur19C"></a><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If any Purchaser (or, if applicable, its Tax Affiliate) determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which amounts payable to it have been increased pursuant to this Section, it shall pay to the Company an amount equal to such refund (but only to the extent of payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such Purchaser (or, if applicable, its Tax Affiliate) and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund).&nbsp;&nbsp;Notwithstanding anything to the contrary in this </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 5.12(d)(iii)</font><font style="color:#000000;">, in no event will a Purchaser be required to pay any amount to the Company pursuant to this </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 5.12(d)(iii)</font><font style="color:#000000;"> the payment of which would place the Purchaser in a less favorable net after-Tax position than the Purchaser would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the additional amounts with respect to such Tax had never been paid.&nbsp;&nbsp;This paragraph shall not be construed to require any Purchaser to make available its Tax Returns (or any other information relating to its Taxes that it deems confidential) to the Company or any other Person.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding anything to the contrary in this Agreement, if a Withholding Action is taken by a Purchaser (or its assignee or successor), the Company shall be required to pay additional amounts pursuant to this </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 5.12(d)</font><font style="color:#000000;"> only to the extent that the Company would have been required to pay such additional amounts pursuant to </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 5.12(d)(ii)</font><font style="color:#000000;"> (including with respect to a Tax Affiliate of such Person) if such Person had not taken such Withholding Action.&nbsp;&nbsp;For purposes of this </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 5.12(d)</font><font style="color:#000000;">, &#8220;</font><font style="text-decoration:underline;color:#000000;">Withholding Action</font><font style="color:#000000;">&#8221; means (i) a permitted assignment under this Agreement (in whole or in part) by a Purchaser to an Affiliate or Third Party that is tax resident in a country other than the United States; and (ii) a change of tax residency of a Purchaser to a country other than the United States.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If any Purchaser is entitled to additional amounts pursuant to this </font><font style="text-decoration:underline;color:#000000;">Section 5.12</font><font style="color:#000000;">, then such Purchaser shall use commercially reasonable efforts to assign its rights and obligations hereunder to another of its Affiliates or a Third Party, if, in the reasonable judgment of such Purchaser, such assignment (i) would eliminate or reduce amounts payable pursuant to this </font><font style="text-decoration:underline;color:#000000;">Section 5.12</font><font style="color:#000000;"> in the future, and (ii) would not subject such Purchaser to any unreimbursed cost or expense and would not otherwise be economically disadvantageous to such Purchaser.&nbsp;&nbsp;The Company hereby agrees to pay all reasonable costs and expenses incurred by any Purchaser in connection with any such assignment.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:8.65%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428942"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.13.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Digital Biotechnologies.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;Digital Biotechnologies, Inc. does not, and will not, own any Core Asset (without giving effect to the last sentence of the definition of &#8220;Core Asset&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:8.65%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428943"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.14.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"><a name="_Toc113428943"></a> </font><font style="color:#000000;">Additional Secured Indebtedness</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc113347348"></a><a name="_Toc113428944"></a><a name="_cp_text_2_345"></a><a name="_cp_text_1_346"></a><a name="_cp_text_2_347"></a><a name="_cp_text_1_349"></a><a name="_cp_text_2_350"></a><a name="_cp_text_1_351"></a><a name="_cp_text_2_352"></a><a name="_cp_text_1_353"></a><a name="_cp_text_2_354"></a><a name="_cp_text_2_355"></a><a name="_cp_text_1_356"></a><a name="_cp_text_2_358"></a><a name="_cp_text_1_359"></a><a name="_cp_text_2_360"></a><a name="_cp_text_1_361"></a>If the Company engages in negotiations with any Third Party in connection with incurring any Indebtedness pursuant to clause (q) of the definition of Permitted Indebtedness (&#8220;<font style="text-decoration:underline;">Additional Secured Indebtedness</font>&#8221;), the Company<a name="_cp_text_2_345"></a> shall give written notice to the Purchaser Agent, such notice setting out all material conditions and terms of such financing&nbsp;&nbsp;(the &#8220;<font style="text-decoration:underline;">Original Terms</font>&#8221;) as proposed by such Third Party (the &#8220;<font style="text-decoration:underline;"><a name="_cp_text_1_346"></a>ROFN Notice</font>&#8221;).&nbsp;&nbsp;The Purchaser Agent shall have the right, within 10 calendar days after its receipt of the ROFN<a name="_cp_text_2_347"></a> Notice, to propose its terms and conditions for advancing Additional Secured Indebtedness to the Company (the &#8220;<font style="text-decoration:underline;"><a name="_cp_text_1_349"></a>ROFN Proposal</font>&#8221;).&nbsp;&nbsp;If the Purchaser Agent<a name="_cp_text_2_350"></a> <a name="_cp_text_1_351"></a>proposes equivalent or more favorable (in the aggregate) terms and conditions in its ROFN Proposal to the Company within 10 calendar days after receipt of the ROFN Notice, the Company<a name="_cp_text_2_352"></a> will <a name="_cp_text_1_353"></a>suspend negotiations with such Third Party for 45 additional calendar days after the ROFN<a name="_cp_text_2_354"></a> Proposal to provide ample time for the Company and the Purchaser Agent to document the terms and conditions of the Additional Secured Indebtedness.&nbsp;&nbsp;If (a) the Purchaser Agent<a name="_cp_text_2_355"></a> fails to <a name="_cp_text_1_356"></a>propose equivalent or more favorable (in the aggregate) terms and conditions within 10 calendar days after receipt of the ROFN Notice, or (b) the Purchaser Agent and the Company<a name="_cp_text_2_358"></a> fail to enter into <a name="_cp_text_1_359"></a>an agreement within 45 calendar days after receipt by the Company of a ROFN<a name="_cp_text_2_360"></a> Proposal from the Purchaser Agent<a name="_cp_text_1_361"></a> with equivalent or more favorable (in the aggregate) terms, the Company shall have the right to negotiate with and enter into any agreement for incurring Additional Secured Indebtedness on the Original Terms.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:8.65%;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428945"></a><font style="Background-color:#auto;text-decoration:none;">Section 5.15.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Supplements to Disclosure Letter. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:8.65%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc113428946"></a>In connection with the Company&#8217;s delivery to the Purchaser Agent of an officer&#8217;s certificate certifying as to the conditions in <font style="text-decoration:underline;">&#8206;Section 2.03(b)(vi)(A)</font> and <font style="text-decoration:underline;">(B)</font>, the Company shall have the right (but not the obligation) to supplement or amend the Disclosure Letter with respect to any matter arising on or prior to the date the Company delivers such officer&#8217;s certificate; <font style="text-decoration:underline;">provided</font> that if the Company exercises such right to supplement or amend the Disclosure Letter (except for (i) supplements or amendments to Schedule 3.13 (Material Contracts<font style="color:#auto;">) or (ii) any other supplement or amendment to the Disclosure Letter (except for any supplement or amendment related to </font><font style="text-decoration:underline;color:#auto;">Section 3.07</font><font style="color:#auto;">, </font><font style="text-decoration:underline;color:#auto;">Section 3.16</font><font style="color:#auto;">, </font><font style="text-decoration:underline;color:#auto;">Section 3.21</font><font style="color:#auto;">, or </font><font style="text-decoration:underline;color:#auto;">Section 3.22</font><font style="color:#auto;">) so long as the information or event underlying such other supplement or amendment does not relate to an event or circumstance which would</font><font style="font-weight:bold;"> </font>reasonably be expected to give rise to a Material Adverse Effect), each Purchaser may, in its sole discretion, have the option not to make its Pro Rata Portion of the Second Payment or Third Payment, as applicable. Any such update to the Disclosure Letter shall not be effective with respect to any period prior to the date that such supplemented or amended Disclosure Letter is delivered to the Purchaser Agent.&nbsp;&nbsp; </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc111294646"></a><a name="_Toc111294647"></a><a name="_Toc110631208"></a><a name="_Toc113428947"></a><font style="Background-color:#auto;text-decoration:none;">Article VI.</font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Toc110631208"></a><a name="_Toc113428947"></a>TERMINATION</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur07F"></a><a name="_Ref_ContractCompanion_9kb9Ur07H"></a><a name="_Ref_ContractCompanion_9kb9Ur08A"></a><a name="_Ref_ContractCompanion_9kb9Ur08C"></a><a name="_Ref_ContractCompanion_9kb9Ur08E"></a><a name="_Toc113428948"></a><font style="Background-color:#auto;text-decoration:none;">Section 6.01.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as provided in this <font style="text-decoration:underline;">&#8206;Section 6.01</font> and in <font style="text-decoration:underline;">&#8206;Section 6.02</font>, this Agreement shall terminate upon expiration of the Revenue Interest Period (the &#8220;<font style="text-decoration:underline;">Term</font>&#8221;).  If any Reimbursable Expenses payments are required to be made by one of the parties hereunder after that date, this Agreement shall remain in full force and effect until any and all such payments have been made in full, and (except as provided in Section 6.02) solely for that purpose. In addition, this Agreement shall sooner terminate if the Purchasers shall have exercised the Put Option in accordance with <font style="text-decoration:underline;">&#8206;Section 5.07(a)</font> or the Company shall have exercised the Call Option in accordance with <font style="text-decoration:underline;">&#8206;Section 5.07(b)</font>, in each case upon the payment of the Put/Call Price and any other Obligations (other than contingent indemnity obligations for which no claim has been made).</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur15C"></a><a name="_Ref_ContractCompanion_9kb9Ur15E"></a><a name="_Ref_ContractCompanion_9kb9Ur167"></a><a name="_Toc113428949"></a><font style="Background-color:#auto;text-decoration:none;">Section 6.02.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Effect of Termination.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of the termination of this Agreement pursuant to <font style="text-decoration:underline;">&#8206;Section 6.01</font>, this Agreement shall forthwith become void and have no effect without any liability on the part of any party hereto or its Affiliates, directors, officers, equityholders, partners, managers or members other than the provisions of this <font style="text-decoration:underline;">&#8206;Section 6.02</font>, <font style="text-decoration:underline;">&#8206;Section 5.04</font>, <font style="text-decoration:underline;">Article VII</font> and <font style="text-decoration:underline;">Article VIII</font> hereof, which shall survive any termination indefinitely, and <font style="text-decoration:underline;">Section 5.01(b)</font>, and <font style="text-decoration:underline;">&#8206;Section 5.01(c)</font>, which shall survive for three (3) years after any termination.&nbsp;&nbsp;Nothing contained in this <font style="text-decoration:underline;">&#8206;Section 6.02</font> shall relieve any party from liability for any breach of this Agreement.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc110631209"></a><a name="_Toc113428950"></a><font style="Background-color:#auto;text-decoration:none;">Article VII.</font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /><br /><a name="_Toc110631209"></a><a name="_Toc113428950"></a>PURCHASER AGENT</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428951"></a><font style="Background-color:#auto;text-decoration:none;">Section 7.01.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Appointment and Authority.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of the Purchasers hereby irrevocably appoints OrbiMed Royalty &amp; Credit Opportunities IV, LP (together with any successor Purchaser Agent pursuant to <font style="text-decoration:underline;">&#8206;Section 7.06</font>) as the Purchaser Agent hereunder and authorizes Purchaser Agent to (i) execute and deliver the Transaction Documents and accept delivery thereof on its behalf from the Company or any of its Subsidiaries, (ii) take such action on its behalf and to exercise all rights, powers and remedies and perform the duties as are expressly delegated to the Purchaser Agent under such Transaction Documents, (iii) act as agent of such Purchaser for purposes of acquiring, holding, enforcing and perfecting all Liens granted by the Company on the Collateral to secure any of the Obligations and (iv) exercise such powers as are reasonably incidental thereto.  Except for the last paragraph of <font style="text-decoration:underline;">Section 7.08</font>, the provisions of this Article VII are solely for the benefit of the Purchaser Agent and the Purchasers, and neither the Company nor any other Obligor shall have rights as a third party beneficiary of any of such provisions. It is understood and agreed that the use of the term &#8220;agent&#8221; herein or in any other Transaction Documents (or any other similar term) with reference to the Purchaser Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable law.&nbsp;&nbsp;Instead, such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between it and the Purchasers.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428952"></a><font style="Background-color:#auto;text-decoration:none;">Section 7.02.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Rights as a Purchaser.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Person serving as the Purchaser Agent hereunder shall have the same rights (including under <font style="text-decoration:underline;">Section 5.12</font>) and powers, and shall be subject to the same obligations under <font style="text-decoration:underline;">Section 5.12</font>, as any other Purchaser and may exercise the same as though it were not the Purchaser Agent and the term &#8220;Purchaser&#8221; or &#8220;Purchasers&#8221; shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Purchaser Agent hereunder.  Such Person and its Affiliates may lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with the Company or any Subsidiary or other Affiliate thereof as if such Person were not the Purchaser Agent hereunder and without any duty to account therefor to the Purchasers.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428953"></a><font style="Background-color:#auto;text-decoration:none;">Section 7.03.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Exculpatory Provisions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Purchaser Agent shall not have any duties or obligations except those expressly set forth herein and in the other Transaction Documents to which it is a party.  Without limiting the generality of the foregoing, the Purchaser Agent:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">shall not be subject to any fiduciary or other implied duties, regardless of whether a default, breach by the Company of the Transaction Documents or a Catch Up Payment Event or Put Option Event, or any event that, with the giving of notice or passage of time, would constitute a Catch Up Payment Event or a Put Option Event, has occurred and is continuing;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Transaction Documents to which it is a party that the Purchaser Agent is required to exercise as directed in writing by the Required Purchasers (or such other number or percentage of the Purchasers as shall be expressly provided for herein or in such other Transaction Documents), </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that the Purchaser Agent shall not be required to take any action that, in its opinion or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">the opinion of its counsel, may expose the Purchaser Agent to liability or that is contrary to any Transaction Document or Applicable Law; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">shall not, except as expressly set forth herein and in the other Transaction Documents to which it is a party, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Company or any of its Affiliates that is communicated to or obtained by the Person serving as the Purchaser Agent or any of its Affiliates in any capacity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Purchaser Agent shall not be liable to any Purchaser for any action taken or not taken by it (i) with the consent or at the request of the Required Purchasers (or such other number or percentage of the Purchasers as shall be necessary, or as the Purchaser Agent shall believe in good faith shall be necessary, under the circumstances as provided in </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 8.08</font><font style="color:#000000;">) or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and non-appealable judgment.  The Purchaser Agent shall be deemed not to have knowledge of any default, breach by the Company of the Transaction Documents, or Catch Up Payment Event or Put Option Event unless and until notice describing such default, breach by the Company of the Transaction Documents or Catch Up Payment Event or Put Option Event is given to the Purchaser Agent in writing by the Company or a Purchaser.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Purchaser Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Transaction Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any default, breach by the Company of the Transaction Documents or Catch Up Payment Event or Put Option Event, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Transaction Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in </font><font style="text-decoration:underline;color:#000000;">Article II</font><font style="color:#000000;"> or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Purchaser Agent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding anything to the contrary herein, the Purchaser Agent&#8217;s sole duty to the Purchasers with respect to the custody, safekeeping and physical preservation of the Collateral in its possession, under the UCC or otherwise, shall be to deal with it in the same manner as the Purchaser Agent deals with similar property for its own account, and the Purchaser Agent shall be deemed to have exercised reasonable care in the custody and preservation of the Collateral in its possession if the Collateral is accorded treatment substantially equal to that which comparable secured parties accord comparable collateral.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In addition to and not in limitation of the provisions of this </font><font style="text-decoration:underline;color:#000000;">Section 7.03</font><font style="color:#000000;">, under no circumstances shall the Purchaser Agent have any duty or obligation to take any actions hereunder, even if instructed to do so by the Required Purchasers, if the Purchaser Agent determines, in its sole and absolute discretion, that such actions would subject it to liability or expense for which indemnity or security satisfactory to it has not been provided hereunder or otherwise or would be contrary to the Transactions Documents or requirements of Applicable Law.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428954"></a><font style="Background-color:#auto;text-decoration:none;">Section 7.04.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Reliance by Purchaser Agent.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Purchaser Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person.&nbsp;&nbsp;The Purchaser Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon.&nbsp;&nbsp;The Purchaser Agent may consult with legal counsel (who may be counsel for the Company), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.&nbsp;&nbsp;All telephonic notices to and other telephonic communications with the Purchaser Agent may be recorded by the Purchaser Agent, and each of the parties hereto hereby consents to such recording.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428955"></a><font style="Background-color:#auto;text-decoration:none;">Section 7.05.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Delegation of Duties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Purchaser Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Transaction Document by or through any one or more sub-agents appointed by the Purchaser Agent.&nbsp;&nbsp;The Purchaser Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Affiliates.&nbsp;&nbsp;The rights, benefits and privileges (including the exculpatory and indemnification provisions) of this Article VII and Article VIII shall apply to any such sub-agent and to the Affiliates of the Purchaser Agent and any such sub-agent.&nbsp;&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur169"></a><a name="_Ref_ContractCompanion_9kb9Ur16B"></a><a name="_Ref_ContractCompanion_9kb9Ur16D"></a><a name="_Toc113428956"></a><font style="Background-color:#auto;text-decoration:none;">Section 7.06.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Resignation of Purchaser Agent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Purchaser Agent may at any time give notice of its resignation to the Purchasers and the Company upon thirty (30) days written notice, and thereafter, the retiring Purchaser Agent shall be discharged from its duties and obligations hereunder.  Upon the receipt of any such notice of resignation, the Required Purchasers shall have the right, in consultation with the Company so long as no default, breach by the Company of the Transaction Documents or Catch Up Payment Event or Put Option Event has occurred and is continuing, to appoint a successor.  If no successor shall have been so appointed by the Required Purchasers and shall have accepted such appointment within thirty (30) days after the retiring Purchaser Agent gives notice of its resignation, then the retiring Purchaser Agent may, on behalf of the Purchasers, appoint a successor Purchaser Agent; <font style="text-decoration:underline;">provided</font> that, whether or not a successor has been appointed or has accepted such appointment, such resignation shall become effective upon delivery of the notice thereof.  Upon the acceptance of a successor&#8217;s appointment as Purchaser Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Purchaser Agent, and the retiring Purchaser Agent shall be discharged from all of its duties and obligations under the Transaction Documents (if not already discharged therefrom as provided above in this <font style="text-decoration:underline;">&#8206;Section 7.06</font>).  After the retiring Purchaser Agent&#8217;s resignation, the provisions of this <font style="text-decoration:underline;">Article VII</font> and <font style="text-decoration:underline;">&#8206;Section 8.04</font> shall continue in effect for the benefit of such retiring Purchaser Agent, its sub-agents and their respective Affiliates in respect of any actions taken or omitted to be taken by any of them while the retiring Purchaser Agent was acting as Purchaser Agent.  Upon any resignation by the Purchaser Agent, all payments (if any), communications and determinations provided to be made by, to or through the Purchaser Agent shall instead be made by, to or through </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">each Purchaser directly, until such time as a Person accepts an appointment as Purchaser Agent in accordance with this </font><font style="text-decoration:underline;">&#8206;</font><font style="text-decoration:underline;">Section 7.06</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428957"></a><font style="Background-color:#auto;text-decoration:none;">Section 7.07.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Non-Reliance on Purchaser Agent and Other Purchasers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Purchaser acknowledges that it has, independently and without reliance upon the Purchaser Agent or any other Purchaser or any of their Affiliates and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement and purchase the Revenue Interests hereunder.  Each Purchaser also acknowledges that it will, independently and without reliance upon the Purchaser Agent or any other Purchaser or any of their Affiliates and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Transaction Document or any related agreement or any document furnished hereunder or thereunder.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur147"></a><a name="_Ref_ContractCompanion_9kb9Ur149"></a><a name="_Ref_ContractCompanion_9kb9Ur14B"></a><a name="_Ref_ContractCompanion_9kb9Ur14D"></a><a name="_Toc113428958"></a><font style="Background-color:#auto;text-decoration:none;">Section 7.08.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Collateral and Guaranty Matters.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Purchaser agrees that any action taken by the Purchaser Agent or the Required Purchasers in accordance with the provisions of this Agreement or of the other Transaction Documents, and the exercise by the Purchaser Agent or Required Purchasers of the powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all of the Purchasers.  Without limiting the generality of the foregoing, the Purchasers irrevocably authorize the Purchaser Agent, at its option and in its discretion:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to release any Lien on any property granted to or held by the Purchaser Agent under any Transaction Document (A) upon the discharge of the Obligations (other than contingent indemnity obligations for which no claim has been made), (B) that is sold, transferred, disposed or to be sold, transferred, disposed as part of or in connection with any sale, transfer or other disposition (other than any sale to an Obligor; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">however</font><font style="color:#000000;">, that the Purchaser Agent may make any filings necessary to reflect the transfer of Collateral from one Obligor to another) permitted hereunder or otherwise becomes an Excluded Property (as defined in the Guaranty and Security Agreement), (C) subject to </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 8.08</font><font style="color:#000000;">, if approved, authorized or ratified in writing by the Required Purchasers or (D) to the extent such property is owned by a Subsidiary Guarantor upon the release of such Subsidiary Guarantor from its obligations under the Guaranty and Security Agreement pursuant to </font><font style="text-decoration:underline;color:#000000;">clause (c)</font><font style="color:#000000;"> below;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to release any Subsidiary Guarantor from its obligations under the Guaranty and Security Agreement if such Person ceases to be a Subsidiary as a result of a transaction permitted hereunder; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to enter into non-disturbance and similar agreements in connection with the licensing of Intellectual Property permitted pursuant to the terms of this Agreement in form and substance reasonably satisfactory to the Purchaser Agent, the Company and the applicable licensor.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon request by the Purchaser Agent at any time, the Required Purchasers will confirm in writing the Purchaser Agent&#8217;s authority to release or subordinate its interest in particular types or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">items of property, or to release any Subsidiary Guarantor from its obligations under the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guaranty and Security Agreement </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursuant to this </font><font style="text-decoration:underline;">&#8206;</font><font style="text-decoration:underline;">Section 7.08</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In each case as specified in this <font style="text-decoration:underline;">&#8206;Section 7.08</font>, the Purchaser Agent will (and each Purchaser irrevocably authorizes the Purchaser Agent to), at the Company&#8217;s expense, execute and deliver to the applicable Obligor such documents as such Obligor may reasonably request (i) to evidence the release or subordination of such item of collateral from the assignment and security interest granted under the Transaction Documents, (ii) to enter into non-disturbance or similar agreements in connection with the licensing of Intellectual Property, (iii) to evidence the release of such Subsidiary Guarantor from its obligations under the Guaranty and Security Agreement, in each case in accordance with the terms of the Transaction Documents and this <font style="text-decoration:underline;">&#8206;Section 7.08</font> and in form and substance reasonably acceptable to the Purchaser Agent.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Purchaser Agent shall deliver to the Purchasers notice of any action taken by it under this <font style="text-decoration:underline;">&#8206;Section 7.08</font> as soon as reasonably practicable after the taking thereof; <font style="text-decoration:underline;">provided</font>, that delivery of or failure to deliver any such notice shall not affect the Purchaser Agent&#8217;s rights, powers, privileges and protections under this <font style="text-decoration:underline;">Article VII</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Purchaser Agent shall have no obligation to give, execute, deliver, file, record, authorize or obtain any financing statements, notices, instruments, documents, agreements, consents or other papers as shall be necessary to (i) create, preserve, perfect or validate any security interest granted to the Purchaser Agent pursuant to the Transaction Documents or (ii) enable the Purchaser Agent to exercise and enforce its rights under the Transaction Documents with respect to any such pledge and security interest.  The Purchaser Agent shall not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Purchaser Agent&#8217;s Lien thereon, or any certificate prepared by the Company or any Subsidiary Guarantor in connection therewith, nor shall the Purchaser Agent be responsible or liable to the Purchasers for any failure to monitor or maintain any portion of the Collateral.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428959"></a><font style="Background-color:#auto;text-decoration:none;">Section 7.09.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Reimbursement by Purchasers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the Company for any reason fails to indefeasibly pay any amount required under <font style="text-decoration:underline;">&#8206;Section 8.04</font> or <font style="text-decoration:underline;">Section 8.13</font> to be paid by it to the Purchaser Agent (or any sub-agent thereof) or any Affiliate of any of the foregoing, each Purchaser severally agrees to pay to the Purchaser Agent (or any such sub-agent) or such Affiliate, as the case may be, such Purchaser&#8217;s pro rata share (based upon the percentages as used in determining the Required Purchasers as of the time that the applicable unreimbursed expense or indemnity payment is sought) of such unpaid amount; <font style="text-decoration:underline;">provided</font> that the unreimbursed expense or indemnified loss, damage, liability or related expense, as the case may be, was incurred by or asserted against the Purchaser Agent (or any such sub-agent) in its capacity as such or against any Affiliate of any of the foregoing acting for the Purchaser Agent (or any sub-agent) in connection with such capacity.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc110631210"></a><a name="_Toc113428960"></a><font style="text-decoration:none;Background-color:#auto;">Article VIII.</font><font style="text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;"><br /></font><font style="text-transform:none;color:#000000;"><br /><a name="_Toc110631210"></a><a name="_Toc113428960"></a></font><font style="text-transform:none;color:#000000;">MISCELLANEOUS</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428961"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.01.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Limitations on Damages.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything to the contrary in this Agreement, in no event shall either party be liable for special, indirect, incidental, punitive or consequential damages of the other party, whether or not caused by or resulting from the actions of such party or the breach of its covenants, agreements, representations or warranties hereunder, even if such party has been advised of the possibility of such damages; <font style="text-decoration:underline;">provided</font>, that nothing contained in this <font style="text-decoration:underline;">Section 8.01</font> shall limit the Company&#8217;s indemnification obligations hereunder to the extent such special, indirect, consequential or punitive damages are included in any third party claim in connection with which such Indemnified Party is entitled to indemnification hereunder. In connection with the foregoing, the parties hereto acknowledge and agree that (i) the Purchasers&#8217; damages, if any, for any such action or claim will typically include losses for payments that the Purchasers were entitled to receive in respect of their ownership of the Revenue Interests but did not receive timely or at all due to such indemnifiable event and (ii) the Purchasers shall be entitled to make claims for all such missing or delayed Revenue Interests as losses hereunder, and such missing or delayed Revenue Interests shall not be deemed special, indirect, incidental, punitive or consequential damages. Notwithstanding any other provision herein to the contrary, each Obligor&#8217;s liability under the Transaction Documents (other than (i) amounts that have been or would be required to be reimbursed under Section 2.02(b), (ii) amounts that have been or would be required to be paid as Indemnified Amounts to the Purchaser Agent or any Purchaser Indemnified Party arising from a Third-Party Claim pursuant to Section 8.04, and (iii) any other out-of-pocket costs or expenses of the Purchaser Agent, any Purchaser or any Purchaser Indemnified Party that have been or would be required to be indemnified pursuant to Section 8.04) shall be limited to an amount not to exceed as of any date of determination the then applicable Return Cap.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428962"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.02.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notices.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All notices, consents, waivers and communications hereunder or under any Transaction Document given by any party to the other shall be in writing and delivered personally, by a recognized overnight courier, by dispatching the same by certified or registered mail, return receipt requested, with postage prepaid, or by email, in each case addressed (with a copy by email):</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to the Purchaser Agent to:</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o OrbiMed Advisors LLC<br />601 Lexington Avenue, 54<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Floor<br />New York, NY 10022</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: OrbiMed Credit Reporting<br />Email: <font style="text-decoration:underline;">RoSCreditOps@OrbiMed.com</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to any Purchaser to:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OrbiMed</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Advisors LLC</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />601 Lexington Avenue, 54</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Floor</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10022<br />Attn: OrbiMed Credit Reporting<br />Email: <font style="text-decoration:underline;">RoSCreditOps@OrbiMed.com</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In each case, with a copy (which shall not constitute notice to):</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Covington &amp; Burling LLP</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The New York Times Building</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620 Eighth Avenue</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10018</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn:&nbsp;&nbsp;Peter Schwartz</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email:&nbsp;&nbsp;<font style="text-decoration:underline;">pschwartz@cov.com</font> </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to the Company to:</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adaptive Biotechnologies Corporation</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1165 Eastlake Avenue East</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seattle, WA 98109<br />Attn: General Counsel<br />Email: <font style="text-decoration:underline;">staylor@adaptivebiotech.com</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to (which shall not constitute notice):</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DLA Piper LLP (US)</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">701 Fifth Avenue, Suite 6900</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seattle, WA 98104-7029</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn:&nbsp;&nbsp;Tyler Hollenbeck</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email:&nbsp;&nbsp;<font style="text-decoration:underline;">tyler.hollenbeck@us.dlapiper.com</font> </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or to such other address or addresses as the Purchaser Agent, any Purchaser or the Company may from time to time designate by notice as provided herein, except that notices of changes of address shall be effective only upon receipt.  All such notices, consents, waivers and communications if mailed and properly addressed with postage prepaid or if properly addressed and sent by pre-paid courier service, shall be deemed given when received; any notice, if transmitted by email, shall be deemed given upon the earlier of (x) confirmation of receipt by the recipient and (y) the opening of business on the next Business Day for the recipient.&nbsp;&nbsp;Unless otherwise indicated, all references to the time of a day in a Transaction Document shall refer to New York City time.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428963"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.03.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Successors and Assigns.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions of this Agreement and the other Transaction Documents shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.  The Company shall not be entitled to assign any of its obligations and rights under the Transaction Documents without the prior written consent of the Required Purchasers; <font style="text-decoration:underline;">provided</font> that each </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchaser shall respond to any request by the Company to assign its obligations and rights within 15 Business Days after its receipt of such request</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Purchaser Agent and any Purchaser may assign any of its rights under the Transaction Documents without restriction to any Eligible Assignee; </font><font style="text-decoration:underline;">provided</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="text-decoration:underline;">however</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, that, except to the extent such Purchaser retains its obligations to make its Pro Rata Portion of future Purchaser Payments, such Eligible Assignee shall assume in writing all such Purchaser&#8217;s obligation to make future Purchaser Payments; </font><font style="text-decoration:underline;">provided</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="text-decoration:underline;">further</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, that the Purchaser shall provide the Company with </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prompt </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">written notice of any assignment; </font><font style="text-decoration:underline;">provided</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="text-decoration:underline;">further</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, that for purposes of </font><font style="text-decoration:underline;">Section 5.12</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (and for purposes of the defined terms used therein), such assignee shall be deemed a &#8220;Purchaser&#8221; and references to the &#8220;Effective Date&#8221; shall be replaced with the date that such assignee acquires an interest in a Purchaser&#8217;s rights hereunder.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchaser Agent</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall maintain a &#8220;register&#8221; for the recordation of the names and addresses of, and the Purchaser Commitments of, and amounts owing to, each Purchaser and assignee owning Revenue Interest Payments, which (together with the payment of the Put/Call Price, if applicable) are intended to be registered obligations for U.S. federal income tax purposes, and the right, title and interest of any Purchaser and its assignees in and to such Revenue Interest Payments and payment of the Put/Call Price, if applicable, shall be transferable only upon notation of such transfer in the register.&nbsp;&nbsp;Any purported assignment not in compliance with the foregoing requirement shall be null and void.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur09B"></a><a name="_Ref_ContractCompanion_9kb9Ur09D"></a><a name="_Ref_ContractCompanion_9kb9Ur09F"></a><a name="_Ref_ContractCompanion_9kb9Ur09H"></a><a name="_Ref_ContractCompanion_9kb9Ur09J"></a><a name="_Ref_ContractCompanion_9kb9Ur0AC"></a><a name="_Toc113428964"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.04.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indemnification.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur02C"></a><a name="_Ref_ContractCompanion_9kb9Ur037"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company hereby indemnifies and holds the Purchaser Agent, each Purchaser and their respective Affiliates and any of their respective partners, directors, managers, members, officers, employees and agents (each, a &#8220;</font><font style="text-decoration:underline;color:#000000;">Purchaser Indemnified Party</font><font style="color:#000000;">&#8221;) harmless from and against (1) any and all Excluded Liabilities, (2) any liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs and expenses that may be imposed on, incurred by, or asserted against any Purchaser Indemnified Party as a result of any breach of representations, warranties or covenants under this Agreement or any other Transaction Document, and (3) any and all Indemnified Liabilities arising, in whole or in part, out of or relating to any claim, notice, suit or proceeding commenced or threatened in writing (including, without limitation, by electronic means) by any Third Party (including any Governmental Authority, but excluding any lender, officer, directors, employee or agent or other representative of a party to this Agreement) (each, a &#8220;</font><font style="text-decoration:underline;color:#000000;">Third Party Claim</font><font style="color:#000000;">&#8221;); provided the Company shall not have any obligation to any Purchaser Indemnified Party hereunder with respect to any Indemnified Liabilities to the extent that a court of competent jurisdiction determines that such Indemnified Liabilities result from (x) the gross negligence or willful misconduct of such Purchaser Indemnified Party or (y) the material breach of this Agreement or any other Transaction Document by such Purchaser Indemnified Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur039"></a><a name="_Ref_ContractCompanion_9kb9Ur03B"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each Purchaser and the Purchaser Agent hereby indemnifies and holds the Company and its respective Affiliates and any of their respective partners, directors, managers, members, officers, employees and agents (each, a &#8220;</font><font style="text-decoration:underline;color:#000000;">Company Indemnified Party</font><font style="color:#000000;">&#8221;; Company Indemnified Party and Purchaser Indemnified Party, each an &#8220;</font><font style="text-decoration:underline;color:#000000;">Indemnified Party</font><font style="color:#000000;">&#8221;) harmless from and against any and all Indemnified Liabilities, in all cases arising out of or resulting from (i) any material breach of this Agreement or any other Transaction Document by such Purchaser or the Purchaser Agent, as applicable, or (ii) the gross negligence or willful misconduct of such Purchaser or the Purchaser Agent, as applicable; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that the Purchasers and the Purchaser Agent shall not have any obligation to any Company Indemnified Party hereunder with respect to any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Excluded Liability or with respect to any Indemnified Liabilities to the extent that such Indemnified Liabilities result from (x) the gross negligence or willful misconduct of such Company Indemnified Party or (y) the material breach of this Agreement or any other Transaction Document by such Company Indemnified Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">A claim by an Indemnified Party under this </font><font style="text-decoration:underline;color:#000000;">Section 8.04</font><font style="color:#000000;"> for any matter in respect of which such Indemnified Party seeks indemnification hereunder may be made by delivering, in good faith, a written notice of demand to the indemnifying party, which notice shall contain (i) a description and the amount of any Indemnified Amounts incurred or suffered or reasonably expected to be incurred or suffered by the Indemnified Party, (ii) a statement that the Indemnified Party is entitled to indemnification under this </font><font style="text-decoration:underline;color:#000000;">Section 8.04</font><font style="color:#000000;"> for such Indemnified Amounts and a reasonable explanation of the basis therefor, (iii) a demand for payment in the amount of such Indemnified Amounts, and (iv) a copy of all papers served, if any.&nbsp;&nbsp;Within thirty (30) days after receipt by the indemnifying party of any such notice, the indemnifying party may deliver to the Indemnified Party that delivered the notice a written response in which the indemnifying party (i) agrees that the Indemnified Party is entitled to the full amount of the Indemnified Amounts claimed in the notice from the Indemnified Party; (ii) agrees that the Indemnified Party is entitled to part, but not all, of the amount of the Indemnified Amounts claimed in the notice from the Indemnified Party; or (iii) indicates that the indemnifying party disputes the entire amount of the Indemnified Amounts claimed in the notice from the Indemnified Party.&nbsp;&nbsp;If the Indemnified Party does not receive such a response from the indemnifying party within such thirty (30)-day period, then the indemnifying party shall be conclusively deemed to have agreed that the Indemnified Party is entitled to the full amount.&nbsp;&nbsp;If the indemnifying party and the Indemnified Party are unable to resolve any dispute relating to any amount of the Indemnified Amounts claimed in the notice from the Indemnified Party within thirty (30) days after the delivery of the response to such notice from the indemnifying party, then the parties shall be entitled to resort to any legal remedy available to such party to resolve such dispute that is provided for in this Agreement, subject to all the terms, conditions and limitations of this Agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428965"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.05.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Implied Representations and Warranties; Survival of Representations and Warranties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each party acknowledges and agrees that, other than the representations and warranties specifically and expressly contained in any of the Transaction Documents, there are no representations or warranties of either party or any other Person either expressed or implied with respect to the Revenue Interests or the transactions contemplated hereby.  Without limiting the foregoing, the Purchaser Agent and each Purchasers acknowledges and agrees that the Purchaser Agent, each Purchaser and their respective Affiliates, together with their representatives, have made their own investigation of each Product and are not relying on any implied warranties or upon any representation or warranty whatsoever as to the future amount or potential amount of the Revenue Interests or as to the creditworthiness of the Company.  All representations and warranties by the parties contained in this Agreement shall survive the execution, delivery and acceptance thereof by the parties and the closing of the transactions described in this Agreement and continue in effect until payment of all amounts due to the Purchasers under the Transaction Documents and the termination of this Agreement pursuant to its terms.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428966"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.06.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Independent Nature of Relationship.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The relationship between the Company and its Subsidiaries, on the one hand, and the Purchaser Agent and the Purchasers, on the other, is solely that of seller and purchaser, and for U.S. federal income Tax purposes, debtor and creditor, and neither the Purchaser Agent and the Purchasers, on the one hand, nor the Company and its Subsidiaries, on the other, has any fiduciary or other special relationship with the other or any of their respective Affiliates.  Nothing contained herein or in any other Transaction Document shall be deemed to constitute the Company and its Subsidiaries and the Purchaser Agent and the Purchasers as a partnership, an association, a joint venture or other kind of entity or legal form for any purposes, including any Tax purposes.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No officer or employee or agent of the Purchaser Agent or any Purchaser will be located at the premises of the Company or any of its Affiliates, except in connection with an audit performed pursuant to Section 5.01 or in connection with the enforcement of remedies as contemplated by the Transaction Documents.&nbsp;&nbsp;No officer, manager or employee of the Purchaser Agent or any Purchaser shall engage in any commercial activity with the Company or any of its Affiliates other than as contemplated herein and in the other Transaction Documents.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428967"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.07.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Entire Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement, together with the Disclosure Letter and the Exhibits and Schedules thereto (which are incorporated herein by reference), the Existing CDA, and the other Transaction Documents constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements, understandings and negotiations, both written and oral, between the parties with respect to the subject matter of this Agreement.  No representation, inducement, promise, understanding, condition or warranty not set forth herein (or in the Exhibits, Schedules or other Transaction Documents) has been made or relied upon by either party hereto.  None of this Agreement, nor any provision hereof, is intended to confer upon any Person other than the parties hereto any rights or remedies hereunder.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur16F"></a><a name="_Ref_ContractCompanion_9kb9Ur178"></a><a name="_Ref_ContractCompanion_9kb9Ur17A"></a><a name="_Toc113428968"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.08.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Amendments; No Waivers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Subject to </font><font style="text-decoration:underline;color:#000000;">Section 8.08(b)</font><font style="color:#000000;">, this Agreement, the other Transaction Documents or any term or provision hereof or thereof may not be amended, changed or modified except with the written consent of the Company, the Purchaser Agent and the Required Purchasers.  No waiver of any right hereunder shall be effective unless such waiver is signed in writing by the party against whom such waiver is sought to be enforced.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Without the prior written consent of the Purchaser Agent and each Purchaser, no amendment, modification, termination or consent shall be effective if the effect thereof would:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">waive, reduce or postpone any Revenue Interest Payment;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">amend, modify, terminate or waive any provision of this </font><font style="text-decoration:underline;color:#000000;">&#8206;Section 8.08</font><font style="color:#000000;">;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">amend the definition of &#8220;Required Purchasers&#8221; or &#8220;Pro Rata Portion&#8221;; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">release all or substantially all of the Collateral or release any Obligor from any of its rights and obligations under any Transaction Document (except as expressly provided in the Transaction Documents).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No failure or delay by either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, </font><font style="color:#000000;">power</font><font style="color:#000000;"> or privilege. </font><font style="color:#000000;"> </font><font style="color:#000000;">The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428969"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.09.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Interpretation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When a reference is made in this Agreement to Articles or Sections, such reference shall be to an Article or Section to this Agreement, and when a reference is made in this Agreement to Schedules or Exhibits, such reference shall be to a Schedule or Exhibit to the Disclosure Letter, in each case unless otherwise indicated.  The words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; when used herein shall be deemed in each case to be followed by the words &#8220;without limitation&#8221;.  Neither party hereto shall be or be deemed to be the drafter of this Agreement for the purposes of construing this Agreement against one party or the other.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428970"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Headings and Captions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The headings and captions in this Agreement or any other Transaction Document are for convenience and reference purposes only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement or such Transaction Document.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428971"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.11.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Counterparts; Effectiveness; Electronic Signature.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement may be executed in two or more counterparts, each of which shall be an original, but all of which together shall constitute one and the same instrument.  This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto.  Any counterpart may be executed by facsimile or pdf signature and such facsimile or pdf signature shall be deemed an original.  The words &#8216;execution&#8217;, &#8216;signed&#8217;, &#8216;signature&#8217;, &#8216;delivery&#8217; and words of like import in or relating to any document to be signed in connection with this Agreement or any other Transaction Document and the transactions contemplated hereby shall be deemed to include Electronic Signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any Applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar State laws based on the Uniform Electronic Transactions Act; <font style="text-decoration:underline;">provided</font>, that nothing herein shall require any Person to accept Electronic Signatures in any form or format without its prior written consent.  Without limiting the generality of the foregoing, the parties hereto hereby (a) agree that, for all purposes, including in connection with any workout, restructuring, enforcement of remedies, bankruptcy proceedings or litigation among the Purchasers and the Obligors, electronic images of this Agreement or any other Transaction Document (in each case, including with respect to any signature pages thereto) shall have the same legal effect, validity and enforceability as any paper original, and (b) waive any argument, defense or right to contest the validity or enforceability of the Transaction Documents based solely on the lack of paper original copies of any Transaction Documents, including with respect to any signature pages thereto.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428972"></a><font style="text-decoration:none;Background-color:#auto;">Section 8.12.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Severability.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions shall nevertheless be given full force and effect.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428973"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.13.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Expenses.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will pay all of its own fees and expenses in connection with entering into and consummating the transactions contemplated by this Agreement. </p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428974"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.14.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Governing Law; Jurisdiction.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each Transaction Document (except as may otherwise expressly stated therein) shall be governed by, and construed, interpreted and enforced in accordance with, the laws of the State of New York, without giving effect to the principles of conflicts of law thereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Any legal action or proceeding with respect to this Agreement or any other Transaction Document may be brought in any state or federal court of competent jurisdiction in the Borough of Manhattan, City of New York, State of New York.  By execution and delivery of this Agreement, each party hereto hereby irrevocably consents to and accepts, for itself and in respect of its property, generally and unconditionally the exclusive jurisdiction of such courts.  Each party hereto hereby further irrevocably waives any objection, including any objection to the laying of venue or based on the grounds of </font><font style="font-style:italic;color:#000000;">forum non conveniens</font><font style="color:#000000;">, which it may now or hereafter have to the bringing of any action or proceeding in such jurisdiction in respect of any Transaction Document.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each party hereto hereby irrevocably consents to the service of process out of any of the courts referred to in </font><font style="text-decoration:underline;color:#000000;">clause (b)</font><font style="color:#000000;"> of this </font><font style="text-decoration:underline;color:#000000;">Section 8.14</font><font style="color:#000000;"> in any such suit, action or proceeding by the mailing of copies thereof by registered or certified mail, postage prepaid, to it at its address set forth in this Agreement.  Each party hereto hereby irrevocably waives any objection to such service of process and further irrevocably waives and agrees not to plead or claim in any suit, action or proceeding commenced hereunder or under any other Transaction Document that service of process was in any way invalid or ineffective.  Nothing herein shall affect the right of a party to serve process on the other party in any other manner permitted by law.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428975"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.15.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Waiver of Jury Trial.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING, CLAIM OR COUNTERCLAIM ARISING OUT OF OR RELATING TO ANY TRANSACTION DOCUMENT OR THE TRANSACTIONS CONTEMPLATED UNDER ANY TRANSACTION DOCUMENT.  THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO ANY TRANSACTION DOCUMENT.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc113428976"></a><font style="Background-color:#auto;text-decoration:none;">Section 8.16.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Specific Performance.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc113428977"></a><a name="_Toc112589879"></a><a name="_Toc113347379"></a>Each of the parties hereto acknowledges and agrees that the other party would be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached or violated.&nbsp;&nbsp;Accordingly, each of the parties hereto agrees that, without posting bond or any similar undertaking, the other party will be entitled to seek an injunction or injunctions to prevent breaches or violations of the provisions of this Agreement and to seek specific performance of this Agreement and the terms and provisions hereof in any action, suit or other proceeding instituted in any court of the United States or any state thereof having jurisdiction over the parties and the matter in addition to any other remedy to which it may be entitled, at law or in equity.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[SIGNATURE PAGE FOLLOWS]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF<font style="font-weight:normal;">, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the date first above written.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:0%;">
<tr>
<td style="width:48.17%;"></td>
<td style="width:48.18%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPANY</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADAPTIVE BIOTECHNOLOGIES CORPORATION</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">&#160;/s/ Chad Robins&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><br />Name: Chad Robins<br />Title: Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Signature Page to Revenue Interest Purchase Agreement</font>]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:0%;">
<tr>
<td style="width:48.17%;"></td>
<td style="width:48.18%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PURCHASER AGENT:</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORBIMED ROYALTY &amp; CREDIT OPPORTUNITIES IV, LP</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;OrbiMed ROF IV LLC,</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its General Partner</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;OrbiMed Advisors LLC, </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its Managing Member</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">&#160;/s/Matthew Rizzo</font><br />Name: Matthew Rizzo<br />Title: Member </p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PURCHASERS:</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORBIMED ROYALTY &amp; CREDIT OPPORTUNITIES III, LP</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;OrbiMed ROF III LLC, </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its General Partner</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: OrbiMed Advisors LLC,</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its Managing Member</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">&#160;/s/Matthew Rizzo</font><br />Name: Matthew Rizzo<br />Title: Member </p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORBIMED ROYALTY &amp; CREDIT OPPORTUNITIES IV, LP</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;OrbiMed ROF IV LLC,</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its General Partner</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;OrbiMed Advisors LLC, </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its Managing Member</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">&#160;/s/Matthew Rizzo</font><br />Name: Matthew Rizzo<br />Title: Member </p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Signature Page to Revenue Interest Purchase Agreement</font>]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>adpt-ex991_47.htm
<DESCRIPTION>EX-99.1 PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
adpt-ex991_47.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="geq3q1aivrp3000001.jpg" title="" alt="" style="width:150px;height:38px;"><font style="margin-left:100pt;"></font><font style="margin-left:36pt;"></font>EXHIBIT 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">OrbiMed for Up to $250 Million</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SEATTLE, September 12, 2022 -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a non-dilutive royalty financing agreement with OrbiMed for up to $250 million. Proceeds from the agreement will strengthen Adaptive's balance sheet, which stood at over $450 million in cash and marketable securities at the end of the second quarter of 2022, and provide the Company with additional capital to support its growth trajectory and path to profitability. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are excited to work with OrbiMed on this creative royalty structure to continue unlocking the full potential of our immune medicine platform,&#8221; said Chad Robins, Chief Executive Officer and Co-Founder of Adaptive Biotechnologies. &#8220;The agreement will extend our cash runway while providing flexibility to invest in growth initiatives in both our MRD and Immune Medicine business areas.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement, Adaptive will receive an initial tranche of $125 million with the option to receive an additional $75 million, both for general corporate purposes. Adaptive can also access a third tranche of $50 million for potential M&amp;A. OrbiMed will be entitled to receive 5% of the Company&#8217;s GAAP revenues, increasing to 8% and 10% if the second and third tranches are drawn, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;This investment reflects our confidence in Adaptive Biotechnologies and the potential to accelerate its significant contributions to the field of immune medicine,&#8221; said Matthew Rizzo, General Partner of OrbiMed. &#8220;The company is well-positioned to deliver revenue growth while continuing to innovate and expand the applications of its platform in clinical diagnostics and drug discovery.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DLA Piper LLP (US) acted as the Company&#8217;s legal advisor, and Covington &amp; Burling LLP acted as OrbiMed&#8217;s legal advisor. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Adaptive Biotechnologies </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adaptive Biotechnologies (&#8220;we&#8221; or &#8220;our&#8221;) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About OrbiMed </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OrbiMed is a leading healthcare investment firm, with approximately $18 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="geq3q1aivrp3000001.jpg" title="" alt="" style="width:150px;height:38px;"><font style="margin-left:100pt;"></font><font style="margin-left:36pt;"></font>EXHIBIT 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">solutions and extensive global team resources to help build world-class healthcare companies. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OrbiMed&#8217;s</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> team of over 130 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets. </font><font style="text-decoration:underline;">www.orbimed.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains forward-looking statements that are based on management&#8217;s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ADAPTIVE MEDIA<font style="font-weight:normal;"><br />Laura Cooper<br />205-908-5603</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">media@adaptivebiotech.com</font> <br /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ADAPTIVE INVESTORS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Karina Calzadilla, Vice President, Investor Relations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201-396-1687</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrie Mendivil, Gilmartin Group</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">investors@adaptivebiotech.com</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>geq3q1aivrp3000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geq3q1aivrp3000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !W =4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ K
MGO%/B73/".B7NO:O,L%C8Q-+-([!%"JK,<D\#A370U^3O_!5K]H2U^%'P'\3
MZ-%J"V.IZEIETELXDVN9)+<A  "&)W= !_\ 7^GX-X:Q?&'$^3<.8*$YULUQ
M^'PON)N485:D83G97?NQ;?X['%F.-IY=@<5C:S4:>&HU*LG)V7N1<K:M=NY\
MY_&S_@LW\+/!7C'5O#>EZK!.=)N#;3^0WFHDF3A2R;@#MPV#AL%2<!A7D]G_
M ,%P? -S=VT?V]5C,T8F=@RJD;NJEB64!57)+$G@#)('-?R%:KJ^H75Y/-/>
M3SSW$AN+F>5]\DUQ(2\LCMT+,S$],#[H  P*,6H7:L1Y\A#C8P)[-P:_V"R_
MZ&'@K@\)A,'CL-G&+Q='#TZ.+Q<<31A&MBO9Q52K"+IMQI^UNXQ;ORI7=]3^
M2Z_C=Q;5K5:N'H9?3H2JN5&E.-;VBH\R<(SE&HDY\B]YI)<VR:/]-[X%?&#1
M/C+X&TGQ3H]S%<)>6D4[&)@PPZ*0>"?7Z5[77\V'_!#+]I.3Q#X-O_ ?B&]_
MTG2K@Z;;))+G=&B1O"RAF/6-UZ# QVY%?TG @@$<@@$'U!Y!K_*#Q=X$K^''
M'_$/"E6$XT\NQU6.%E+7VF%D^:C*,MI+D<=3^IN',XI9]DN7YK1:<<7AZ=5I
M?9E**<HM=&GHT[6[+86BBBOS4]L**** "BBB@ KYG_:5_:6\&?LY>$;OQ'XK
MO(K1([=Y8WE=5484G/S%1GC Y_7%?3%?ST?\%ZXKB3X-1F*<Q*D44C*&(#B-
MT=E/8A@-I'>OT?PDX4R_C?Q#X8X8S2K4HY?FV94,/BJE+^(J4IQ4N7S:=CQ.
M(\RK91DF99EAZ<:E;!X2M7ITY.T92IP<DF[.RNMSDK__ (+@^ /MTWV:_5[?
MS"8W"LP,8)VE3M^Z1@\$YZ\5^L_[%'[5&F_M3>")/%^E-YEI@F-^S#>%S[>F
M.,8QZ5_G._;;O<?W[@8'&?<\?X>E?W"_\$1K.UL_V=K%+6$1*;&%B 2269D+
M,Q))9B22S$Y8DD\U_;'TI_H_>&/A=X<X;.>$\#F-+-:N;4,(ZV+Q%.I3]C[-
MRJ>["$'SR?+:WNVOY'X[X7>('$7%N=8O"YI]3CAL/A(U8QP\*JFZE2:C%7G.
M2<4HN^SO:W4_;JBBBO\ . _?0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *X?XC>*!X-\(:OXB;IIT#S'Z*CM_[+7<5XS^T JO\ "?Q:CJ&4Z?,"IZ']
MU+7?E=*G7S+ 4*JYJ57&8>G4CWA.K",E\TVC.M*4:524?B4)->J6A^'OC[_@
ML]X1\(^)M7T&6[43:7=R6LZ %RCJQ 5CM.TX&[!P=K \BOJK]D'_ (*E?#3]
MH;Q2G@>#4(FUMTCE\EVV.(Y7=%95;!QN0@D#&>#VK^,G]K!?L'QL\=QV6+:.
M;43/(D? :4RS1ESC&6V0HONJKZ5]3?\ !*2:ZD_:D\-RB=A)%IKKN.<E9+RU
M)&1[H..>W3'/^J?&GT5O".AX08_BG+,+FV"SK"\*8?/*5>>(ISHO%NE1E.$X
M*%_92<W9*5TN5^1_-F3^*7$];C>ED&(A@:F!J9MB, W"-55E1IJ;A-2E)Q<[
M0C=<J3U2Z'^@8CK(BNI!5U#*1R"",BG5B^'"YT332YW,;6(L??8,_K6U7^4%
M2/).<+WY9.-^]G8_I9.Z3[I,^,_VV/CO_P */^$/B'6K;:=0_LVY>W1PI#.(
MF**0W') '/'/Y?P,?M ?M-?$/XV^)CK_ (DO_P"SV::XFCL=+9[$1M+*Q47,
MEN8GFEB0E"#\F_+;20A7^\O]O/X%7GQJ^#?B'3=+3S=3BTRZ6UC"EB9#$VPX
M&,X;'Y5_ Q\8?V>OB9\)]>?1O&?AC48;Q)9X1=6]I<S07)BF93+\D)\DS "4
M1G(7<55VQD_Z??0.P_ DLFXDKU_[)EQK'%8>-!9A.FL5' RC555X&G5?+-?#
M[5J+E'2UE=G\Z>.E3B"/]F0PGUU9/*%?ZY]4BW3]JG1=%8B4/WD4WSN"3Y&[
MJ?V4?=?_  3J_;9^(7PH^)W@;PI-<V^J>'=1U![.YGNHTDU"WC(#PM)=2*7E
M1 IAWNQF8LC,SMO8_P!U_P /?%</C3PEH_B&'[M_:Q2D]06:-6)[]SC\*_@E
M_8#_ &/_ (I?%#XM^ ]:M_#=Y9^%K747N[^]NX9H9)(EVB*-(9(U*K(Q$@D9
ML[4V[/G+)_>A\,?"2^"/!>B>'5_Y<+2*,^Q$: CK[5^7?3HH<#4N,\DEPY_9
MD<]J9=S9_'*YPE2]NZM2TL0J;=.&)M;GC%))6=KMGTO@M4SZ?#]?^U_K3H1Q
M4EE[QD7&M]55.ER<O,E.5*]^24[R?5M),[^BBBOX//V<**** "BBB@ HHHH
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M=BB@9W*XP?7(]_\ 0O'^*?#V!\2\K\,*LV\]S3 U<<JW.E2H2A3E5IX>:?\
MR]JQBN75:SBDC^?<-P9F&(X3Q7%D9-87#5%"&'4+RJTE.%.I64K[0;D]MH2O
MHTSYM_X)P?'35OA-^T-X+3^T#;:!KFIFVOHB[(OGA(Y(Y"0VW!CMW3&.2P.>
M,5_H)^!O$]EXN\,:3K=A(LL%W9VS[T(*EC"FX@CKDYYK_+W\-ZQ?^']:T[4K
M"0PWNGW<=W;R E=LL?(Y&#R,J?9B,$<'^]O_ ()1_M 0_%O]GGPI%?W0?65T
MRS>>)Y TR2>2NY&&2<AB0?<9STK^*_IX^'7/2R#Q&P.'2T_L;-Y0C[TJ\.:K
M2KU;+[5)J',_^??S/V;P)XB]IA\?P[7J2<\/+ZWA%)MI8:IRQ]G"[TY:BE+E
MZ*<?E^K=%%%?YF']%!2$@ DD #DD\ #U)/ K$\1>(M)\+:3=:UK=W%9V%I&T
MDTTK*B@*"3RQ Z#\*_GZ_;?_ ."ROA_X5WMYX6^&1C\0Z@9'M2ME/%B%P=I>
M>4NJQ(G+,S'/&U5=RJM]]X?^&G&'B9FT,GX2RC$9CB&U[6K&/+AL/'2\Z]>5
MJ=-).]YR2TU:/'SK/LJX?PD\;FN+I86A!;S?O2?:$5>4I/9**;;T29_0-<^)
M- M"5NM8T^ @X(ENHD(/XM5:/QAX6E.(]?TMCTP+R+/Y;J_@B^)G_!4KX]^-
M;J:XT[59-'$LC.$2^DD"@MP-J8&<$\9&".IZUY=H?_!1']HW2KQ)Y?%US=QA
M]S(]U.N1G( ^9^W !Q]17];8;Z _B)5PBJXG/,EPV*<$WA754VI.*?(YP<H;
MNU^:Q^6U?'/A.%;V=..,JPO;VT</44-][.*EY[/0_P!$BVOK.]&ZTNH+@8SF
M&19!CU^4FOY_/^"\P8?!;<1A?LO#=NP//3K[U^7?P&_X+8?$?P+J^DVOBS3I
MKW2WN8(;Z[6[6?R86D56EDB=E=HP#\VT,0,G;M!(][_X*2?ML_"K]J+X'VNG
MZ3K-E<:FUD#+;03QLZ2&/S"I122,'.5QZ9'->9P1]'CQ)\)O&'@?&9[E$\1E
M"S>C4>:8!K%8:-.G4BYRJ2HN2I-:.U1IV>W4]+,..>'.*N%<\AEF84I5_J-:
MG*A6O1JQG4I2Y$X5%&33_F2<79V;>A_,9W/T'\S7]S'_  1._P"3>+'_ *\+
M?^<=?PS @LVWM@?JW^?Z5_<S_P $3O\ DWBQ_P"O"W_G'7]2?3I=_"C -;//
MJ+_\I1/R7P(_Y*#-/^P'#_\ IR1^V-%(2%!9B J@DD\  #))/8 <DU^?'[7?
M[?7PP_9HT6Z%[K5B^O+%,8+1IXC(\D<;/L6/=NS\C>^.<8Z?Y*\/<.9UQ5FF
M&R;(,NQ.99CBZD:='#8:G*I-N3M=J*=HKJWHEJ?U3B\9AL#0J8G%UJ="A2BY
M3J5)*$8I;W<FD??=WJ6GV S>WEO:C&?WTJ1\>OS$5CGQEX4!VGQ!I0/I]LB_
M^*K^*/XX?\%GOBQ\1[S41X?LKC1K)I94LY9;U8II(=S!)3#$7*>8NUU5\2*K
M?.B,"H^(KG_@H1^T?/>FY7QG=HOF;A&+F=E !S@DL,Y '.,#\,G^R\C^@?XG
M9A@J>)S;,,IR2O4A&?U2O7C5JQYDGRR]DY\K6S4K-/=)Z'Y+CO&WA#"U73H3
MQ.-C&3BZE"A4<-.L92C%279IM/IIJ?Z)-KKNC7Q"V>IV5RQZ"*XC<G\C6K7\
M&'PG_P""MOQR\ W%K/J4DFM>2Z%U;4"I<#!./-"@D\X''/&?7^@3]EO_ (+"
M?#+XG>#6N?&6I6NC:[;6):2RO+B&.X2=$(,;*7.65UQE2RMU4E2#7YSXC_1,
M\5/#[#+,9Y='.\L=14GB\JFL2X3DTH\]*FY5(1E?XI12Z7N?1<.^)G"W$=1T
M,+CHT<2H\[H8B,J,N56NU[114K7UY6[*SV=S]QY)HHO]9+''G^^ZK_,BFK<0
M.<)-$QZ85U)SZ<'K[5_(=^T%_P %N?&MC\2?$NA^"])-[H6D7_V6VOC?1PQW
M)"B1C$N7+1JKH ^ "X88^7)^CO\ @GU_P4Q^(_[1GQ?F\%ZSIDMI;V]K8WK2
M+<K<1LEW-<Q!25QL<?9V)####!!.#MPS3Z*'BMDO!N(XWS7+\+A,GPN6T<TQ
M'/BZ'UBEAL1[/V3G051U5.7M8KD<%)-^\HZHO"^)7"N-SF&187'^VS">(JX:
M%*%.HXNK1C*56*J<GLWR*$VVI6M%]=_Z:"RJ-S$!1U).!^=0?:K;_GXA_P"_
MB_XUX/\ M$^.-3\ _!7Q)XPTQ&>_TO2S=Q*IY+I;R28XQR=N/_KU_)7??\%M
M?C!:ZC=0_P#"/N!!>W,!6344C<&&X>+:Z$%D<;<,F?E/R]C7RGA5X!\=>,.%
MS7%<(4,+7AD]>C0QBKXFC0E&5=2=-I5:D.9/DE=QO:QZ/$O&N1<)RPL<YQ,L
M/]<4W0:IU*BE[-QYM:<96LI)ZV\NQ_:F&##*D,#T(.0?Q'%-DDCB0O*ZQH.K
M.P51]2<"OP"_8B_X*\>%_B/X6OI/BE<P:!J-G+<1&"\NHC\T+,J-'+O(=)$"
M2*>"%;#!6#(/E_\ ;(_X+9W>B^*+[P3\+[+^U[&*(F35+:ZAAM(2Y(1#+OW2
M2N 3LC5MH7]X4WQ[O2RWZ,_BUF?&6-X*H<.UHYCETY+&8FI*,,!2IP:4JJQ<
MFJ$HZ^[RU'S77+>Z,<3Q]POA,GHYW6S.BL%B(P=&2YG4FYI.,52BG5YFG=QY
M>:-GS6L[?U!2^*/#D!(FUO38R.H>[B!'X;OS].]$/BCP[<$+!K6FRD] EW$Q
M/X!LU_G_ 'C/_@II^T#XCO)KBTUV?3DED+JB7TK;0<\$*H#8]<^F2:=X(_X*
M;?M >&;Y+J]UZ?4DC;<(WOI4!QCCYN!GZYR.#S@?N7_$A'B/]5]I_;62_6N6
M_P!5]LK\UOA]IS<F^GQ?,^)7CEPBZWL_]K5._P#&>&J\MM-;<JEU_E/]!J.2
M.50\3K(AZ,A#*?H1Q3Z_E?\ V1?^"W$VK:[8^$OB=:_V3;.\,:7]Q<Q2VLRL
MPCRLV_Y'4L,I(J'D;=V#7]+/PR^*/A/XK>';3Q%X4U*#4+2XMXIF,,B2;/,4
M'JA/'0]!C<!S7\O^)7@[QWX4XY8/BW)ZV$IU'_L^-IVK8/$1TY7#$4^:DV[_
M  J3:>CUT/TGA_BC)>)L,L3E&-IXF*^."]VI3EUC.G*TXM?WDM-5H>A/-#'_
M *R6-/\ >=5_F:\=^/$UK+\*_%:_:(ANT^?:0ZG)$,G3GFOR1_X*:_MR^-_V
M8+R'^P+*:\CFNX;4*DODQJTTJQAG=OE106Z\D]!DX%?B?XT_X+0_%SQ'X=O_
M  Y-H!1+J&2%Y/[2C(^=2HXQG@'T]AZU^G^&WT7?$WCC*,EXTR'"8.MDU?&T
MW&I/%X>E4B\/.$ZJ=.I44O=5MHO?1W/GN(/$?A?(<97RK,\9*AC8T54]E[*K
M-N$VXQ=Z=.2U:=M;Z'YK_M@1B/XX^-U#!@+H<CGK<79ZY/\ ]?.:^I/^"3$:
M2?M1: 'D$:_V;DL<< 7L&>I_'\:_.GXA^.-0^(/BG5?$^I+LNM3F\R1=V[&'
M=@,XY^^?H:[KX _&S7/@3X\LO&V@P^?>6D9B$?F^5N7>''S8/(8#Z]*_ULXD
MX9S+-/"?'\&X50_M?$\)4LFIJ4HJE]<A2HP:<V^7EO3:4M([/S/Y0RS.,#AN
M.J6>U9N.7QSFOC'/E;?L*L:BC+D7O?:6B3?ET/\ 3'T*>UCT?3E%S$0+6'DR
M+UV#U-;"7$#G:DT3GT5U)_(&OXF;+_@MY\8;>S@M/^$>8^4B+N_M*,9"KCTR
M,8Z=.O2OT!_X)Z?\%-/B3^T=\;T\#:YI;V=F+&UO6D%RMPI\V>6$JP7[I_=Y
M&<[OJM?Y-<5_1%\6.%,@SKBG-\%@J65Y/1J8S&5(XW#5)JC[2,5*-.%5RD^:
MI%62ZG]595XH\(YOC\)E> Q[K8S%R<*%)4:T>:48.;5Y4XQ5H1DW=[+3L_Z9
MY4CDC>.94:)U*NKXVE3U!SQ_AUKYU\;_ +,7P+^(%Y]N\2^%M(O;O>7,CK:-
MR3D\-&<'/O73?'KQ=?\ @GX2^*/%.G*6O-+TR2ZB5>"76"1P!^(K^1?6O^"V
M/Q@T_5]4M%T%\6VIW]HH?4$C<"VNY;<;T/*-\GS(3E3D=0:^.\'/!KQ)\3H9
MMC_#^K[&>33H4\=4CCXX"I'ZQS>SLW5I.:?)*Z3LK:[Z^OQ3Q?P]PPL+#/JJ
MIQQCG[!2HSK*4J?*Y*T83LU=.[MY7/Z]? 'P=^&/PWC2#P=H>FZ=L&%$(M\_
M\!"*N/USWS7JTL\,.#+(D8/3>P7/YU_+'^PY_P %4OB=\>OC_P"&_AWJ^CSV
MUEJ5O+<S7"7(N88Q!<6L/ERE<>6\GVD-$#G>(Y3QY;9_;O\ ;J\:_$7P#\(K
MKQ7\.;.:^U;3[62X:WAW9D$2&0J2O3<" #VZ^E</'G@_QMPAQUE/!W&&(HT\
M^SR&'JTZ^(QL*].,<5/DI2K8GVDXQO+?FFK;NQT9)Q/D^=915S;*)2K8"A*I
M!^SI3@W*E\<84W&,KKHE&SZ'V[]KM>OVF''_ %T3_&IDDCD&Z-U=?5&##\P3
M7\45W_P6K^-FF,]E>^&Y8+NUGEM+J"?44CEAN;9VAGAECYV21R*R2+DX8,-Q
M')^T_P!BC_@LQK7CWXFZ7X \?6']F+K\\5MIMQ)<QSV]Q-(K,T*N#E9HPC.%
M=%!3!C9\.$_0N(OH=^,G#F1YAGV(RK"XG!Y;A?KN(6$QN&KU'A5%5)5Z<*56
M<YPC2_>-QB[0O)Z)GS^7^*O!N98ZAEV'S*V*Q-7V%.%6E6I7K7Y?9-U*<8QG
MS>ZHMIN7NI-M(_J-HJAI=_#JFG66HV[AX;RVAN$9<$$2QJ_8D<$XJ_7\JRBX
MRE&2M*+<6GT:=FODS]'3OJMF%(6"@EB% ZDG 'U)X%(S!%9VX"J6)] HR?T%
M?A!_P4D_X*?W'[-^HV7A3P5;C5=7N[HV\D,5Q'$(5C1Y)9)I"<(!&C '!+,5
M7'.1]IP#P!Q+XE<187ACA;!/&YGB[N$.90IPA%-RG4J2:A",4FW*3226K/*S
MG.<OR' 5LRS.O'#X2@N:I4E=VU2225Y-MM)))N[/W9^UVO\ S\P\=?WJ?XTJ
M7-N[;4GB=O174_R-?Q/I_P %N/C&[N/[!X9N3_::84'U_'KSCKCG%?NM_P $
MQ/VA_BS^TYX4F\=>,=*N]*T[[7<+:QS[SYMM'<O#;W",P&^*>)8YHGV@-&X8
M#!K]:\0?HP^(OAEPW6XHXLAEV"RVEB*6%ARX[#5:U;$54Y1ITJ5.K.<](OF:
MC:/6UTG\UD'B)PWQ-CO[/R?$U,5B52E6FE0K0C"E%QBY3G.G&,;N244W=[I6
M3/V1J.26.%#)*ZQHO5G(51^)KQ[XR_''P-\$_#=WXA\8:O::?#;P/*JS31I]
MU2<L&8>G3W!/%?S0_M4_\%P=2C\07_A;X9V)U/3XO-4ZI#<Q16BCI&JR[@TL
MC#Y]J(P 'SL-RAOB/#3P6X_\5L6Z'"F35L1AJ<K8C,*UJ&"HI6OS8BJX4FU=
M>[SW?1-GK\0<5Y'PQ05?-\;2PZD[0IM\U6;Z*%.*E.3](NRNW9(_JDF\5>&[
M8E9];TV)AV>[B!_+=U]NM,B\7>&)FVQ:]I;M_=6[B)_+=FO\_GQQ_P %,/V@
M_$]Y+/9>()=-CD+'8MY+)C/( V;5Y)ZY&,#K6'X6_P""C?[1.AWT5S<^*KF^
MC217,374R;@N,#G>#DY.<@C\Z_IZG] 7Q"EA55GG^2PQ/+?ZLZE_>LO=]HKT
M]]$^:U['YO+QSX3594U#&2@VOWJP]3DMIKJE+[HOHC_0]@N;>Z3S+>:.=/[T
M3AU_,$U/7\>?[-__  6]\7Z#KNE>'_'6F2#3+F1(9-3-TEQ#&?E&)QO#QAAN
MPQC*9 4L&9=_]2_[/WQR\,?'GP%I7C/PY?VUW#?VT4^(94?Y98PX("D\<GD=
MOH:_FWQ3\"O$#PCJ4I<4Y5*GE^)GR87,\/*-?!UI;J/M:3G",[:\CES);I'Z
M%PWQCD/%5.4\HQL*\Z?\6B[PJT]OBIS49J_1\MGT;/=:***_&SZD***X;XD>
M+(/!'@S7/$MS(L<6FV<TQ9B !MC=OXB/[OK^E:T*%3$UZ.'HQ<ZM>I"E3BE=
MRG4DHQ2]6T*4E&+E)VC%-M]DE=G\YW_!<_\ :32U\&/\,-'U/R=0N+JW@FBB
MEVRBV>[A2Y.U3_#$S8SQU)'2OY&V4S7#A3D*6(/L/S^M???_  4:^-[_ !J_
M:(\5ZU!?/<Z9IF+"T42%HQ.+FX:Y8 -L8E1;[3SCGL37R3\)_ &K_$CQKHGA
M72(&N+K5[N"*1%!8BU:Z@BNG"@')6.;(]R,\5_N[]'_@K!^%_A#D>%QJAAJM
M; RXCSRM)*#I.M0C4E"I)ZVHTX1DKVM*<EU/XC\1LXK\5<9XBEA;U%AZL,IP
M5-.\9U%4_>5(K9.4Y\K:WC33[']1O_!"+]G*\T&QUCXB:_:?/JTZ:A9&6/\
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M-4_\,ZVC8X^P6^/KNB'\B:\OZ<[_ .-2Y?\ ]CVC^-**.KP(UXAS3_L!HO\
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M>WQ=++Y\.Y[3;3DHJ@\)3Y_.I@[:O5N,GZ_@GB/DM3A?C&O5P])4J5?$0S7
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MH^UN_P#GX?S9?\%./VZ_%7Q]^).N^%=%UQU\ Z=*\+06\S,FH2>>P,+LKA!
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M5J6$\1Z$L7)0BLVS2BW-I+VTZM6G%-O[4I^ZK?::74_O<M0%MK=0,!8(0!Z
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MQCXLQ_T,NN_^G2YK^5?V?W_(M\0?^PS+ORJ'Z?X__#P]_P!?,9_Z;IGZK_\
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MM^TA'\*_BS=>"M=UA(=-UA+.32X+FXVH[3F6*XBA1V ?RRJ,=HPJRHIZC/\
MH/\ 2Z\-Y\:^%F*S;+Z<,1FG!M?^UL+5P\H5:E7"3E2IU8QG2<FX0M&JE=I+
MFEI8_ /!WB%Y-Q/_ &9BG4I4,ZIJCR5HRIQIXFBIS7N5.6TJD7*+:5VXPCKH
M>%_\%8_V5KWX(_&[5/%$5G+#I'C'4+B8E86\A;MD>2.5W "(9D18P68!SY:
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MVGDWNFS/&(Y1-"Y1TD1XY8V'!#*P#HP[@@,*MC4=2/5IP<9_ULP7(QCC=CC
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MJ0=I0G3E&<7:]G%I-.S3U1UJ<9)-233V::LSOZ***YR@HHHH **** "BBB@
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+EJ_5EFBBBN8L_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>adpt-20220912.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-09-10T00:28:18.6370020+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : f5286ce828ba4b7b9b6c8cfa7e802bff -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:adpt="http://www.adaptivebiotech.com/20220912" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adaptivebiotech.com/20220912" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" namespace="http://xbrl.sec.gov/currency/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" namespace="http://xbrl.sec.gov/exch/2022" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" namespace="http://xbrl.sec.gov/sic/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" namespace="http://fasb.org/srt-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" namespace="http://fasb.org/srt-types/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" namespace="http://fasb.org/us-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" namespace="http://fasb.org/us-types/2022" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.adaptivebiotech.com/20220912/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adpt-20220912_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adpt-20220912_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>adpt-20220912_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-09-10T00:28:18.6380002+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : f5286ce828ba4b7b9b6c8cfa7e802bff -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>adpt-20220912_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-09-10T00:28:18.6380002+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : f5286ce828ba4b7b9b6c8cfa7e802bff -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20220912/role/TemplateLink" xlink:href="adpt-20220912.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="adpt-20220912.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140600956638720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 12,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADAPTIVE BIOTECHNOLOGIES CORPORATION<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001478320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0907024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1165 Eastlake Avenue East<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Seattle<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">659-0067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADPT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>adpt-8k_20220912_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adpt-20220912.xsd" xlink:type="simple"/>
    <context id="C_0001478320_20220912_20220912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2022-09-12</startDate>
            <endDate>2022-09-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0001478320_20220912_20220912" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0001478320_20220912_20220912" id="F_000004">0001478320</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0001478320_20220912_20220912" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0001478320_20220912_20220912" id="F_000002">2022-09-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0001478320_20220912_20220912" id="F_000003">ADAPTIVE BIOTECHNOLOGIES CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001478320_20220912_20220912" id="F_000005">WA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0001478320_20220912_20220912" id="F_000006">001-38957</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001478320_20220912_20220912" id="F_000007">27-0907024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001478320_20220912_20220912" id="F_000008">1165 Eastlake Avenue East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001478320_20220912_20220912" id="F_000009">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001478320_20220912_20220912" id="F_000010">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001478320_20220912_20220912" id="F_000011">98109</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001478320_20220912_20220912" id="F_000012">206</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001478320_20220912_20220912" id="F_000013">659-0067</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0001478320_20220912_20220912" id="F_000014">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0001478320_20220912_20220912" id="F_000015">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0001478320_20220912_20220912" id="F_000016">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0001478320_20220912_20220912" id="F_000017">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0001478320_20220912_20220912" id="F_000018">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001478320_20220912_20220912" id="F_000019">ADPT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001478320_20220912_20220912" id="F_000020">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001478320_20220912_20220912" id="F_000021">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M7>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " "H12Q5)!Z;HJT
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M2P$"% ,4    " "H12Q5!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *A%+%4!_' ?[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M *A%+%697)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ J$4L54BW@^MF!   K!   !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M *A%+%6?H!OPL0(  .(,   -              "  :D,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ J$4L59>*NQS     $P(   L              ( !
MA0\  %]R96QS+RYR96QS4$L! A0#%     @ J$4L51PX9>H_ 0  / (   \
M             ( !;A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *A%
M+%4D'INBK0   /@!   :              "  =H1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *A%+%5ED'F2&0$  ,\#   3
M          "  ;\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(   D4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="adpt-8k_20220912.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="adpt-8k_20220912.htm">adpt-8k_20220912.htm</File>
    <File>adpt-20220912.xsd</File>
    <File>adpt-20220912_lab.xml</File>
    <File>adpt-20220912_pre.xml</File>
    <File>adpt-ex101_62.htm</File>
    <File>adpt-ex991_47.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "adpt-8k_20220912.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "adpt-8k_20220912.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adpt-20220912_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adpt-20220912_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "adpt-20220912.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "adpt",
   "nsuri": "http://www.adaptivebiotech.com/20220912",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "adpt-8k_20220912.htm",
      "contextRef": "C_0001478320_20220912_20220912",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "adpt-8k_20220912.htm",
      "contextRef": "C_0001478320_20220912_20220912",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptivebiotech.com/20220912/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001564590-22-031433-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-031433-xbrl.zip
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MTUL#N&%_=1"F1?4'T7P%C(V\?7B8U8#8[Q\L8\UO3MRE"ZJ=?@YH#^RO"F)
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MTV)IS!*:U-"X66SO&9+]@82\X0.5\GE[=C>9E%\X%"'44S<?47^<!9?EI<A
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MR_ZID5G[K5;+S>Z^F&I69@AA???+_=V03&F,;1@JR )B&M"LK;.+=Y)D8W0
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M*GX^?BAEYS/&P\3$(UQ(/Q1C5&ACH1[C7R_;<_C7[9*&3*]G_"WYR!W\W.5
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M>Y=\ 5<ESK[8[XIN<%=T'OTO0>XO.(%FG]G?=*X1#<!?":!<X9;H(^DPUW]
M,L%"I!Y2+?Q"NMQ%&<@EX7@NQ 'R43Z1?!"ZBGK,#Z4[))(J+KM#W3)NX'>
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M6_MXF@T7H ER@-;?RH#,(K(L2-IRO18=_A7@NO6'U%5#&.^H>HIOGSA<D>L
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M2J7HEX[BG&A 0(R1)1EJ[BRW0W0'SN%X(J]T4[@YXP#D;KPLG3:D.M3^UA/
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MH8-9%H%V"=^.\VP6E/"209G1OV%0XI3^\S]>[NQL[=]81-O2-)D(W;^]OQG
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MK).D6?^O\]7"1GI:*!8 NG1 4]:7Y-LQVAZG%MNV;>.V_</ROES,->JZ8DF
M),(,U5M&^+@7&:5^]6R%PY[-Y]9+6R?\]N855C&:*U_CUB3UTZ,M4+?O0=]8
M<M_FTW2XCMV(#;M'Q37:LVEWNIE^"F;SD.H -A:$+6WL>4OT.**$8EO;VV#>
M].P]^J=&$*^1SJ2VSR&V%47[\;/U!5ZF'9XKA-[#%N=8U.7:C%C#0BDM15'-
MN%IKJ*F!;ZU$=+APEL,H9"F_[5V;*IQW%_>1!K=IB2^XT8R&-IMQF_119]%B
MM-XE>\1<O=GJ NM<W[,EP>GCYG+0#DXF^7#AC7)=5$G;[R">R**CU3@NCO6Q
MLE<H2^D*<IS1(+S"(?5LG9>M-3+1LJ*;I(R#BQQ9K?5'FFV]1,^6V>>#]3CN
M-$O!OL)JX=GJ/MMLGW$[XQH:3J6!.\!G"E#/,,JM]5<X!?%L6$EP5YQ_)N/[
MY6#K&0H\#'0/-WW+XL9&K*[2=S8#BVI!LW!<KJ$;-@C)5XQ?8DBJ*,2[JRY5
M'F%I"NL<* !&8EBKF9J0FUBG*N'Q0#6)9_@OAW1"C$#@/W]4T40&S+7"T(,I
M4XZR$87PJ'"FX&HS&+"0(K8H+BQ%-*-D0 BIHC+E2^!P108RNE'0MOHY]@$P
M7)Q>8 *:>*3K4IY5]X[UJHEA>*[0"1%[F\9A;3;;F45AG3>;"<+:GQ57\=>7
M#A7VH\\X0ZF95.>DS 6)NBSXZZK$Y;9ET6X-H+,V3NX-50MELYG.*:'E)B/!
MJV0IW931H_%G2I>A!2-"(<F6V@!-.V@WP]@,OA?%(:J<-;+0Q$-SBOM+!$,*
M3Z?+C"-LIFXU8F(XDD1"T0)9+K07K8S%[SF>4*;KX$@VNS"7E/6/!;V1GLVY
MT@M%YW 1F%#0<$D7TBGLT$@;O8]4)_8I=3^Q=3O'8<>AF^*"Z;*AJSA@,(ZI
MEV*KSC,.X2X$ %#)IF>838;YV6E_?*\%Z22V?$%ZHUIPJ<-]M\Q*&&C"7ETG
M&-AX.WZ5Q[K$B&^.[[1"1%A.\0>PO2**1R9<C?M]F>5)5+/<'/$E&+<"[J]2
MYS,^N'D9PVW@<["7KPW*AIA"0"S"X4-U6!YX9MC*(3726=XB3E\W7BY.*?C*
M27;PC&D:8T)UI$JU#\,-<:DQV1O39899]K78!U$<NQ?!4)3'+4_8E\P2D 2Y
MQH]?T^SRZ32[W$<69_%DF@^.#30&<"JS#G-*SC;+4*7.9W>Y>(E@U:)JQ(X,
M@]A!T@_5!@(*P:P;S>YX'BE0\]KKOR^YX##?*[:)W@P.S=<BE+=,U0R%F63Y
M!(W?(C#&2/F99'@)_*O29AX0;,LDRR(*O8-XRD!0VCIZM-7V04' 1%)^3&-J
MN 2-N8VR^4+VV&RY\X)UG'^)'BA#E<F;TMO)4A1BQP %DWA"^L>,9!<L:*PP
M_E$ ?REDI-"=G?Q$.$$*58W F5K]9,Q,B"T.S)BN;M34OA-)J2ZRF',_\*JL
M&L*9Z#SP:-"BQ[(0FQ1^.L)!/7OL7*TO<TQ]7*':@W(TFTG)%1)#"B\CIR1T
MC@(KF9;X)+=7E"Z^WKF\<7630L=Q(DDJ#76E:$(6F6B<QJ3DU(R 7 'NYV ;
M5G,$&WHP&8"5T2SRH!H0SA@=46(0JL=E##HIW@KK ERD7$%:F ^#^P*3(+PB
M+1! 29)=+J68$A_2<TPZ@2D2PT75FN?8E3@CJ4/(Y@D&$!V(YM1BZ<HR((?!
M8')9*6="7N@DF[/BUTZ9Q-/TP=PHN[EFU;G/?4;*?6:D](H-]L6+=\?J7&0T
MQ-K.U3>PW$"S<]+C>_5NUYHQ=VX(L+W3OS#[P#ME;XO!<C5Y2,8\& XFWU5F
MTC6PC.B5MA/R(:ZJF FOK,0P11>Q':.=ERJ6:Z.L4;:*U!S8I"2CY]A$7G3;
M.C47$JWK2'$']>N;U>"XP*"@QDGQ!5MPMRDF0)51JN4L=#@[EBGWMBZ**)9R
M;6M%DC$DL?:CX.*/PJG^<-X&;W;<F)M<T=>JO#CF&KX3B;AQS40B=<@"G<D5
M[/@E.\V:]1CNJH=48=<NPJP#>W(+8V<6#=]G1S38&4+<?%+,P276_&#RL4;B
MJ$7D! 'FC 1.AZH*V F.3U]Z-DQ9;TI4EJ//S6(&K.%Q9P-F,&C?:>%4?UQ1
MS(+%K1<Q5X_/12?'(]%9B8MQ&Y,)7BOP3]_7S]L8NWGBSH&@"":JZ!A&RJHD
MHG3Y!':*G7FJ<*XF*")U93*X4?FC504+#>/V'(E"JC;&4HELIV9AD?AXQ,#3
MB/P+-\YOKYXG%3-?<T$#=,]4!-1Y,^08BI"+UM6.<%(P.F&JJ<P'>),+E51<
M('4)AT(_K>;(>^C/"*BTJ'\!VVO9Y&A-UCN,WYR<GG6:W$TD"^(NN.NGTJ#Q
MC+U,7B["^@6_ Y5A#0M*D7<PT+V"B#>U5+\!)^?! 8FSE96\Z-JKJ"RN=JJ[
M?@IR-6=)-B$7=*ZPX')$\H8<E"PKJT);2#@#^&/JY5FH-IHEB-S"@L/*%FK&
MN14K5/%+0(GB0%64S,(A0RX#,C_[+?Z?-+M,=#19#?&FV#_VU5P(&A:Z.=P8
M=U2A-H$U5Q[DO5[1%H;5R@5NW(!$7W_!^H9?T_:*K$Q2,7 9=!4FVA4EYS_<
M7!:,ICJJ@*BW!UO;=;&%<:H>Q<4HR0KD8.^I(#BT:/.8CG$11WA83,[<2.NH
ML*U4',LKQWI+#I*1"OH7S-!3B=@"*XE#F[88F>U0(.9*Z*2P2#8$?O448:\S
M\RF1."DG+V'P5BS4D *"V@PM*:F-(N]F*X,A)DR2.1+5P#1&_3/6)I(Z]E!<
M*1@Q?' PQE #Z9%$<Q,TX+FZE>TB=!<$Y],X-\ER=13YRC"(IR:AINZP69U2
M@ZTS&%,L,3=8CE!4P_K+>N%E9+_$%/Q:F;R1X*\AG)Q1-1OF@L)@H:-,&G2!
M]7IY.>%40HE.<EANK'/)0A#OA1P28S1(!@'\7L.&4=X%HW<L/8H\5((UT8 ?
M 380.(XP=L_-XK*DU$K:;(\6].:#2JNQ(NV_M>=X7NX^&JSY2AK"#;Y@_Y>!
M5Q=!SKD+H1M&#=$%@KCK[)&J 0NL>TJ8O7T/^@%;6I#G$5AQ(G^D<3&E/^=J
M]%5-Z$\0'YI_1W??7)R546#,6U.9Q8^RT ]$?92+4>H.^(5PS8 &7OBP[GV&
M=1]P:_L2]3/>T20&%FT..Q_COM5/992B6&:@;/1L9DV^Z9?OMLOW)RC;%F2
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M*'<V!&LX3JAB;*8132,>L;9@% 2XYE;9CT:[8RC7F71-J;&[T/P#A8,'FR!
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M<:D2^*BSBD\<78I_H"B[!!)?!!L[6YO8@*Z03CXP?MBL'2/[[J8E@*$4^IF
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M9.[/91#0 6)<AG@<D_;BWI;E]C*L?U?"D@]J7>>]NAQ<T:_^L6S(;V<'G?N
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M\V7A]QFD[]6AZ@A-/NCAOI7[!\YXCF+U%"3BZE#KP[V/T25"6R 98=Z2P%3
M%VDU"W("T!W7^788!".7D""Y8 FG6@1_5EE9-WSZ'27]60D,J S^.ZORE+HQ
MT4^RE'-:&AQ=YN)M-4LT&9*,"CYCY_5NJRWL[!EH#5_>Q *V3YS/58HEM:YM
MC&%(L.=, BUG\-L?49#4GSZ;&"=V:+)E)O7O9#W6FR_/11*X\KE2@PN7.8!H
M2\]J J:MG][02(G<W7KUZM76JY>2_W@'TL'0[$K#34*WH0W7DG,U2]B*<T$V
M,6^VC+$;'&9@'R+*\0'Z9L.&@8X "$XQ,%;T7N@$E)C(YM;"7S/J489_%5D2
M4>?9,H_!X"=7,O 2Z4]6>^KJ4#2UH[M!9^.-NK'F43RA[F]O8^!(HVF:)=F$
MRDE/TM%@L_$"QIDLZT)YP+(R<6I>QK@,V$,^ UXWU/6+KA]!WI'HT';/LPM8
M>#'B5_$N]M?4UY <^4 T@IMRP&4 _ZY_(]8F#[&;%UJ8#O)+F70'N/3C$5AX
M;]_#?_:VMS:^;B)5PMM=9&2M L6&P></!^23/OYRP&()R_718F27,87J:KI[
M=R0FHV1)S$';1@\%S U6'<0A&$CPWLBU/#58:J!(3N?^;ZA-YOIRZ0ILX(WA
M)N<;6Q!QDR]N,09 [LD@<+PW1CSL*5OQ6$EF2+)8<4?$=SBE9V/[L]WQ7%W:
M;$_^%N''8(.>"H8"#XZT:U.E-S2/;$$M<CW20"1 -E+-K@P^6:G22<S?-TNJ
ML ;*AL(^UQQ*&.O23ZN6<<Q3D7PF#K"A]@6/(Y!?NS $^%CSO! 6WB3^D*0X
M=+BR+:)Q9\!N%4')R2[Y"-62(,"5:?!YVE"$0%G5*;2NLX 7F7">$K\()]N;
M,C-"^G<T5"4EN_RVS3F%@J9*O33555C6*Z<7=M2!V(<X$/.I1OK 7TUA6V-]
MEQ:TL>2DEL_$(15BVCX]UI3&.0N/I#SE71YFV5?CFD-PH*5,89ZF X^A47<3
MW#O,^T(D)-=36Q-W9IJW4O0.F-\D(W+-6W&V^JWAIZE.YN,JL0O>!+S1-2V5
M#@(JIL+AV]AZ5RF:YH,I+]^>R'Y@XNMA,,TNL5M#*#7MWS8Y6=:BC#@L.W1+
MM5V-8/G)H87+)K[@4J 0%5,@Q2XY;FT"VB;\45==T/'(\O!&I!BV:/%*':=9
MJ1$VL<<C] E%Q@IK<NO:$O-"3%CJ4P'%_RY,_%MU018.<27WQ78;45[1V9M/
M%;SE2%<<SK(JODO5L!+I4PLT;\O>V#_/>JT[P9B1=2;4H"RJB;TQO>9\2(6K
MYZM63@MGI>;T-2++1O0K:--BC<!"3-(,B&SDJ?!*P=Y-D'#.NTG0A.D:$JDE
MC6U)"\KIFP@KX(:_M#:^*9C"6B6 9XOTM>K %:J D_T37J?SXTR[7]I$'SES
MX,;K;D&S=P?;VS5H_$I,;!\K>F,=-+<-78SC'/%EP*(";C.?"@RZ/_NMS@'W
MOJP_8R!HSP>"?"#H)PD$M1J!G.HYPKNF)16V]30X="67N>T*"$;:;6\[$V-Q
M#YN6=K=1>,"5\C&K)?JNPSMWCEN-KHI,P2T&3TJR/AD]YL3:WN)>:S7@L7&E
M=G-0:0.*H,N)A;CC[YQ&+'/&G&W-QD)K802'NK7<6L?<;A V3\!-2_:J4+V'
M6"HS2UFA_ZQNF2AS6TYE.,_+P=:SV@CPV[%\I#I-4?(_B8ON'6FC<CF?<5C=
M#&/,X@8W '?GTSBWW_JUKENJ_@A*!QG[PE-ZU^H'AV#P4VRY3N7Q6_$P6T&]
MA5>Z8['6S08&DB2[Q"VA1L>^66)OFB7B1KU5Z=>\FI>C!>^H+Z.^TR[=8\]"
M.DHY=SC' KV$I'25JOE<JX0R(!S0B2R/J)%5'JA+A7%'6WU@X2R,<WB4J'A&
M7N$PB,?!D%J#HV>8FXJ#%E\E',6][KGR6/O4S;HE1(T-23U_R-2PZ@4!,>MO
M:(,7R2*H<X>:R6;A4@//NG! 3!@,IQS\_^R]Z7+<2)(M_"JP_J:O,<T@%A>M
MK9DQHRBJ2C-5*EU)-7W'KGTVADP@29200#864NRGO[[%!@0R03)33)'XT=4B
MB240BX>'^_%SYEC*"#M#-1$I GS4OQP>:#D"B<J90X>NKBU)RPN3+.<15BXY
M=:^B]8$9V29G*A!T?9DJF].4[<^<PA3!N8GB,RJ3*K6S1O9!=&?:A;N$NE),
MTC102E5=U^<ZI;?2^R'W/8.G]%AS(PD#0>/FR-A\NX@:DLY!.$.TE&2 4FXN
MK?Z)$(J:%C$;]90&[OA@0E@U*E6^3&S^<'@SI>(YE>R4-D=4O8S/L?M#IN3@
M[PJQ;SC#SX23RR1G+!E]I9/3:&5>-7#V>Y*ZW[5D71+IPU[%V((;31/30^<X
ME"6F@FBIMG=\M!1**,D6"C^9V"=V%2\8]&ZJ6KM,E$)+< G;3$POF:8\J"1%
MP9E:+?LP3>HKG,3"Z0##'UD'&+HN*?G!] A9H6I.2OB!FTL=!N]O9E*>I->S
MINK&WB!5;\KD6D9%P AO)HH^FU^,[B@M,NA3.BGS=?AK$KYBZA]N+!MB MIB
MMR[5 4T<J%OTZ5B-?YM-?(ORL+@:3R^0D@G'49*L&$&K&IRV,+FZZ7_!UR94
M]\6<#0K AB@UO8GE26UP,CI^!G>?4_&_I7X _\MM'@M8W#^=,@0PG26OX9YQ
MWMQBWFQ1RA7G@<9=OL6!1V1XF8P1;W,BM::P/]8=::Q:+%4T<8(H8W!JZ7E!
M-X\A7S2%5:>3>2JE-ZZ073K$IKF&[$7HTB(VAG]41'Z6"]-/46$[O@%-*/<6
MC3AUV)<M<)>'ZS[RF'P\3GA7=&CY(TX2I&VT/R5P>0YM'# 7?T0XP?,13G /
M<((?P>AXK4N/)=IN3&:%T1ET^Y"+-F^\AIT>'0/GM6I#GM.Q?$.))?W6<1B;
M]PPU.@D+G[-\/(+2!Y.!'[[$X$U],:BE49Y#ZTJ&U_,Y[4PQM%%ZPFO/#X\.
M]@_^JFL!FH6B5.YF\T8>K!T\QMVKLW%7#R,PZT.K_ 5JTJ^?T$0-U5E81T^'
MWM^S()Z-"^('/I\^O 5QQPF]VF,/@^^07KL?OQU.TTW5+GEJT1"T06)^E@%=
M(E>T\D!&_U3H+NKD]?#4?BM<'VAB5S>$X"8+3,CWGTE9/#P P#LE(ME#W^7M
MFRE6R64D!X%I,%W;&"NER=9=:64TV%'*"^/KZ5BQ_^__&VP&H^B8V\N )UMQ
M+%7-P\J>C+)HW]+1_U1UL#B3WZ;5/WI?-@Z$7:I.!):]N):?-7LE$BR(4J*4
M=6%N)]*_P@L#X8VFXG<I'9[QKH2:$O.DUF79+.G S+CT[V2.K'LS$C#35)^A
MXM9U:Y3I!B$!43P?]$]-\4$WL" H,7VHUU%]<3Y++!5WJ]J,4E;=<G,DG+YD
M@<AV5;(N.#/L'IJZX?2WSU[^!N(:QO<K(H>>3N;F]?Q1XYF1_U)X4;5"KF+$
M$#NE.XA:HPJYW4I)JU;8T!%Z+KL9$6)GHAE61$VN&\TXWT^4ND6,O<P%HLB9
M.*Y5#ZU$;PUFI'DG]M84+UX1W,'X;&'P%NMZ5W&J5"C!DL[4-(*INYBBE HO
M'+WHLVB:9(),X&?0I%.X\UD6594AV)SHNDQF^<3UJ]Z6L= @_&N6)1$+$,*_
MD[+F^_$GMB",_[$)7-;WP+),GC!FOZA@2JG&]A#"5!.U*?6LQR[E@K9/KE$R
MYFAA<RZ0K11MZE 48Y&<E/^?IA;_D^YG.$*4&6J&'H/FI<^P[!G"4M!]U7:L
M1<&*DPKY6@5M93&G,CIJB3Z0IDG5Q%K3)$_F."Z*6X0N0,;7-@]242[1VU15
MY:69[:IN7!JJO@Y+RI<1D:]WKB!_&4>C3"Y36,&7!3@(R-XU5LI:9N0=$>#[
MX?-B1:PUSW3Y\(^X@(6+IQ*%.<G2KWC:F0JY/<%GN@9?(^-81(TX]:?(]H$S
MP&/<%%%_5'<?MA\$W>\0)UTV%L/HC:<9H0['PG*;^<=KWAY8E>J+,:UT#VFE
ML4KU%E6JG\25(._X[-N2W($=*[GLF,D=:]\*4<U[:8]FHV(\\ P6%KP'K/:.
MM7-6J-K-1":>31QO?P68@C)/KBLIO@SF2>+>2,";JR0CREET**.TPOTL(;<5
M=I@F(\>2?Q'%EVF%VQC_2$^#%S<EL5+FBL(-]TL2,:K !09GAD*.# %'FD+5
M!A&UP9\GYC'8#H5K+^8[UO/ACK6G(Q9$[J@^[N]@:[OY@!UKY,X-,1SZEA&?
MONA8PY$G%A^#?^Y:<_/DO*C3B(^14;P I[FJY?3(&'!U&N?: OQIQ[Z!JFOQ
M2E%M>UO,&KMZ=U?:Z;)":0O:)H(V]3@_R;G&2M=X\G,_RN>/^%KMBW:2M;TZ
M.-;07Q&5K\&HM\G4*ZG0"IX=_'6,:7Y*,"(VJY-X=3$_,?8BC)F(WG-#W=:*
MJ<4P8DQ2BP4T^.^PY4)1==!%5"9<(&AX.'5<CP*3^(,OT61EH_I9%$/HD"OF
M'@6_D1+L15-7=23[#!(+$Z=A$B>+);>\3&K1,0H#\#R^DO/1\)=6*0Q>9-7'
M: (2(Q,^@\96J::LAF]JDI[^8(C"_7>$QC[0RX@BF+$/JM;OMJTKA[4.7EY:
M591PQ=4%ASPIG6BW:!;EG/RM+D(J.Z&V,?OE=87YD$P5FL83*8R:\8>IBBI*
M]->%#'0H]*P< 1.X0,G%F*1(26VV^NJ*A,VIT'7)=L2D:8@'EL)N,[)9JN>^
MTSB.9LS@7&Y5AQ'*@NR"Q)X/!HGIQ93.VUL2U;UB(%1*J&(_Q=!-V"*4 G6J
M>8,Z^+@ZR9]<PU'UMOBX%X,_?3\(^M$<?Y.(/^P< <W)?_L+ K\PTEC3<7Y*
MQ83_]I>#OP0S.+(+^$S_O$2Y./E9.H;O0  :E0[_3?WC=<"A3 EDUB7^)U9W
M\=^.C_>/7OV5,&9U[/_[\? __\3OD!==RO?!DOI+H.Z3[Z-U5A587WJP_^+9
ML@X4E$U=(&MSY34$F5MY!=DB_R5_&1137V$B;-P>_NP&@/$7MAV@"J:;VI"-
MQ%U7+9R5$]ERO<WXCZ.Z^Z-J[#]X*[E.0"H@W^'!OU;-LGNX>_GLKZ_Q"4\N
M^.,.C\!T7&):&QP*Z4<<]G_'> X\80#X?C+.H0<PA]C%VMJT63ME'L2^,MSW
M'#A][L<7_9?#HV>*<N%!K.J',BY'!\_#HV?CN.S<N!R^#%]TQF4T:;LT1 <'
MHTG;P7$Y/A['92?'Y9EO7$:3MD-#=.0=HG%<[GM<GAX>A<_&<=F]<3E^X1D7
M-FD_4606?A>GE]M*+#QRH.C-,QQ<P/HF\DO1#<AQN(Q^5T69Q4^NTIAIW$I^
M?D<MDG0U;ZNUC+F0M%9J<I$MEOES@W4D=5%.*-N(=:^8U4/%TS HB^LHJW7J
M#GX#8Y)4-1+2FM\I$3OS&VPLI^2P_^E;$.T'W\@]JG. 'K([-]UF59FFG+XN
M.:U!6)*?3TX^AHI<E-66*E2Q^P=\%).0QL(%HLN%.^.Q'P1?+/4*'%=3Y*JN
ME-=C@4I.G)+P,1557&A,RR*I+XI8=_L2Y7'36:)U*V<)M!,KN2I^F.A6JY9+
M+V@=BPB&%;\:>7=S+%7A(CG)\SPL8/[+$9C_:.SMKL"[;@W,[^$OV#'TVAJM
M'ZIPV[$FB^W>L5:IK<3:9+IS@(BQ0[T!>G@KTEQWOVSL7;DD:Z^;7@<+Q,8O
ML^L=1+!Z&<[NL3U>,K5[;,]DUP8,Y]N)1?J;E.@FP&Z'$VW'VJI)@#R>]JZT
MD8N-T:5T'<Y=:^9>L6M-ZHBL&XU4MROYF"22 Z*'(+Z\AYB, ?^Q=4$6P2-C
MEAFH=ZP3N@<5Z!3#_MWZ-J*HJD;!Q1T/"+2\@5Z(O$QIJ>GNC'9]41;-^06?
M]QT&%3Z]VA.E#6W4L,9^EBUX+$F]V#P7Q$P?U?#0/Y9&&XY?T]%+0;2O0W5F
M4YLU.;%E)1%T#G+?R"D[B5FWQ!#"J7:KRD%%&T=HX!CU%F-DKX !AC.T_5>%
MZ=2,<IZHP&:DOEQ"NM;IW*:Y:Q/6;;I%FL2VQ7U'7<I*%UCY%%4I[NV6#DV7
MAVL$*'>\[E[.!^E BDS#9I364K>;JC4U)$!'&B,Q+Y6H#I9<^M(^ E#,J;6H
M^A8P>AXR!S)4/"GU'H+E >H%HG$R&7!L&>?$I]_??0@^%'57/6"EHJ!9I(=/
MQTZD3OQ8%LNBZM QC=TX7(V8*.%D-O88)RJ8PDH;XJ))LE@4AC1!#;.;T=83
ME]%5A!=>167.K#72I!A+$N)B5A>E>C[3SE(]/3&DGB.K##V<>*:8K@Z,8U+6
M#OT0Q[DQZ<%#F595PT)B**2&CS%UHYK'%3_#RD-(S4T/EY1+,H?V.3F'9V;1
M["NQ'G++7+8DY)?+4E4#09LAD]V,=(<PS7(:JO8,VXJ$ZO'^T=$HH6IU_MEI
M[^D ^@QV;&+O0L?A[-N,R8Q)S+VJ,%\U]I^C6.WMRG]Y\<RHL_%)1N?TD'FV
M4\5>J;B!>GB[)H5/9QOT[8_V#XYA5> 18UP9K9'U=G[OFJ&#,<;6F=Q6'5E-
MO)-W*#!FK+/FHR^P==ANTEPSE-/)WF4ZV7NCSX^2<SDG#59YK3MUQP$W#H!W
M=-MI*ZM&5U5NPV.7\F0N7%;!$;MFN%/O>Q%=$D](#3X/!@HQL_^G<,S.@\L"
M&1RA0_'0IPBK9WB=S*TDDY%', %5DQ>EXF@%XY#FZ-',TG+6++ -Z!VE52!D
MXS6,05!<Y2@(R3=GUW9A>G9-TJ8VD[-='\Y.E_J#^F+?E\!GX$?J ^L-VM??
M,FIXJWW[0?!'+CSI"=$;PY!;W"%"_6U\3S/L:KS+9(Y&F!@3N[7ZCJ/H'+O'
M)>3#\O2>&WK[D>,3. F"<_44=<GO6@)5S7'\K;R, Q_BMB K99DP_RV&(_CJ
M*.<Y>Z[OT!>E1-*P8$)<:!M-QH %EJ,9N?%^@SW16JKG^,PD[KF.6"^F">S]
M<Q,2,ZK24? K,HF)JC*T07V'7C300HSJ](>!4D1T%:*,K3KG%"NAX8+(5?@<
MT&]WE3/(BP<&#GHU@H.V"0ZZQZ'=E536&8$HP82\$_9YRTKJ4P-Q.K1%+/Q(
MRK8R-NV4UH4L)(\&.5CQZOT'JQ-STQWN2_2MK891!K=XR(IXVCQ!:"I*,M3$
MPY$5,Y:05X($=?0-?IM<7C,3>54C[!35&**J L>'4V;S!!TG%!%GYY IPU&W
M64A^>!^$W:<D2G-#^PUS+/G&*2Z!WA+[.9$7!5$<HZ_(G8N9<6CD8HGTT\R<
M!I-%D5(C?1(=3YG5W,!PB4L3&RX2Z[CC1]_HW3K(MF?O:_C$G/GD\RC3 0DD
M 6%/@$)R3*&"1.>3T1.#*1:<S'$@^DZKV.WZ"@J86OZ*\L!FT9).K:@T03L\
M,QH&[S]]#OYNS:=WZ#BU,=0^=,0X,C@RG*=>$5%G,8&2+@O9+;5X;]61#VG?
MDUD6:4T& \L.'6$ N"9=<+X.#C<-YMV5Y -%V$EWA98IOY+INNHZFET(B% 6
MEC$<]DVD.Y!RE+VU*^D_T6EJG5J*'*W)/HXSY4M2+KY'3/SY_L'A=L-^MBS@
M#S4 ?1 :!#^07<- !6U@&$@Q8< %[,H$@<%P'H-LP(3.BX;K-8C1]K*-O.K4
MV2#Q7!RTN&O(@Z/7[=715Y3VPWAQHN@4<5;P&R<MH"\'9WPU'":1WX*"H=/!
MOR'2L%1J5^2+".<S31(FJ2L['FF<9$AP C_?*J+9Q9\<48S:!L7<^6'Z:;<_
MZWJ.#C0_L00JG5GD[[BIABX)$:,-1:DNJOVC\Z#ZF;&4ULJRUI(^X%C8M%LO
MF_]H8%$<'X3!T<'1T;B9?+E(2PSVEW6_G)P*Y-(&3S*3WB@67:I^&;;KYH2M
M$GZ;EH'%Y.E@D> Z[7N..[T].,$I^FK?8]M_N7_P=$R%=P=A12;7T G<,),K
MS_Z.B=PQD]L>V >;R'4F[CC<JPC]6Z6(2!++VQ.F$^N+M#+)CW!(AH0O>@O^
M2%94J.']*\'60O:F,7Y%+T T+7B-X-+4UR:O$[E/40+A^N&5EB=5\2WT#;,,
MX[8JWL8G=7.'\071I2?I#(S7L>2-1MGW2"%@@/&\&,FCU22:)_[L)1&#DZHC
M].)E<LV2M28F*B0$*,@XU?_&E+C%#1^GU;(0;GBA:% SI"W"R*]"8<[S7*:+
MO*K].(P:TVA*N!=5-3$(BT*@H7I-3H@"G#9\8JRD5H,#?>S "7LY:4-Q[ A>
M7\Q2$V7%QX_3Y(_3?OC<'WE*@3NC\ G_C!-*1M.PBH" PZ0/T^0\K5C?=X++
MUIR.4B;@M[:@/\&.5'%*J_AAZ2,>'XR9UFUF6G=JT>U*[O66- Q@ X)W'+<!
M@_U9QVUVK$C28Z!.3Y\<JI 3GBJM[($?#*,%]ZZ'X&)VK .T,JX$*W:L>2%'
M /6!<IYF*Q2N:HX)PY<@+FX.?FQQI8JK.D(.ENXA;B"2-H7]J'\&D".@,TA&
M0;JRYP#&(9.*F(&H@A2#TC@5X/]WK'-%$_TFLW?WITN!,5)R#3S-U^6A7AB9
MBPL;ZZ>5*<^)YXIL>+^PF',5>M4GX-^!2S:ZPS8DX(3<TJT$,JTRO:.]>+*7
M7@X(=@W6+?!Y:%V1 KM');TI))$W&*_64#1+6-!83^T?#RZ)>R)B.']CG_!?
MHR '0_UO?_F?+\7L\/#@^?'AT<%3%*.)VG\[?GKT\N5+]3>[L]]$LZ_G)1P&
MXR=VJK8]!C15_O+O)RAJ ,>/]^_W>WVEUORR:2^/GT/#W2[#)@U[4.>^:1G\
MI/Y[RZ[X^,>GTU]./I\%O[\+/IW]U]F'/\Z"]Q^^G'TZ^_SE\^O@X\E__W;V
MX<OGM482O^[V*_S[3+'^U3YD=G&W/;OS#+)BG(?>.72K^=*^YJ,6Y)MW&:Z^
MPYZWSA#?UYC>?MQ,NFCSH_6'HI! IHY*'3S^%$B0%',HP)^S;_CBMIH) 7]-
MD?(*7& 516/?3@71% >=E=,D#A_G=]:3M- CA6=GLV19&PH575,\A\LE@(;8
M"0R^@0^.$'\$:C7VL[6OUM8E[>5G$Z+0+GE)V\GK,KOQ >.2KEDLDAAC>N 1
M:P:/-KT(!0>7A"!I\7F\(_""RJ8XR8X;':';,Z&3S/).NO9=87NZ6+RJ#%ZL
M6*%Q?L?F]:.G5K;O>V"H'Z#%F6[/XGRQ[ 2>;Z?7C#+QL2;*F9 1S4K6FW'.
M*I;B#0+9N&??,=OD%<MB61(45YY:S.=$96 *>? =A(O&JK8T;P1\:1[6QE$*
M*YSGM5<7"!S3D>2)SC1U:!3T\;%P?LVX<?#CDUIU@:"2)'PPMTG^?HVN-'A,
M:(L9W\V_LN/8%84I2B2@AE=5BH[!ZI_6N=?D13Q4E[W\ENIP3_:X>R)>4\DU
MO/1LO9OQ6+S&YYOT&H^VZ#4J=B.7)&3T%^_97QR^0>L1A&7]:0W1[:"=>TM#
M?_AL__CEPQU[O]NVD37Z/F]Q^+?+:0U'&;'[=W!987NCT&%WN])>. S#=BA8
MK@9WN+OEA KR9>5I;<"1O+J?5&T(N;-VUC7WWY[A*E2_FZC/MD"82X(8>H@"
M1:K9D!E2VJ!6Y*@+^-1IHGK-IO&S0>;"],;]U6UCI^;9-,0E?-1-\/ZQ^\)Q
M@=YN@6YQA?[=1_+>I@D,;3)=<E[GSI&2TU>#%]ZJ=658DCM<A:O7Z_JY]2/"
M*PY'>,7W@E?\:$;$:RUZ+ L9D2U:D7>P:+&^,:V%I"_-9R7AZ.3$YB62'_+D
M/@AD*\0UY%$NC]*@6[2W$:G"R3RC@EDZAI/.M&%H&O0YV@X.N]H!N:^^UD))
MK[YPR$7X?<.N,V,]=#B_QWQPH-:!?QB'O,X>ZHUU[M )2Q_Q@\RJ1WSLUD&4
M3\G\?P@<'LUJ=H1@BO[/JZ_35W^4!R=G[03GZLM_OMGE[^\<M=ED!'=X#.!3
MDBZF35F1*3C[MD0,]K##/F=6UCN<"B4$?_:^S"[8U\BC!*OJBS)/KG7&AN@P
M*-^D;D175?-I:/*,/#DOZM0Z[MI)+ZSUG34EU81:I/UF*VECPA1T+ RF34U*
M?)HHG^O^4CPH[AT?3%"XHFHAS%;DB"(DG;\L4D(+.JP<)D?6ZD/H\O?$-E$3
M@3Q*V5EG>CRR8LF@/(1 <OXC@7\8_./V^HY)H%4UP!UCQX6_TNXXK6!?\T8M
M*G-PYBKA*_!\H#M4K9%+L!'V?#"?U87[)8E]W?ZQ)0X%GTW[&9Z/_ _%B+R,
M:VP(_K!M>X<P1]XT%3*T5#"[8+(X)<Y*Z-!->>H]=*\HO3HL3G(Q-*_$4O>]
M0_>-_A=VGC+91RYKW-HU&:-3]=()"JFP3V?-S[[FQ566Q.>2 \9ER#-SSQ5I
M"-0\P74A"QQ&ABH_&-!OJ6\*46S+%=$3GJMY]+R!W\Z2LHZ0MKQ9+(1&[PLE
MSZ><CI@F]166C3L)<?C][^4T_0W:=!)?IE6!1^=??SVEOQ"S(XU4N[&\S/A\
M;GD\0H3IGS33!/O6>3VL\H(I_/CF1?35.%D])E;J5OSOD&(*<T_JLF7R,F#@
MZX++758LB$?L;MQAAY_=8Y0?,1,L9_HZ.,4=,)]=8RG=)2Q@>,#KX%<T!ZN4
M$3T>P$E^[0CH31,GCJQY*COY1MRD%+6I9IQ4655?8:(Y0] +8#&[Z-(84Y(E
MK>BK%->2KOR:._"-Z#)*,UH92.^#^) 3<DQ6:.](JY;^?!<89D,#L+0R*A:C
M2,]609G=.%GD6@= K7G*[VX.*.(I:!\RP)-6IW?P/[Z*;"3>;,-ST'%AVS13
M,V^F9YYYB:;KZ#EC*JU%50HH9@HZG3I6SRF!#?E>0=^!.R)O:1%<@(IZL@M.
MFVL%64 4%'FDC%VV],GFZ!SN/6OOY?*(3M04.DTJX+%-NLV\(U'R8(G%C]4%
M%S&@3_UW;.SG&O;*.OB/HBES+%>DJ8DRSV>,[<*=_NKJ:O^J^G-_5BQ&U,RM
M+'*\O9B<SZY4+?R(S=+;(JLAG@0/4$/4I!QB!'4TH7L(LA(WB6.8S@N4+XMP
M)=$248;*+'&B+1+KAUQ--/.-" >6K'S"WRRS!@\@Z,@M.7($IY_]@X._3O!G
M^+:\601[EBRJK)UI5*6L-R)W7T!#\'.K]!N=H)[S$8H9E!@Q2/7@=*R"$]*R
M2N*)\4GP"\F#12ZGC#\=B[$:E($J22\-V:W95UU$W](%M$M_(7W<$H%OM>B<
MN"B<$8ZBX"@O-@E'.=X^B-GXJ*_1O5% V(]X](X' 8T>K)W4P_M+]A6&]_GQ
MBV>O[HY1OR?L2F>X![JL[VTYOA82UDIM6ACJI9HZ5'MSIU;/LJA!$((_U-=%
MZK+G((&*JXAT(L7]_*2V"U>PNB8ZJ:K([ !*R!*2;=BC29WH[03MKA.[=]#"
MKO=GHEI,@L!N_&8@S<_V#Y\-"QD5P>RB*"KBF<&?T*WW.J$ZMM+Z9#B N-F*
MM*41B-6=='XFCLY$%WIVZ4R<+5>)79B[G%I1;,YGX18-CO</CX.]WQ!3R?0'
M'&;V"\A*'[Q[9\R'V(MWQT-3(%UQBKYF6H>/!Y79/QJS^ENEI]_537!=8K"S
MJ(<LIU5;ZZ#UN)=\X_(8Q7G2LQIUJF!3M2/@NK\8MA=MZGV'S[_O^XX&59V0
MB/'&7GDT*+QR^W[H;(.6<@$GAPSI--+F7&HL?D81#MH'R>YO+*G>-V/C E8O
M[LT\=44,DEN$J!5+T$C<G:NBR6P2@HTU$5&KW]#YX05TCH&<$@&7Q+FM=]^3
M&,-&*A6XN9'<V'=XPF/H\&"6PT02(YVTTAP.5BK-<F_O[-1VB/@F>R>#>B3H
M0[D,?[=A_+OE P8U]&^/&#<[#/_P].3NY\@MXN-^S^TLIY?@,FS'MCN(!DL%
MUX=RYP+7&Y>LNL6A>Z3(QMI>J'&54UQK9<)><M(ZC;VUM &6$PT\N4YNG(<9
M5]B:%?;B[096V/:7V$HU4(WM:.-B"JECN)\EV H(C&MP7(/^-?CRYTVLP>TO
MPE5$SCNZ!MT0W+@$'V]R8O4*_%%QMKY4U%A3^R/4U-YMC)5Y<G'%VG8ZWO\M
M8->:?\?"$V#VN\5CSJ:9]'$,\;D?1;C^K#LP\VUW-MN?1S3__ &0C>SQ;1:G
MN(%]1#'8M\!IKS=H/1[U>/K#3!L:SP'J"9U!ID4ORWT<Y0V-\ND66=OZ&833
M7!0-F$EZ3F)R!#Z,SE%SN!X'>QN#_79[@QW!A@O'FR<TGET9DQ8ZF %V!<'O
MW]M**!]%YV(<\@T-^=DVAWP&6RZT&!$YS+J%A\53G9-)QIWZNXSQN^V-L4FP
M<3T-^]P)UBUA]A*/]GG5E)3*M(1/+6@OC+F%<#K<BR:O-XG;?M0#__/V!AYK
MZ6"\%UBDE27GJ#*_3'/%DHGB0%62:8"</H2E-M1P$T(1HY'8T%SY97MS)8AP
MQR^3.BI-;-6R',X&$.5"7TF!07OVB*HX>H%R<X+UB.=1GOXS<B7;PL U3'-&
M^^O:3:XS@HNG7'G3NMA]*\D_5$76U&IZXSP\)SUR?-BTB*\[=SU(@.#Q2/VS
M39!@U_[\,,:FX_LU-;C[Z3\ULDJM"]P1<.)CW8E(4/HT%VG5(54K[@]X56VN
MJHC$-@'7DG!_ P,*R-$[;A8;VBS>;_'4D&6&2EE[B7LI%4MJ7D*93I55*-N%
MBH>M"B8N?/+O&,JLZP?C!/R9;#QQ:63!"4]I))08/=1-3:3_V.+1!!Q2WLYQ
M2G5G!Q?487K6:%6I>@C?U?RHW+"D=',8X[S8U+SXSRT:&.U@^GQ1Y3ERU;-.
MI6\2'.K3W=X-C&C[LM?XJC'YM8'Y_.LVPVP?F.('S%,7W_*)=?:8+Y^.V#78
MM>Q:T=<LY%0%>ZS1Z;O;Y#K[=I%.TSHX&9/Y/P3_[F:R^2YB\'L/_:,V+EO,
MK'_IP+$MW$0Q8]ZX\5BU^RGU+C'A(.A+L-I;&IVE<2>[\TZV<UN9 [P==[)Q
M)QL'<L=VLE9YBF\DQU#,[B/ ;NF4A*-7<K,0SOJU,,9P[A4==UOO7 -M;@::
M8 I@&\+Q4?.^G<S^T:25TLI5))&8D4&F8+S"C2/!7YC!LLZN#2_E(OK*0I2>
M2B;FFL0'*YINI&%-8HM=U[U!41AQ_92OI:$.YL<ZH=,B#US;EW9U%+'I)?,T
M3U5!ELC9>]\N"O5;XYM\X.LJO;R/ \#__93 V%\F\?\_'NZV-K3W,K)]1[M6
M%>=XOMNNN,A_WD0MY/#H^&:7;X"D<<N'S3)9EDFE=#@XW7P5E5C4@GGI._N@
M)^#CSK(D>/_^_2"7TQ98)/F 8=SB==E@@30>JU25GH)UTV/@JH7*E@N"7Y-#
MVW(*%I&D,.U^3QV-NW)G7117R>4P:JB0O2L1K.:>P5J'?S3P__-4UX\C =34
MZ1<11%@S<>CI408>7WQ-VAKJP3%[<S'_>WKMO%UD,O"+652EF/](_3]ORJ'4
M7*&2O4 &3%]?/DAHYM,1ECG",M?",BTSDGS#E5%E:&_F2<G"P4CZAB8< REL
MO<E6#=I?4,!NT(738:IZ[OEMT"VWVJLB _O"+WX]Z$VC0[CS<6(D&_Y06++4
MP=EE3[!8%(\(5YSF#>DY$1=P7G0UI&_P%*6+Q$_2H,(W)1U%!CUBC&/_"'%L
MAV\'';NN@IJM$=T^@X9MK= >6A\E8P$F2ZPT*\.T>'B"/9< J"N^MEX)S4V5
M471MJ'(;DV]X><0Z7.J381##QS3%!QZ [RY"L<V =EO#?1BO?I<ZBZRC%L+K
MPZBHF3E/P>VDV=G1(MI3&NY4AH[:56"+BYA88; (G=81:B921==U^QV3((HO
MF9#7U55LS7,OOYC%I]_'/^9RT]P(K*GAEOOL\O)_1^VCVZR(#:K1M:]IRT?"
M'*\OQ.F6]"1\<GE-(YMV2>=@72S2VHK-U)B*R&'Z/&8JWKND';;(7^-LOYB[
M2N)P'*7[!CJWKR&U7!PH<;^%L2 *WD3YU[)9UK-K]O;#,;-W_]B^WM%+OB7E
M+#7RO]:)#S;>SOE-_B2%A+:.',M=GZ)Q=2]R^#W'J7#?2=[V-9+-2'BIPDD;
M"X.5Y-#)Q"ORU-*(7D^%OO?&_R#7JPWAYV6=+*9P_^%1&!P='#WC*,"I__:6
M!]R]^Q'SG]YANFU1Q/*=V(D(#M4L\@IV)RZ::1TZ1]_MR*79D+-!D<H[*Z5]
MOPGX T@_OMRD]./3+4H_WD;AVCE WH_9&9X\NVVFK#6L1\]>OGKQZGD;?,!#
M?OSTQ=&KI_Z_T71XQ7];H?F-G%C@1R1P9)NS<VDV&)<]?'<$P.UI,(I4;UFD
MVNYLU$?NJGBV!)+U1%NACJRFE%\%>=0W[M$W?DB @&<C(."[BSE^A]WKL8MO
MOSK8I ?V;'L>V(<B.*DJV*=C6]+^.SC3]V-O/.%MSMO0/DYG"YNC/2ALYT;E
M75JA\+ =H4&T6X2X>T*K(.!$3C-P\H>]X;V8>MDQ2Q9 CG 45).R-)JF!(A#
MQTR/B]KTU+ZI6C<G%<&3.9)/*W+ JPOX%_@?,#=K<*Q1D3KAC9F19AF![9)O
M:55S1!&>5:;DNN _*_B26A(X9!3- XS/Y_7V%+WJ55HE^T& S@+Y)NJ;$-6#
M'VX^J[)]-/1;%,4B,AHNX&?G6ORU_:QNG[0Z8P__+(41 X^SR XRRQI,YOUJ
M7B6+0NHH)H-WXH&+X^"[&KEFB4X23-C;6[J#Y\>'1P?/^@\>KP[O; 4M^+#7
M"/K6_NV!^ZT'=>Z;EL%/ZK^W[(M/9Q\_G7T^^_#EY,O[WS]\#DX^O W^?O+I
MT\F'+^_//@>_OPN^_'(6G/[^V\>3#__]4,WP&6LF(T D(>ED%$+-Q:J6&'LL
MR#Z#D<J1_12]<2VY+@N^(_<<=HZI4PNE[ "4JWX>B;AES4-!WG5IU(:$8]<G
MW=4;;Y1YYT1[EA57N#B#T=TZVIB[!2?&P^VY6S:KXX-ULLYLAF%PIY!AOUQ*
M?^,&G:4+"@ 9-V>F4U?N1"?B_317]W/Q #8@B3O77D*GQ<33#SZ-H4]N<2JS
M]\+AEJM*^4Z2[L"E_6<#;E"<:M%EH\>-S[O EQ+WI[1HY?<$R^(J*0V'([25
M,'+0=F&>9:<F-%RB=.D2?=(H<X,G,[!=UQBT:#5XJ@)%$<IU7U%$GU%]]*R*
M-$J*2D=@S-][ F'])+82E_=RX8*OUQYX&CU3]P&OCPNGN1'V+DR\O#U#U*^'
MSQ0:[*H[WBE)ED/'.>.**"H*FY$EC=(,MQ%N7U6(COG4J5>V]<<)[M6K.XY.
M[\HMXW,SK=(XA773=5_Q.)"A3T[AJ<'NJMX<T7R)75%[7&>C7.&X/I;]XGB3
M^\71]O:+$]M,/(X-0UE8,$M@)1!J1D:4C9F0&U^[!-VAHN:GBZ2$?@5KMPZ:
MIS7O3\NH% DO^)/B\[9*_^WSIX2Q^2*VB? 8DQ41A\[YL;"8"=:8V+X'*?/J
M/7-CGTT3BIMCHD0F#>Z16K/ ZIFN#IET0,UPS="($WK?AM]2IW53,]B;-UZN
M"4C9Z+HABU5O2G+HQEE"T6TEFN4PL2-J8@:+CW/8:H]*2WL'1(QAA6F9Z9_P
MFU#85.31"K!>)IA*PKT71U!#IQ#&6A79)::-0KBHL#RT$%DGHAKZLEG@KE3!
M;I1%)7L.$5MVE'F 'DWAJDI87H(25T85P(DB*0D8"_?*#P%NZ#77EY;@V*3+
M+*E&@ZS3EQLQR,?;,\@^KO4';IV_7"CI$^4$BQVY[I@11:1R ZMKU*C%I-(Z
MAP<[5D#<=,<.6PG9N$@JBJ**OTS128&^DSV;*<=2_&QX01@8N3XT*R'=Y.72
MOT8[2A&+N:!JY#[YWC].3X-W6B#PLQ$(5"E1OKPR+O;GL]/]%<?V'S&3]WQ4
M7;EY-N^QF'<?#X;7CO?8?,>\;Q&0]/L5[-+51;KTOF*;];6/!_08;;W"\3_S
MXBI+8H.\T<AH)U-TE1.:^@*6#VY'[,9*B"8XIPIT80 S9Q%Q[;"FB8\'6+];
MK],!516V$TD$GB,"!8G/WO'&L.](@V^F8:TWG5@Q)3YI:*XA:?D<L2]4C)XA
MT$4427Y-X:W!'F= ":MLR,7H;Q/O4NG8IW'M;&+M3+\+N5_HX.Z<@MNHJF!L
MW"+@5EH[I FL(W)X#6%U<3H3JB^DB;4B)9ZAHDU&\'C$IGDF9GZMKQPP0>'H
MK!-.!EKE,NFYTNQYX<0CO@@DL>0 -"W!A%T[?$5+%ACSYURL"4_^HM&,<E_/
M7>Q^+HO23O1W^T=5?^CN,1^G?-,J,DFR[@/T5ZL3.'PJ=%B%+S5=Z,FH.U%+
M"M+D8G7P,Q$ZCD?QR,:8=M6257O>1 0.L*T>/I)<:\3)Z><B4#+4D-"049<R
M^#05.YF\RC: \G!-O\I6$AZ8UEDB"0+5,VFN@C7^GNN^J'\&D:=?-+4P)=&A
M1)%$%E/$."@(225+"2_D<="'#04SE<0  TOX;JZ2QW"*O3C=8+.#Q&@AZ\U'
MK#^V/A8?]?DF0Q!;A&S)23/*K)/F:^00Z<M'K-N?O6,Q[M"[Y]W"PCUI8DJ(
M^28!^:)78*T0X[6,!.K>CI[^?'+RD:P*(;\0!T9IM$0KQJ'9DG@,4@_,"N&C
M942%MDX(B]#6Q= TY46M+DZ%\)8<WWF4EN1,$!JCG^=(F<4"?%YR4^?Z2W6I
M4B=IAG:\O449V$8L47=DDU/1)@X@-QFKZ:&7+F$EM8OZO_Z^.W0LL]M!KYE<
MA'0QKLG[69-6XD>Y51&76=^MAG&610WR&?50,'2VRPV0Y?<4HGNX(^4T-JT4
M'<"\*&H<YTHYL;R8J&CE24*Y4QBH((K10#!@8[0EN\6]\@XKB-["08HJJX\/
MJ;+ZD/E620@^:V)56N;!E8"-T7G@W#IXNNP "C2NUR6LG\LB:W*4O:>S7JY_
M#-7!1)L$3-F8<C8!\M Q1 )=?H2Z_3+\%FC>4DX@^I3"D'FFJF?XMWK:0C7#
M^\8]TS%XS1GF5Z_M$_/<@O#S"6MB/JA5B>9I+P*(,$R&1B54&2R5;9IGB4)2
M,2:S3,X+;(JQD)79"SB=C1?R2JT5/9( R_"9QGYS0I_!.R[Q4_<DRLFM%8?!
MK;'^WWRUT_+Z(=;ZW<KSOU">T#,-# S##B"HP^,S9,>+)N0X$-",YL$.>@_*
M;1 O8J7W\+!2G2_&5.>]%"[NEC&Y90LV/1O7.>8K/(_[;KI-JKF+S?.?1FY^
MT*F<DXY[FJG:YGB'.\1/C[\CC=O,(= Z]MWTQO2F-ZPZZ]UW;][B-+OV_'K?
MW[298_,.?^ ..?D_TI$^V=Z1_G.*\ZQSIO>=UXD7CB"*:3EK%EC ,H,#9Y+2
MP16!U9=IW"@XL1BYZ/P<3IP2 8@8"'X1Q8QTQ"(6JX)EFMRDB&5,"TI:\.X,
MUE9:\/E6F1S^R$VXP*I;?[#(9 ?X@#HZ-B\ GJ%1=K+6_/-<KNN-T3NQ-2<X
M,\&-X2<I1-!07DV<97N"-KJ7UZC()<B[X= .;R^QAJTIV3G1$:V*#(6.C(OS
MN"B0$2@A+B-_VA=Y].7H+X!D@WYY#\,TA7_@"UYC@_9FD[Z:/XO\PRJ1] *Y
ME?%BY@ISX%]/RF"[R#JV^#7%NFPP7E6!A7J&9R*:S<H&:UA89D(D=:=PV&G0
MWL4)4TLS)$?]I.JCD;[*5/$Y#%1E@B@;":6H\5PQE/NK@6U#$N6/Q59NCG<0
M;.6+[=G*SU+P0[")=R7X>$V&:TS%S!^LQ?S2.KBVRU%AZ41?P1^AVMRKBX(J
M:X6A1M5)4:"09&<3+=&'T<W&V"V7X,_BJ3XMXL1R7^:FZQG8%0D5C?4'30<H
M[]#&A9Z./_P]JI"BOBYREZ9.,>KHVCLK37F[&N>0=A4ZO%O!3T+<44G7990U
M;="QQI[Y^EM5C"'?#D+0J@#\.4,+3"TML!2%F?WPT2O,K.\-1++1YM]9""<0
M[A[K'N";$G%!,X)<R":W59T75!P?+5-L-%E1J;/&>KQS)$-,N8!=[7P24)[=
MKB'4 IZ<O-<BGK'$]L'=UTJ7@X<*QI?+-^E:W$"FG).Q>V::7!<Z&ZUJSK$H
M-)**).]=#%U$%WM6+!*]2=%G<%_'^P':&IO;4F>PKB).#>';;=\".T*A4"5K
M9A56MN_2WD;KSML5^;=9L,A_J?LH/JW*)L13<D+C(I7BK"2+N-H*C :N:W6F
M40.#Z[W!3C*5E%KK3+[BL59(KA37>;J*;NC5)K?BE]O;BG^%%73^X LH86Y3
MSICV#UX\"%M)T:,MIVDMS!<B,4_*;K,L2A<8S;Q,JEI74ZMDN;DRV-,.<PS;
M'1P$\&&78!S_A",-'1AL(#"2H4J1=JD#8JL*9F@_(L"QE&>OS)?3,6,ZH=^>
MV[64:8Y.^/5VWZ[S\U;.OL-G?_-(L,9T<E1T<#AT:NZ;%C@B>]\F*^BDUL=X
MKNX4TZ&QN9X0B2YT6XW,N90WO)?6K*I_?= V71OI5P>;8PD%(_UJ>T8:%QSX
M.QIQ\&MT-2"J]".F]E^.:?VM5##O\,)\:.[&!W&O[9TR[V[4%!^EJJ?+M-"T
M]R&E$,36+QU">DR)57(Q'K0&[>"I"B>Z?DQK3PZ5VZ 3(M;.+ZQE%]#E\!/=
M"5?35>?0-EOC$#_1_AHFTXVNPJ!L\+C($5B),91<'*N^6WH(G*9SK@&$BRD<
M6:*7!I873D.AE _R^8_K<<G(F6.7GT#"UE7%S_5X,4)QT3KQ]A4!4KF8%.XZ
M),5VX:3K!I%G=.>LT&/?LN].:6NV[,.#;6[9^1QF'.8(U!CJ _W#S0C9MJ^'
MLT;A@>>WB')H"ALGP&(8Q'(#[=%4-D(Z,SP *95&_"CZYU6:97\C@\V<XV /
M$DJ+T @+>PV#E3BI,67I;GB$:]L-<Q=<%"?S".\0#IV",BY)EI2*I,S^"BUN
M.V5(M(,*-R+U-ITZGG/^1C#6P59X)07/;0WTFL?J,5U[KC6(=)=^3(*W!I3.
M(5:RK8)*HAT+#03GX5+IE)F$=D(N&.?/FAD)53IVP8&^4;7#0UIJS<>"T/_>
MFYR]YN:?AV%'_!Z>W@O...ITY.[.T; [1_E8RSSC])DS_,8Y[-:<7C#TLQ*!
MF5X3 =R>#L;8G'$<;M$?P;^)E069K"V0>$VQ\%O13866&\ ^$<=1P0R6HB5@
M_9H=*I,<=8D'.XQ5;DKG8U0KNFRPE'$">\+7X/?Y/.5%W;WAM%A><U$_7Z67
MLX\:*^SP>-%H8/>C\^20=EF<7HI$0=$9E.O8O-P">TH:WZS$'@8KGI 7&I0(
MFJ=:#L6*@*,EXL<4[IOA),TR/8WT3+9LG]RY0O0A[#-,5GU+P.V-@JRH= &,
M7@E36)GSM&8>&*N<I.-GLJU*)C8QQ K* Z<AOOW37O^$T$077SHC72R+*K6[
M@B@RX$=%L.,U0VM64\H+VF+>Z7&EC=<L<Z,#(W7+>^X20X17#@\AZG(S8K7D
MB!LLB"'AN;4LQ1\,R4G_&<3>3F1ZJUT+&8[L>5KJW4ZM ^CB,M7<>T3F'"G^
M97*A+,/I*(AX-WKC*I G(5(E/-]LC@V2\D*,C1$CZ;4$O#?N#43935:?GX8_
M1DY:X1@>7776VB2K_^$66?V]G%]C>>T]TV<,K[NVV-,/#WN:T"GW[F-7#VB;
M(DV35=HA$=7Q-25C=\M&&*XPT)[4S &O*-AP!TRKJD$A7/*[&$NB,FG*%^,(
MD^@)\):'KAFMJXJL)]8'$@Y.N6SNKZNDO$0'3OXB2@3ZH>R-:F^/;S1>L7VW
M\T=J#+3&>M-,>8.5_RWZ[ZT'<>WAY00<:M*%PD]S+A&5EP3VKQH_VHF H=-K
M:OI5<20]4""#UMEC)9_? *#]CYC\>#76-=X\ ?(HK/C-N%JW2;ABF/P,UEW7
M)E-5_$HB3DM;8X>VC!0Q>E,!<:^LLM,/ SLW(/TRY$D6!7\XY/I_K1J]#LQL
M?/GLKZ^QIYY<\'0^/(*%=HG'M%F4R5*!A4!H:7C H+&V>1%89A>/[LN4<'Z4
M !KR%#EW)ZM*3<T846I)4'SP?ICGL8X7#,#QP^U7!/=AS"4VFLXS_"RF!E2'
MN-8Q(DN_(MTFD2F:,%G?\<!&NJZEO4U6+1K:(!W_(F#IQ:Z_L+O+ASAR!]/T
M6%-^R#VC*[]C3#EF$]C(8F)"6A:/KU6-]@(F%N9DBNM$JD-5W$/PJ6V\,JTC
MK3N*"&4.P5"82U6I7"89[$0Q!8_I>>FTD=1K.R0F%TM(8[)F8U.A8B<49C6'
MFJ+58$2HA3SJ =N(47BQ]5HP\5(C(%OG%863U0HJ6LVA$(A)@^NFA19A*V8>
M;(K6T.%HM2A:R;RN[A%I <Q.[$&Z8=6SXY3G$<YI3-7-*'IS*:]M?0L]S70N
MINN65B@W(YWVT69\9\:=(38#U\DZ%Y'RAC3-,'YXE2<=4#W.'"-=NEO;X8#U
MC)4$%*GT]P!"E36Q?(W$LGDSQX!O2<X,/ :,(R*+83;9/G=U,Z\$?UCQ:"?[
MH=Y@I%[2?([ZVK",%VE%BHG+,NW0'@M<B?-"$CS10>$>NX&1 .@"'GAEIPOT
M(&D:**E6#(D['_RV*54):95^>X)X*46YM"*'A*.1MSNG%9"WU*S1'Q:R[5A;
M8(6 &C+V)D>#>=LFE\ +TJP7"_JK]7UHFL$/I*^*&'S]UFQ+X<V'3XT:C8([
M< P?\(^)*@>QNWXD.]@QLH,A"][4#3?Y,DJQ/(HJAICL(,KS1C+5X(HE5S %
MYNA]B6N&V13PV^*&4G$68$$O;8GB7?+L5BE%<M=@3R?CB!VNTTB+I+Z Y0E_
M;I#=S_RXL":V%(!3R46%T4/E:ZE9K32L)']\ZM@+>U7O*1GZ.^T6VHN5KQXR
M-EJT/KB/4=K=F,SHIMW&B,RW2JBLBJ6T-)PPI>"NCU&?< 4^6? ]B1QOH.V$
M"*+\1%WCDBR6RBR$[/S/X?D"']+%5W"@^18IZ(9;EF6C..P_I/F?32Z578@/
M:@25ED4E*_"8?+9;J!5 >^HGK U2)I<IC*_]W,)3VX7?HZN[[(LOH ^D-1;<
M.N2\$JYAI]X,#1ZJO- _"1.1*PP3H7IH/T^KBC/VS@,5W,X!?8"3@LD=+%P+
M]F8%K71H;89( %%/P<0WQ9VX\ A&=2,F$9S@)=:&W\04VD)(]E:RTE;!][;-
M+Z$^E2 *>2G2F@Z2W:)PG5V@9Y6?*X<1O*PH(T0"G;49I:3.VER%+&<1DB?3
MBB$W;:SKH=N67G6A.NH8*)'C#_K+\%PGU6@ZVN(N'*01SY5(-MK>JTP=^3:G
M*UFY!W%9-@&N.G:,1OP61OQ\VT:\/;%,Z6?/HA **\5Y.Z7\;-U#8-T]&JFY
MN6+VJM.,.H8HO-!#3.<^/1C3N=M,Y_XP=J&;5KL>E#B[\>9R(X=[Y19M;5+#
M3YZ#HF8K@V)^JY%6"N*N2.8C5C3S,GZVW]BR-'#[H';>M//'/? V>^#%=]%3
MU!S!3AP/A>N)T&:FHV;D*4L:*P'G/,*PKJ"]P'6*&I&^+M#IKQ%IRPPSX-@C
M'$I!I;'J@JGO(O8<&4?&<+ */7?%V&+1(MCN)(= :ZU$FGR;94W%KKR$QRM#
M!(^OU,Q'^"+_G&VYV_(NG9RVTN;S*,TP\()N'O20DN_NR_5MDM5R7"3=1>(G
M]=W-1.[Z\/?F,[U*B=0NP9#UA34>564!Y_6ZI+#_DV4SA?6$[BB.'<UR/*J7
M:26.,C-3&@[)FRPM@15I1#X?,K%;-YG]Q<^(30Y*)U?:1DAGB06KCQ](JUUU
M?6AU>VB>(WMR71@[UV/CZ&EV5TJNN*F2[M^*/#-)<U42TTW"N(E> O2:'/;-
MTETV5Z9MBGO(,JV]8I6IUA7S-)6J"P$:&)A/89^'Q-;:53STA5$WF=\>)C,.
M7Y-DR;]S/L.=W5VK;DV2#5CRD71354D<;[)*XFA[51(^,?+78PQG5\HE;N._
M$E-A= GNFC!;<%A.Z5(%)^>\S9I8'Y/O6CEX]0<G&6VEN#DKW4>K81']XIXV
MX[)@(;BR)]PYTKT&>R?$>6+[%)=I)77HE\57Q@DH]\ S8;7TMP1)NZ]89:LQ
MY1U=,\IHIM$H$O,OE#ZX[[7M1!H6-;YI?0L9]<2M]9P9XB;)8LH63A9>T0]X
M@KHWV=K<C*&D J(9C[+-9J_SLZLY2*C>I3.:\DZBR0>_!BYWB+U=Q7J8/11J
MW) "Y,DP1 Y6=MY- /+-L!?A+"JP>DA7M\ZPI0-I9;"/E<9?2D=.7 0A3=VX
MC*ZD4)P<G6L]]3S3<K39M['96U:C7:E+M"P0P%#1<<6W'UNXKT(7U=*B1#TI
M#@U8RH_M$G(#B+ 8]<V]-!]SKJ">P0) C"7XD"F^N/]11'W;PVG5^4 ''J78
M Y@<RN1)G;?9668Q87W&:ZT9'&#<LB2*-044;CH*?E4U8-/RBOYM\0;0IE'$
MA@'!SH[YAM#EP(9Q=@L#;3:%BJ1S)<-+@Z;/1\(_2@6"O&,3Y!'+MV%%S_A'
M-O5Q5$?JU$QA(MQ2P,+1$%"_XAX>!DV=(F P%K;D8!I5*6-IN')<5 L\?,5J
M.N.LQ3E)E?MDE_R;);H,^(9W;T^,H]'=JMM3;@6M*$.3396'40/#=IFY"L>=
MW/H6>?":=I \-): AJ;^D_L3_)#9"EWFEIPR'8'5<*JO>)"9K<,QLS5FMGRY
M%N_NU2QC1B7 J02AIZ%:60P-=.UK96(BCMWL,Y1,+H8FT"2N;V@ ]F^>[AH&
M$+]S::"-3"Z(MP<15G&*G5?@/P?5%^K0*G2!=8)<QX2D?A.=*V$LI%'+:CPC
MX3;O%>AKOWQ0BFXB!]D\ )\82_&U6*\ 1]GNSB,^>5GB%.9".>IUK3O>$!$P
M"BY1<3G8N=S'MC1JW/A=]ZF#QA_V#0:]=KTKZ?0ACS&,99KGB\D+ZE"ZS?1"
MZ'[M@I(W=B<-\9"$Q@LIPK2'H!81J3?001T]OV4!"_1:<Y7!YPF8C"1=PN /
M'DU+Z0F&4P<4WT6T9;\ITVFBA,G?9Q0C#WZ&[;TA;8=0X&)6N0?TZ[/GP3O4
M=("!V0^>/C]\=1CL?88#/<N\'1Z$P>&K5X>3$:.^:Y6#:Z):> !(<SMLPBQC
M7(F,A#U:O=7#C<NW"4DMIYJL@K=Y$C,M*ZV',,@*//Y(#@H&,2?8*),D5C;;
M446WY'%4QI60(;'?R2#,2HCV"=?D**NXLF;OWKT]/9$:^5\^P[].?WT/_ZU2
M&/VHU(TPW'BAY73KMN#?%TUVKJ1"*!?6L4_\&I7'1>*-%H/X,#;: 2F_UYWL
MG"]0V<$>RK%PQL"S2'-4P:F+_RT!/MZD%G:@T28HI"?E3]I?1TW9S,@7I3WX
M&^PV28ZMS5G!>&LJ2':@%'O7VB\LRK4?Z'R?269%<;'$CZ'OE6,5;3:)JIT*
M-]$+8P!KQXHT3S#\KB-#2:6@*+ASSQ7-]C P*%J"2L4QP:9)+5\&EIH?@_Z$
MGG!Q@H7+R/6@:[0E\<UDYPV13S#M$C&.(E]2D6&T&5>\6R&L);\PBP^K(XNF
MA10!"+<HGDJ(:Q-M,#D]_-3@ F8+FY/D&R4X$N$$D>7:?H->NJ%D9"DV@MN8
M9D.E3'>S+#1Y!<M/1;@FYTU&,DRS,EUJLV<J8"^2**LO9M;CRM&EV;6R.XSQ
M8<9#+1L*';6BJQ*!Y8F/)U$8Z>0BRN;KP0?VT8$V>Y6#HK"5>7!OE*KK3V&H
M3NT<OR(OM'%4\,]%4UM<D2&X-X7U14M$B!")[5XD"24,E^)B5Z*$8B-P@4O6
M"SXBN<2#8^I4N>B=9\)0F+YOX+_,8%1C\Q&XUY2II"01CU? R,"E%&>.-7!/
MJH<K&W01"B["[*"A9 031/H5\X0B#3*8U2QE&=N9:7"[C@,-F%K$1FJ0MT"C
MIB:S09N&OH0M-DW(Z7K[Q&E!G^;$JN)EXX9QK!UC,A68J9BJL70ULL>WQ.D4
ME31](H<?/'58ER6Q.BV@PPC%"'9ZIK&\B>(^5OZQ0]9K1^-IVY#9=U%DL0K!
M;W"1K<@:CP9WUTH45PFL^ KVD1VZO^ZI"C@]HHCR>Y .A44;ORS3&4/1T?]-
M%U.DH1+,EH@J2IG@W )_M=@0DV^(.2:<H5Y$G7G8_Z9N#;2IWF&S8]1A^8@$
MGX7ZGUB2*16%^DVBOV+9&'RF7,0D+N+7JP9IKF]9) \RS7$TICE&/L9-\#%N
ML]1O+>!ZR%/ P3!4(J+9/&PO]41\^J $5H:& EME(M*YCA/KPTY)/*]R'#8Z
MNBE/2V'&R%==.)]B'%8GA'QT&)SNO]O_M$]51A7\?!#"?P[ID2^/#AS_ZN^V
M6ZP<%O"&,.@BZ.?:)J@/5^+0^*OQJ,B'8HO%I7/ ]L%(5O$:]R$U6KF=CB?8
M*@;6[I\59.KC<&^%.=^>R%Y$+F_/=IK:=!4R_KS1=157%4!OOM&4T[I.5M+@
M>])Y-56D,1&_79_ "(NBG+2F'?Q+RU-3_9#-7N(N-H=,3?9UI'M,:K7WH\*Y
M.4;HTAV/P!BM,8:!4YC#@2/B 0T/,S,19M#*+_1L]U18J9:PHD]E%SG4+G-4
MZ+86#WS>!@_+/PVJ,['=L3XHCOVZ:6*_L>]U!@]$1**"QXLR_2&>MX1=_H'>
M.4\<GWP"H2@0SFVJ/H-#);V5 #XVVU-LLSWI8)0ST^S>[^WY 58EJ"XXOIY$
ME:C(J$6LGB)73!/=-[E!^W KEEDTNVEAQC"3U=IXL,<Y!(#G5>Y6(C]$) $Z
MR)S\T&**[NIL\3<PZ;DJ Z0^5/XT;EM"0[9>N@^6Y-RMH2.8:*D$E%<)3HS'
MS-TJ(/4<,\.VJR."<ZY@ET%JY ,8X>1^!Z5!D(LJ-.%QV' N4YIH*O:!D2\*
MJN3GT;DYZBFH)TYHT58!*QDGTZBD8V.*RFAYK+*'X 3]L?]Y_W0_^%__W^%S
MV.V.CY]%*'2'C6##]<]55TXG!IX@1:IX:*P,GL(N=7IZU'K&X?'10?3DQ53.
MM[R_..DW"F)9IM5\B2F++1R2%V0*8Z*+<47M6+7I0&5<QS=%R78'4!H%?X\X
MV:[H-M]AX@;^].3IR^-005#^R(ED-E97*1@)[I"2<3>E+T[DLU R;8:NQ/63
M2'U.*+IU'E7J.NS@-WLIUY.5_G6?7JW_U1&I.FFII38I#R,*'*_0..=L'G3D
MMN?K=<-6Z3:IT\TY1G:[138=]U"<7W)68*)^C<[IGPZ598>[DKH/X[URLB@3
M##KAL[6HXUPGY*WB)=8\AF\J,C[<Q+@IQPG'E_$WO.]FURTTEJXWM>;BG?5Z
M1PMT8POTY[:)D4P<(B^"S]$\@1G]@8/!' =>B\MPRA6LR:9/6DM9#9KXK9MC
M<$(CFU"'5OH\-_X KK>P(#;N:<E' 8"5?!:&TNG$E5\:4N&<=:O!M.!E631-
M,LM!;_/7HD4]Q?M;)1HF7\2047T@<OS\<3W>9CU^O6\X8%](<#7"CQ[(0"CO
MCLW;EPI;+<OT,IIQ*XQBZUP@&!W$>8(<$&4!>XZC)&T%P[3C+P3X=N@2?_T+
M/_A]7C4E?=&#3*$<CRF4L5+$QVU6@-\JQ)JXGDYFL/?E^E<GL''L_?+^X\G)
M1(%_*]2HS<CM)1\.O&!<Y(1!IYAX"_<![6:_6$'+R%&MB/\"X[=IWB1QJT";
M2@02(G9R8:7CQG&;C2/;+NBJ[1N0 Y-\0^7&OOP([2C;X+L^ZOG8P:H1XPR[
MS0Q;[*QK0G"2U04(+?_$/<J+WT'83RIXXISIE'CR5^'U.!')KPI.P,X]^<]T
M]G4*_4J%. B;W^L-Q.U-)Q-V3V;I98HU.AD<+TZI%)F-\G$K#JBB@2^.7GF7
MDS7-H('0%9W!2.#:Y!^#>"FE;>KKJB:O+F!E<C'T$DF8HFN.BT"/]G_F1>LY
M=E_#+G)>1@LKMF@*,OJ?* \\I4[[#29GC<&#CTD.#\;4"G5=W\W1Q*KT0(1^
MQU6U:SX8MVR=C732^;6DQ,R,HWEEJE,\WZFC2GUQ*"QS*9MS OXD4HR.S[*C
M4*_5P5/("%6__I8@B0@K.,@/*1>Q$Q_QWA>,T 7_Y[_>OW]/E\C/[_^/^K3/
M!:5C/BM_'+IQ<H.NHD,N]==H76]C7?/O8UW1MUO#9+2",4--!\L2.P%-LL;>
MV9V2$'$;O# A=(70'' \US2CB^OHY8'0T)1E43,IF[UFF#XACE/!ROJ>T'V9
MX^ZT&!F@J7$Q:]C\M7+UEOR/$QJ6]A$GB3K9"EZZ!S-K)XR]==./G@[NZ2;I
MX(ZW1P>G@XBG F;Y'A1P]Q.%&.C?NQ[]L?3&$*%YC$>NE)#O=G;8RLQ$" )9
M*'VT%B,"[F-UL1\$Z\VF93(5?XG3JEFQ3!D?XF\7O&15,8$#&$G)H&!4!4R*
M^!&=)W)= $*/(HP=&_>E>R4'P=7S2G5/2&QDEVG<$'LJ/P\;%YV?8Q"OWE Q
M(G6O$K]AHK,V"9$$R=$L&]4,41D&>PGSF+)6L#"P:G(=SUHT<8I9S1;6Z0(/
M?N<GWXC<4(&.T6PKAB0,X$00G./QV6(QI=(67)W<LY2IM1@_"$@UY6&Y +.0
MX.$CQ*P\N)\T?B;F'R<9W R[7J66WNK6S-:T!JMXLJ1DYCH$_=2-@N]+B1\-
MXZK)NA>O>0=+$!F6J,3&SL,PT^*][GG!'ATL]+*WTQ@,0LIAWA&D25X(,P8F
M;P7/=>"KY'=T'C_!2;R^J!@+)L_)@!AX$K)\,548^20<2'&R0@P$[$P?L4XT
M[W2/W-?'.Q9\A6*U DA6[ ]UFRK802(\1E]+-65]HS=2F'5;94D&PJ!;JU1=
M)G2=G2VS",PZWSUL_KCC7]@V57=@>W/P;0/^-MS_/G#BW1HIYF/(N(7%.RCR
MMFGVU$(/&+Y"?'//V@HU8!X:/F\R(B25D'6B^9@?4M[HZ9@WNGG>Z+$<L9YY
MCE@WJ\BQCEA/MW?$^HA8:%SG;X02YL&>L*QSB:9&6)9PPDF7"(91_6"H<687
M:3+'&LA98V%F ZWN(#]SF;;:0M8BV)$9OPJX6 &+Q=M)_M,"E2,I-AF5R:HR
M&GJEJS!^FT/DTW6'2#QN>>2G5=$)N!PQ<>KAH0(\RP2\Z=)1V)[X>P(<BM!F
MQG"8DHPJMN)IKA6'I8+9(>:=EQY[0N#1SO%,2?! ?!O]J46 R3?OCP;J^29C
M0,^V9Z!.P=H4"T5G];G!S '\])#-%)H3/MGD>%HD'9=!WK4%,7>\:X>VP%&G
MQ=" 2<NI&FN;2QA>:I^&.8G48G<N<A(<G2;U%2(659GZ[U,8"!)J$5Z9''&-
MN9#D$-97!E=Q].#D6QH@K;J/O$V^TRZJ6O_\2J;+\.=C])F/0QA_#A6[U-V]
M^K4HW,=ND%YLTB ]WYY!>IN>8Y8X>).BO-I%#G\^QTQ#;V;9-0ZK= Q['HW"
MR[/]("X2)JLJKKB0YK0 2W%2H0NPIY+LYS!-8;/D$Y>R&!D2$2+E0R*!)2[;
MFZ=YJH[;4I)@'JG5X,<,BF>ROMSD9'VQ1?<>M<OI1:_1^2K0SZ1F/.3]$Y7)
M%=PU>*L3CC/:'"4ZHO&SQ/9$C&A4^@@;QZ]I@I4LLM59_OBR*1%:H!EXB:]$
MY?"GUXIZT?-H\]BK-,O@WM"PK6%$/KM6!=A+UDA'!8)019[)!,#"M^CD1?%=
M^*DQ!HC%>5%MQ$[\?;#D^9!X.\"T<L_%!9LJVY5W@6>!W6+>,940WDT_:")I
M)-878/P$3A#MRG?E@^)V,IY'6ZOP^+I#:@ND**%"N76RKU-BRE.+Q0BDP2/C
MM"Y*%9X4_\,5N.=H_#ZU7[I%6F*7&?:/$$T0<A;F:0EF&R[ZRA01J8&[T$7<
M5$>^CXE_,,TA=Z'<S&JHTU_^?0EK"+EJJT:=!-7=V'[Y+)@"N2BL"\$SI7O2
M"D9 J<'MI8HW@LZ:X-H5,<^=C_HN[A(4IQ&'"%RTA)JL/U"R*PY$R$D;\J#K
M0[P^D.L+])_X;?S WBZ?C,[7P:M-[F<OM[>?Z5*$A[Q_2=537QP=*>RD'D,A
MR[7N):_+,EDV-2T=<RF55>8IDPVT>0H-O2Z?R! 9*'P#<A.Q@5JEF28)1[83
MNDK5K&(B+*T;>R^J,! #'0S/A@>+MHL^M5(+-/=7GY:J3Z0*OV2!F/R5[;9:
M3>T4!)$T?WBK;3B$JIW+4E4.H'O:$C_@G4U*[:VQH'"8^4FDU9")11AE]&-#
M4TB:<WT;ZZ%^TRHZ3/)-W#0TX. (D.H+SJ"F:A39I^Z>-/?-'\W^>+U,1G-X
M>+!)<_AJ>^;P2_3MP1K"LZ$1=4Q,BQ,])UD)].-@J1:+Q'(M-7 %^BSXE-1-
M*8L';U\BZ)<8Q..&:NKQ*J:;N<J5WD:32.0HUS <*4YE-R/-'UB"\]F8X-QZ
M8=P.H WOL1V&W%,6G.7U^Q77?&Z Z$BW#AG[*VH][N5C=ZT]-I*P!J,8$<::
M3G(8B"!I(9-%\"G ^NTQJ^YI>\L>FAEBQ=;/QU<EK7&9,,F>, [">XDF<1ZQ
M5@:?XQ%U#L=$JJFTE!I%)4/"+TAN6UXFEGYPZSXM79+2,3Y4WI+F V)Y0>P_
MS2/R\\G)1XN3@3"M=&9EENP=&UG>I^"R]<[!8_'H#C?HT1T=;#.[H++O0VH7
M-EH)-'RJWGK;<4?FZ-G+5R\/5>BA-6K'3U\<'[[P_XU&](C_AC@XA42T&1 8
ME8:%9W"*+O.TNN@GLY>]Q?QZ#:$L&AL*!E=\=.*$H$^2U!MV5&R=UM^<"*X*
M)Y.ST\WHH'M*B4WA5U+@5C)*'/Z3[VPC1JA\B***YE,_<CFB=05,] (52[V7
M8.._$,UHWR-:%+AIQ3R5$O:NHZ\)!1(C,-<%$4V(JJFG$*!?U53BO7:= 67&
MC*:B\&NT-/2,^F.:"\.E$J&C\Z\C;]MM*[YCD58HT$M26GA21PRPS ]7"YC#
MCKPIP5]%Q%5/QM>6QL(%X6$G^)L_$T73@4R:"RU4(YKI17F%A%9947SE%EB<
M'R4)YG+9N+D9R6J22PX,P0H&7UJ)$=H4.HE*AA-*AD$SDLYH]0N.*'4N,TYJ
ML1H>$Y4HN/&75$:!#S_$BFHS$\*Y4,)2O*.@D7 *$VQ:>^%&C<HR<K(7_D:%
MQE-8T2B9P=AC+%&,J[CFF%O(F(0FGW%]-),'ISDNS+Q6O(>K^F5 "S1UDCM/
M*)Q6P+1"&C.N"!&M#(EP52K-(4..1,6LL#R7BJK'[AL<;](W.-QF\!M9IVGU
M*L-W\ET(H^['BQV@H=$N]8IR!61(35_-#.A3V!4C]3MUM1249DFLKJ*T8?_#
M-%>CA5]<)%$N?%[XHW^T\*^'KYX>K +#/Y9UM\DRU*.C[:V[W]^=G+YFGHHO
M25D695HMB'[\$9?LZ_'\E,S_1Y6?\#R' ?F?5U^GK_XH#UYTG/O5E[^Y\XS8
MB[;(#=M%08=M8MA.2?K HBA=BM-^ EHU4^)'H1/6L:H0!R9.F#9?:+>6=+$$
M6G#OWQ/."XN3E/P1<%/%08@7:8Z,0R4_KTT4BY0@P=L$ZWV4XC5GT\%[;$H#
MI_^=$?'PYW>BZ4E0LHKKDXHL['O:YUJ?/O[(4W0M/P@V1/-JG,(,F*7RB+,&
MD3)@H/_(R5/_)4&]@C_!WIK&J-89WTHKO%E?KEE$]F;8@1*)TA2]=V1?4N\9
M,KL4X$Y#7)%WAX0EB_(<EHGXG.#D4F4@UX<1(QE_(XQ>F1([@XJPM<9<M\9B
ME B-Q(7 G9"T&[WI<P$&_O$52<ID<*KBR2RB>?86"62JKS S"SBKZ4[_E"R;
M*9S]VI?_VER I5EQ^6DSC<+@/=BC,/A ]0S_"5,H8M#W-5BDR6ALUUC/IW>'
M].]-MV<]/?F\L.O$#:M#K-M\]CKE'EK4]H:OGO#@Y_IPZ9&;;/%@F;6B0@W*
MHIT69=E@MD%+]FBO[L4+CGX@38*2@J6J;"\+4*V9?X(]O&HC%N?=Z<>3&QD;
MA937D7+5 Q&Z.S/^6((DL AGC]"C2_O0DZ:]3+3ZHL0+%&S% !&T#@VS)&IB
MQ ?)//I\3*Z.K*.ME8D2NGG<RP#*QLICJ"2Z"^O_1FMZS!"ITZBO8O?6I]$M
MDB*]*8NO%L3U79(\Z&*X 9L*Q38Y5H_7S81B4I.")*RSX9"E"*(;=7Z95PRK
M5]V>G2>)+ZWC@I['\.GA)BM)C[98ZOXVJN$D;7&HO[>2&NJ<^8A/&;L9=%EK
M K0/::"Z%MXCQD'752LM)FX$O(0VHZ"<%'J>I?CWA9<T)%_8%GA99M?*1B2!
MHX'3D2X<J)G>C3AI\]01);)9#:B=5O8*&6H,LL!"LBB"1:P0= KP^07@AECY
M3N*Y0:Q5>IFHK%;[ \RQQ\EIVPH$NGPJKYK%0J>\I>ZCCQ:;$_(;2F%3^&I%
M&MM4V+"X4:)J:SH=VV;(X=IA^C188G-:84[?WSQ"R %"5_FR(Z'D'0Q7Y-#@
MO6I+V524R-2PD?:,0F>MGB!FMPTM/!9"UE-FI</R+2]NS,<+Y]$5I\[&26<O
MXG!@C"#W<%9TA;Q40DE)0TG DA:(+=VXIAMTQVM3(]10"* C\P!&I<DMO3HF
M3T(NN*J2;/),\&?LH\##<,<*@_=?5*O@HM,BGS,S&/S=VL"<D5Y_6AXWL>\:
M^QKFQRK)7F$9P.I",H[./B%>3,&,*Q+EE]W,G3G]^*45253"6RB5L^S:!HA8
MS2-&B:Z*-C2C%E<.O[)ARDFW4>1XJ1F]AB9>ND#M&?8.:YUJE4M'&;F6P1O0
MZWQRL+YS07D#[HLD)R(<3J5DW=Z7<</C>1+KO3\MG<ZR/F-T+V^S,F?;79G&
MP#+R:,X*U Q&PXILI=0D])SHH^ VJK%D#%(2^6B+'<53O4+>B1/P]JB,2W34
M^9.&9&OG2:[TR":W7W)[K6/3-6JC- P1E>*>#"PDQ65:-I5&1\@OJ^7U%9)9
MM7Z]P%!C]]=7T,7MWWTIBS]A!X7-LTK4G_:@?[AHC8Q11"&SQ8(*Y:P"9%7-
M5\SK*P[^LVL_P4*]"E8\&I]9$3,*"UV5LE$A-9TZ5'J<>!UIN:FGP22N<; #
MJ3J$&9O75NY5![#IV35E!EC"!Q&.6!$/[RNN55M(.*/& OJ28WVAGG2.]] B
M7RY""XWN7LD>A@IXQ.118)D4?)WZ"/C7=04.+0Y]#;W_U?KP.+E,VV+9@\PJ
M?!?V+2(=0U<6"2>H\-:#&6B6#.F#S\<$-+&B$=MNKVH2-Y9F7X5)ZUS8CL^3
M'&D:,O:JEEQ&(,<X4^"ZA[RY/"7RB#!SNH!5%L*JY=O^5I'%L&P&$7AJ$B!]
M."6>(3(EDE?=34/Q(-,L+\8ZMFVF6GY@/^1FC)Q[\7<Y(0S2Z(+5.^BZGC1L
MRQY;] &6(TRFQ8I_"0XE8CT0L,L7UQ7L0? O!2#";KP4F3HDL,*_&G^Z;;#1
M^F@+K0_*SD&%G:]!^!EZZY +Z=U#+L26#+EN _O(L/84ZH3E;B<AE:NIJ "%
M2-").-?1$D<M%(\Q?5&$<-5AS8$-S3F^(Z^@@FM7?=0)^($G5AJH&D\TBC51
M%09?JTHWN/IEHN-&'F\FY%A)E7*;R6.2G"8VIM;]8KM)Y-3 D70\@MWF");<
M=W"$C^DX@Z+&>#>2]LNRWJ@%$LC"ERF>K(X!VL3B]00*[%4S02VU@]<LDY=8
M^O5QPIK8TP96%)V<Q(W'],*"UAF?'R@(*N5CO,0(A\P+2J?SM=.N@T7J!5(Y
M8C>DP7Z:-XP>$)80^ZQ;-KF"&/H[5@AIQ.W5_073%-SPWBR&Z1<:59BKJ@UL
M'^8143@493<$BSU&WE-<7.6JQD40$A4,A[CXCHB&';8]>@KV(*\OY'2&46Z9
M2Z:_TLKJ3/UKV\"H1PY/QV 8C(DCJ%)08F4W\?UOZI8/M%@'WS75W"QA8#!9
M<?M\\^'1JZ?/CX[;F'+ZV\'SX\,CS6KLRU/?G6#TI*S3&4S]]__ES5+[K/.M
M+*3O09W[IF7PD_KO+;OBT]G'3V>?SSY\.?GR_O</GX.3#V^#OY]\^G3RX<O[
ML\_![^^"+[^<!1__^'3ZR\GGLT^?'RK,Y,QAC^NR"4J9L"XQ9 X^55[H\%2L
M(FS?1.Y2M>U&-;AXP[S(LN(*E]:(6-D<>^O3_8,M%OS];AVX'BS&ZW/C+#ZJ
M=XD;HMF6LH>0.5OA5T2+KI+5BB.$-G[-.DF3G41E);WU)YQ\JCB=J<";?8K5
M!%"$Y'".M\&RN!);@'^$M00N'L%%Y#0228P8G4I&EJOC,DEK:C814N,JL48C
MI_;HC9^R[%?=4%YO ,\+1DO<DY8#NI"(GY?UTO'0NF- (_"/!OJ=BKLQ8EU8
M3<?NK[HC@)@$"MXZG>X<[='!(T^9GE@5@M&S:]&O?<3IAD]&B-.%$*$0J:TN
M^6=+3 W[WDXHVL*[C]T@;H[^$PSB%BLQ3^RU]U@LHK)/)M]HF29=OT9G4-*-
MRS$=Q+(UB=!#$NMRORU@KZ(P^<U,:^NV4O!"[PP7L7E):QNZI1!$UH^%!?-:
M8ZWZ'B3%)?Z6&R0;62P3*M)=$-M]8)%2N_X>@76\;"V&98(KZCSJ:KJ/-(^F
M?GBHBBGYS"PQK58#/(RLG0HG2G)J.M!0:!_DX:J.$N&&,>7,<*RB_"L>6F<4
M#ZR*[!+.T?!O.(A:.QT&R4I4=4Z;!64V)=-)6VC$'BPF2(7[NA+SJ@BY3=(-
M[I4? MSZ:HF^D,!2EHP\$Z^.-L<J"E9VURH,?L3$X,LQ*;@5];X=7I>/P%?X
MWN4PMSZ!C#O"YE@)84?88ND,Y@OA!%P_W$HSFVQ()!\E/*#EO\DC=@0O'.$/
MK_,("\MB46M%.1@"GDLY@G-<+8W;;.&%5OO.3%HH^5,J8/B;TF^'&\'Y2SA1
MC ,IV#);:MAH&7/)0RJ"< [+FJ.-'#)JW5$SM[]"\]M-K\.^"H5*"BL4*RN\
M\F]:0(YJSK%ZGHDO5.V\(C#Y&8%B.>7$LN!$G81"-2Q_-O$Y_C%DHK^0:"(Q
MHP:^;!(JJ7!2P*/8SKK']HVEBZ:.-%2?U7QJKE&ZMJ5:T+CB G_MR-GIKE'8
M87#RU50+V3;7:MHQ3''H%&-ESMLV'AY$K16((^?I7P=[TUV96IT9Q"=7-YPG
M2XI>Q[^)]2&R<VKC@9E-5!0O8.ZQVI9%#$762+Y7GL\'L=#>7.$O?5.*F:M#
ME5.D4AYI/C*7GA?X_,&JKK,,TYE58,KQ.OH_JVXW,&LZ7;*S0/)(Z]4/UP?I
MZ ;1RNCTMQ-\,-/1#CZL$?$9G8FCHTTZ$UM4=/U5ZYP\6&_"*K6C+5A5R6%E
M'"RN<IK6@@2VZ^:H7@Y7&Q('ZHB2 G68*X.]JXN$N1T<W%V(6UZ*2(V6_+(J
M\;-J#;_:\/]VR,K2D>V)6*%YG/*V=6[;MC1'>WF]^3<J<3VGZK%=,G@72TGH
MP<&F<FKNFQ:7R1 3>35,(/8>3>@*2LI-0>)^ #.Z.398,*-;U*%]E^;@"L''
M['^'<L^="6Y8E19@ DCU_D)E+Z)KFO(?RR+X1'5Z16F?GCI@"9CQK3? ,"LK
MI80J;K:&-->R)JVFE5M,$?2*!G&N1VU<;+#8-D<!"XMMBSJZ)[J*RJZYOA\D
M\?WH-!P?^?%DJ--P?-"/-3L27J4!*XT6^$44"[H=M7:;7'*;98*\Y=:9C1$@
M!G/>KD66HRSEZ6Z"Y36D_$6 SIIYMP_UR?252N#61$2%3D8QVIU]@\\&:X#W
M2X15GOR/!GR]UF=%U5?>W.F/<J8-53ZU3&8)%UE45R@KB&CBT*&_O^RR3( Y
MFH&71OUC.F=0V9DKM>"HKK8O5KE!U>$N206=*F&48PQIQ&[Y+"DP1$K!(\&H
MVXR.\VY>NQV TVBXFR)<+E3MJ)Z%6 ZYO$!XT<Q @PS\F-0XV78+6-I"/*.U
M,[,X15SQDC45YD%R&66-S$RJ)WE(";178P+MNQ,8?@?S;^^$]]B.,JV^LJ%9
MP"ID>T6+A*%F8NBMH'BO#-?]M-];MG:/[?&DYE)_Y=D]-E(;]QUKU^J]9L<:
M^_T\TQ_@C+$Y?D(X8VQ5VUP)ACRN@\73%0>+GD,'C>L+[\$B18?L*[M;F (S
MA:*:C:3(2"M8Y5U9R(T"9GH$-/]()'X=PN\(%YW,J7K5Q %^B<KZR><9C,"3
M3T6<Y@4IA=0EC%#P?H''":&*,SSASU?QA,,=BR9CYB<+36F*;\'SK"G&0$Q)
M?%(Y?!Z<[K_;_[0?8(D?N. O#P[W#_?2R=[A9/(:G5?,!*:S)HO*L!TYM!XM
MR$_<;*OV*4!+5%03P9DPHXF*L? ;TB4[NQ( Q2DA:5M,O6(W@A>MZW&9M]VF
MQ(@J.$]IWUH= X:6R3WN^C@N_%HAFGAT]\H750/W(Y3 #>B)T]__Z^S#R8<O
M#[:V[1T6&^-*(6$_*4.M+V"\SR\DB*(6/V%?,,_/2^T3BLDU*&2%PC 5"2RG
M1=PJ)PN0K@?.Q6@Q+I2*PO6*(K-'Y'G<2/WHL+L1KKZ\4^"Y^O+-%;T]VVK1
MVX>"9#5>!QQS?=W+<CGR.-PO4W-_@K1G2(>,?DM)A$V*(C9#PZ.T?G-Z9I^B
M;Z>$MS*X&F6X6"OS;UN:1H?/]H]?/MQYE&Z/#^0C[%A+9#+;DRI/G @T6$IM
M41/POE%^XMOH&KS29@G6J9=%63@8>/\J9LR8-M.POX_@5?_.% ]GEP2Y([K#
MJ 9?^8^E+K#6?S.$% QM4_BU%LU:EW)8WJ?V30OEYX ]'#C;S6"G6\L(/_1)
MO;NS>A5EY[J9_9N"E)P(I.1,("6EW0B"UPP$J?0\<5M;\H.?=EN<=U^*<\:*
MZ=SD/QHXJ,-.?6TEM"Q&>U,IN6S*JA&*B[LY !A-.7C^VG(@C\ 3Z=E$.L1N
MLL?#VW"B^O3([6)[JB3'W#'_2$&"L],PV#N9**>!\PA$.B>5+SE, SVIE0]-
M"P2#- IG[2PF?95[B$+"I*7!9ZU_J/>!8=#D&2$.K&7.A<"P..-K23S#&(JT
M '$@M07L*YBI!#HA045\E$:7,6?NP%8RXS9R4<W*=*G"-1@DRM*O&$M+H8$&
MH[8JO]Y.$1/GDYZ&6K2< (9O[ $3OBS:8E&B]%)*7CVP<;2()LX4[!52V1'E
M:,M205YZBFZQL=0Q$XWA[O1,2WA!RD;VODW$\)+<0U.J\[36')W#.,%C9/%1
M])%-KG<1(HQHFM"S]'+<Q#*@?KU>U]9I^B3*<Z0N7]*1?\"K,1[9>OV<F+P,
M).+L=&O"! ]]@[C<WO[P]U7.QS"/NC4]ALU"#4\.T6Q$UIS#$'#%JR]+;1ST
M0ZQ!?G8PDA/?"XQBUTQ">UT:N']E2KR&,M+>A$E8=LPAUYI#[##N85.!-N1Z
M5>1XO4R$E)BW7D0 LNLQ91*DC?BB=U3VUHIU!R]OTLL==/^0FV-P=K)BV0>*
MZ/9[[C&>5OF(Z<SBKIWY>7:1Q%B@.;@C9!=XJQ6Q@E]I;0RY>3Q?WLI]V*+W
M\'OOUIWF3%V#(D2L8/:)"WA1H1Z#M#,="4.1-"YJN1(66"&B[6@6>'3#]GMB
MQ28B;(M#@$.#>;!*O=IBRM5KS-4UHB>SPZL^:%OPC(<^#;<8Y1 O%A,#>X<'
M;2]6=I;-^[%$FJP<V15^+,=G-6VR12P\Q],7AW5EF0BS)Q=N2VA:Q.DP$YME
M":M*?>0*[6L=BK[)2]03Y07V.[TO&2WO+:?\?<]Y*QJ\U5GN*Q&@2H5EW;&U
M]D8@?)FMF3Y.M]M.M_N>;VK,MV9*]2Q2B6"DI&AR5;6AN?7[*!=<N,N[MR?!
M7O)-!V^%! G;S*/##Y1&3L9Y>;OXU;?MS<H/"(3D2'G4.SF79:JH<9"X@X:9
M"[)2QB&:6#?^H!5$=!CX=RP!+0P95I:<P[1"W U)H2QP^O/OB%V+/-55Q,/C
M1+K51-KB//KB&"PF!Y(3B"N]'*I\;<]<,P 390O;AYBYWY!QKD-H(!A1L"!M
M<CS7)/FYLEDTS\B6$14I$\DHDE$Y2)5TEBJKBW2IWJ>JH%?ZDA@HL+)^2KK8
M]1#90LY8]% Q-Y \$'T+M'-B.:1&#[K#8^&3AB;MD58MIVKS5N+,]LOY"(GT
M4YS>:&.(S!?JU)D:9"6Q$LR;,D^KB_:MDD-3@TW<7J4.; EBVI)7B9,Z2C.F
M!2H(9ETI#VY,H]S2>FS1.;K--N1RS<GZI *#E&74-.)GCCPJ"M/68H;37%-B
ML$ZLB@>:=/8O3HNJIFF,S%-<$?TOAP<A? /^[W5@:ZB-D^MFDVN+LXMJ7-A\
MND7(_#M'>ZT2-)M%U>-#2"XBV#;8N84^)*.9HC=C87^D.OWA\HO HL45HN4+
MH.-P9]?[#M/;E=?N)H%D?AJ1.AA^2@SNC(/U<!?(3@:>PF .(DE!L*070K(M
M,J.I!1 1ECK$6?#.A#]U4O@]FZ:JI>I<KQ\?7<(V13O67K)_OA]BRJ=$TX)H
M OCT26CT'QBTT=UPIXDB!5 0LPK>4I'R!-$2&@=, 4)\0@ZOAW>>8GE0'<8U
M7IV&15E%FHN,W","P&OO@(N/Y=!!**U#8NSZ-EF'N]*3H(N2"A\6;<"SPS'G
MO?6<]_T,;;< ^G[:@1@G<?-7+S8NKNPL.:)D!8?^GY.6H3Z/2AT\:B%M?0AR
MQH\_:>/'*<I@L&5O"$3^"/?9*JD%G$@T>MU]%]4T,4&#+HHY6.,U;7$UU^DA
M[V:J]FF\AZUX3_F(%F]C7MV9NQ<PL<M<D\#.A(\8SYL=T!OOL2WT+!,MW'!G
MISJKVQ"YVK-9W2][467"#C!@3V2_LJ?XGDYXJGA$I"NG![?@MP\?WP=<]2,-
MD'KJB>^\O6)?W4-%$N/\+IE1%\E[ELF,I:FFUYV[K&-ZFG>=W$EWNT>9U9*5
M7+5:3K]K9[MU>6!];+#7=A0YMIQ(2MR"3#(/4N72((F*[ P>D*4&EVKY/Y4A
MED*%ELE^$*Q&\)$JC,[#Z($UJLA>=Z8D<V:M)@UT39$4>2Z:I@XY.B.)36=8
MCA]!93N*J1U:O?M<(1W1Q#:Y:/OS.KZK\5E9FZ>G8]N\IJW7*D9PKHQ?V\E]
M+[*M#T7<8I)@1TKM)4OS]-RXQR,FC.4L/RPJ=C@KKVWI=K DI)1GGM^A6E3*
MF?:^V3#;PAI+-'EM<;'!>@T[3^T[/"09UZL4O!=3.&]N?L(?&;"L+I2 +O6M
M=QD)#MHI/WWO_U1Z9N6\32ABNX9/GRS6V)S.K)'^-^9$,<M[YJFWHA*_GFMY
M""BFXL:*U>*&*@<XA17AN\R 95%5B982P1&?MH(2GB/4NKW)P<*G-<N1N*;2
M;?OWH+1]2$&LZ7U4!_\6$8V(TFE\4Q3"^O4)[XYO7S;\-4F6 H5)R?OA&"J)
M?E-<P3":X(3R7<YB[C4-$$JF,]@&_7YD4YA24]'WG\V@CVM)7E"K@R@&SY"T
M"PH2:8?E23&U.1H(>NQ2:&CA'ZPH]Q.F7Z)K,L_M[<?'R%#!9W^6) 2]4UO$
MKXFD)-2WP)J9TZZ.A.&+AA*6%3XNV'LQ":Z32)@DVR00LRA+4%:=+G& R&04
M\='WQ%:T"TMM$/7"P;,;\4 </'MSL\O?WIG8P2@_?,]U_]X@1#^1F. -%KK?
M%: =C5 H^+R0=KE%@6*SF)1!"E18 &HBLVM#FMI.=A-G']+7LQ=%>Y L;^9O
M+A?LY:LST9WZH/T=GQP:UR$=H@Y6^$E8,NZ<:QRVUKY2O (9M24J;<F^7)&&
MP;IZOJ[5Q%O24FRC;1!U5K<HE>FP8NW*MKTA#932;^\L-MH,60P1T3OGG#5R
M>)$M%KUDCC,$41.GYN33:91FU15T+]MWNJ?O!BF88[M@ZA@O"O"X0ZG=I(IM
M;PY0=3JG EO1B/,4#?+4?Q1NARKLD4&Q)YV3:+F*OHEE)YHC36V]JHO$867-
M)%_S6B_ !996LT9*6!5'[K YX(XWT3"8\::-D>=LV:8%>WW'<H966L 3S:1=
M)ZUA7YMU[AY4S$&A!SR2]"3E^&#R+2EG*9VQL:P3K9ECR!*.9\A4Q Y"JQ;R
M<0,?7,'&H8HWU4/!+:"9#:Z :Q1#!5X0(2J>_T9WO!/),F<#[7!$K5FA+0^R
M!^2(OFAI'9E<$+^NA%^@;GH$SRS*>H[/E4*6+A&5Q%*=/#8=W)!"C4ZQS_XZ
M:5-7<S[=(NGF>7!-J9HHFPE-'309YP"1]/.2T WRG>&FM)U<.$M*OEG/3OI"
MY_#8CHC6%Y;B$XP'9B/:,682HS/5N@^R&O)HS J-E9 MB\E2&DVD\RQ#S&PK
MMS+DEG!P>67+; ^J>_-[J!':"/  Z*A)QH;/FKC6R4X-VE)6>AI#GD#>R*#/
M$(]ET+4Z@5!]AYX5;M$A=^0<FDXI#V@ =^"NE$D?C;AGLA1F-&_Q:;=P]6TA
M"LW5X$I'*%];-IY-UPJK$\"-BH73H<QO@V"ZG0T8X7!I3"BHX+P ?V<>4<XD
MO[9'5REM#'E'GP/>3AJ)A^0<,Z+@5U83Q5Q0ES6#KP,7R@",#9.PE>8QT#^R
M G2O>O @TAPO4^*J&]Z[;EDT;.UYNJ.ROM3C,&D].!_2^@:]$.KSSK -016
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MQ?)U\-\P4<Z#7W_]: @(;("/,5L]4)_U@.E5F01PDVKA<::/K^JBB$UXD-[
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M;BJDRJ "RJ(YY_'XDI"55(3<4M!(3U95ELS'32:>3N%>-J?'YU/M9@+FC!,
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M%,3U30$>[.B80F4X-+DPF%(%86'H[T@ HP\\761G&,:%YN,0JGGM"\E+FWL
M/6(<*HU[J4]-86RGV'_1-/J8J1==WP=70$;K\7^P>G<V'A,\-( 6%CPX$)0H
M-L&Z+:@4H 4S'1(XPRO&*=>8U^J?M:+81D@"H6XZ>ODG72ZR:75NK*:J;87A
M@\&2ZJ[9SBA=>ZS<+D0I*947US$-;E62:#RC,:>O((:LC#KE?J.@N>8898$6
M)($7EH2";V%7T<-"BFG#_Q?*5DOCR]BM_M O\S)8NTFP[4Z\S4X<W\=./''I
MNFHE AWWY*$OD!43[?1DHE6>TQS2FK:H)X\6)KWJ^ 2/LJ3A_;:D85O2X+.
MJ#S("H0G5 W9T=JN^)2ZY'$UUKYN;;?JJ)N<!)=.4DTOX&R[7=KJ^3HFP?3,
MW%US6N3!651%P6E>V'9R+4BSSH#> DA<;=N!'0O8JM+&DMA\4&4;QC5'GQWX
M6L#+;2GSTKZJ(-G2$ P>LA.9AX)8;JC20,.6<'5Q;"T,7D%;)6,>J2KLOSH\
M1KX/6/S>)XZP9D&FO5TG9-J[S4&F@=I-H9 (O,!3ADW^H+3R)5B0>8%\;&JC
M1.G6O;B54;=!^M6+NO_IDH)J+M X(>%DD4U!Y#R:E4+$9)$WJ#\>*1FK;E1R
MUL)MI%QB616)A==LZ!1*"].#JV$L0.N4GFC"<,CX-8(6RC  O.AA/IE U0WB
M<]@!E#%4<946:2-(-/@_Y:!$@LZ-DLB!::<<%44XS#!TQAJ&QU^)(\%,/U J
M:MI5C4F9C8A34.I!$*K;XE4=V6#G-LDJ4W85-0$Z2M11(37I$*-^E3C<*="K
M566C>\"--'29-/=MZA27K.H 7Q[?(I,C*UA OT/..8;<.RYCW2//9D73!_2W
M'("AQ$^)*=E:Z]<50W13&17A;R/>IX"VXP"E%K(&&EH/Z4*%%$2]>9&B@?IO
M3DR<]/RZ'Y$"X"]FCC0WI?)B;3&K#NO:IQUST<SDIG1]1;VRG!WS2E_-/I9D
M8^#CL$B1*T FIW9"82_ HWTJ+'643Z;;D<(29HB:ES--O:L>9:5QH2%].2OJ
M $)AZJ^:NLT^?@C'7QLL?;=<CN-H#B,:&M?PXBHIF( -'ZAD:1H5I(/^,1M=
M2M)."=9G]9?![]P/0M@$I%5L;D.=\:[W55+&'%>#Q*15MN<A:J8:/OWX<92D
M,\*51\G&D5EXD54 -)#".JE*,<5_^JCU1TKTE )OO61+PO/E+."<TD' F@88
MDAXY5=%0,Y8MD2"'&&<"Y*</E7D4SWSHE0=ZGH6R&V"G">-)THDZD?MSIFMK
MIMS"3/E)O*IV=VHZ9_0*)&YT*:1^DA42-GD^B/%AN3G0U0P TP13 0ZG=<A?
MPBV*/G,[N(K3$?MIA Q!P-;XZR9-ICU]'MGW4X33]N3=+\)!_9ICMOSMK9(M
MH,>DTQE;U +&3G:),?7.A_;A89$,Z,"A"HG'2 =,>MUFV,'GE+UMD$""!._6
M&21XO[D@P3?2XZ<,3O03-.S]!-J;F@J(1&8<K]/83!R49, QCF1*P9-:D1R0
M@_C78,DJ3P C>!:3'K1ZY04ZLL-HJK17"NX*B'E.[E,%RCB.2SLT6RXO&3:A
MO[9QBZ%M!F@.:=\ 1($NG4S59EY$P8;ZL,L@A;;:\Y[GCRI9\V9WFZQ9/5GS
M5"3^>X_$]XKV%C5@2_R]W0TR:5!$!\[Y?JZ\PP@B4EOS[F'%?V]EWIGP#ND&
MF^$*\O4.8H*3H/I]0^N_]_KYRW>/=P,DF]L U,=-A+P%]#V7LTE,V#18]H9X
M.PF' EW82'807>UO7[(I9^ZQK_9#66[,(A-&638WA*@<AZYT&D39H,I>5$].
M,=: @>0(:#JB[#+1/3[R4Z]6'$!M(35!@V$=;HS%<$/+$/E1FM2M95<B9L%V
M.]YR.VYP/U*$/B9FPA\0);,RC("2)U$^6.PSCMK%VO70RPV5*^M4+O;'D7'Q
MA%:\O[GUQC(>*T@+]2$(;==<VU)@Q)@.<YW']TDO[\?-+6]=K/N66XX\Q;)_
M0,((:H@(ND7'O[D8*H%=,9A1,$%:V: T04D(#A;^YTRM/H)#'_P/=.):9:#2
M0$"YS>T&6M,&VO\Y&VB9;.!B04Q2JB^%+O+)-,WGV F=0[L*MYR0%LD+;U1)
M[E$CRH<_$'\%;%OWMSG5#MO9&F#XAOG%-GV\:)8!4?%-5(R<"XL8DIQ4[]=Z
M&9X&2DM#P J<9KSZ6>/-=AU+ U\RH\+)JSP=,?-N%$Q-'20>A@7GQ9T>;%.A
M\""462#8J_7P*OK+ZMAF,!<:BKQ*@.=['^RVK.WQN]OQ^_3SY'>ML$N?2)+.
MOG.)*5/I!=. K1 \#O[7ZU"]!?XGB=5Q4D*GV3R.+$+D=0;X'OE.2*XWMQ7^
M2ZUN7%S'H_^[7&]N5Z:^,AM<F$@=M!%#>J&;-+Q2GG6,+O2)C1EF( 8Q^ZXF
M)(L+W:P+(!B<AA=*[>5PO0SZJ0G'&O##L1_D<.MZWVX7;=#SOA"H;\08T#T"
M86!R]%N'^N$[U'#D9@RY(6Q_^ ^H"[J.4K)!N2YOFI>ZJB+)H&(/RH4D[5R[
M(!^ GP7!PIN\R)Y!N!^#<,4TG97X^"F%8!SPX>4E?&M3)T]Z2VW8B4\RFW1D
M@X'4)[V(&W:DU0P6<ZK":M90;1?QX;MC4:"U=*V?4%*TJ*L[!TA_Q5J8O6TM
MS.JU,'<YN@_ZG&Z%U=V$U<'FA!5V)9=,:R,_ ) U%"9*[G@=YN%VJ3LM]>?-
M&A=E1(E]:/?!8)_4! '&JRPJ$T0)+C"A0!JTI&7-/MY*5>R>4QMJ@OCJA?HI
M3>V(=3[N$$O<[J%.>^B/S>XAJSDL5.ZC\C;2E)L%(1>B_(_XAHI*<)<A=98P
M0LQ*KAK 'E+Y;3+18'3^QLB=7-"* $@AJA@*LXBKO&<@P,3,LOI:-/D&;DL;
MK U!=]WLQ])AX+NI0X;B+T4<]*&H)N1"::LI%"%P4NI.,H>@$9/+ #6CT:CH
M_P+#1;SF)>C2$H0MDZW=0"$"7<=E4N#'"XL'PXER3:)6%NK]V[.^GK/^9?.Q
M1C0(CM6V,ON]?+Y.8?V$ENMZHV6")J5@Y>@"*-*P>KA"?3HUQ\[<:2&D]GR8
MF;8._-K3>VM5W4]K-VQP.TRD]_LPNX[+2F"7/B67V';T,8%*_ZM,W76)M9N'
MV?!Y>\./DR*FW#!HX?_U8M?.#Z-]<'E9Q)?8)&18C#19WN+7#]0DP>HX/<%_
MS"*U.E5>Z*)3KF2EJX-I5!CR/9T3V9B(^@4<[COLR9_:#XZE!C6(@AQDRF5T
M&4N]@8T-#H:@LIXXRVFA,5@7 1>:L$(,YC5.IM $Y^ !N(_"8!(7ET#KI*RE
M,D]GS"8&*5L!G["?H7:OT_5M@T50:\4$MBWW]1G&^00+H&P>)O2[X_@'6I3X
M"WR 5:0$CQ] 2C_2V"4QEO5@9TYHEQCAI0ZFHVU2+LGU;GMSN5/KU>X:>W/W
M]C8)X%7."M@5'X(C)1?5'T?!=R %*92!O9\3OH[N#MTV<3VT)JZF-'1@H:1.
M,I%E)O8:D'SH38(:;%XSQ <F%-'#'\@A<^^U_N"[%2D:2L1XHE<I+ZZ$I!32
M4$3%2)G_]NB1AGL\*[*DO&ICG 7H<2*S4R^(L71XB!A!*8- >;Y3HV00_H5,
MC_J%B_!D@3FA5V_!A@S3"/Q=I=74$]+\)@1[-5=^*XE,=?J%5:.5B=WB3E)S
M'J=C#SL<4D^F,8I8 '.'HN>XR68I =7?U"]FR+)COAH>:H70U#8&-C7BR.!K
M>E3=QWS=B-Q?(M1X_3UI(NA.YEX<HL%$"1GO!) @:0J0R,X))F"8P.8@C#0Z
M?#E47T*,(4K@@+)F=6-M-"*N(,YCCC*:]ZFW0;2Y"E[N!J-H7M8:$@5LW;^;
MMJ;=0S/MOJL%5ILP4]L7PG7O=WNTJF-ECC-H?=.EV!&B%[38@Q&Z#!I]U I%
M&1Z3.O4 [8>>2QQ&TG2)0*)Z"3E]CE30<F>=A/9@#+2HD_HM6U5]F]V]03B=
M![B[9V5L1YL'R!EG< @?95'!BVU1P2:+"GX9P5 _GH)GW2+I(W4"V3]"TD0*
M(PTM@.TA@"*N2!7%73R7T!%4Y9W8@K#>TG7+=4@US06,M<9@'D,5V)B5R+ZQ
MHE=C/MYJDA4TR6BK28PF67*XFH&&,!C-D)X8$10U8N$X@5PC\8T159+#:D[-
MGN 64*R,T5:'0J)K.7\Y=;39%\9$]RNHL +G"C<.HZ* MCEQVKCL3C\0R0FM
ME]63PO:A'<58:FT*)!"M&$ >E4<&46OYO0<K 2'"/#'MTL'70TZ@$>)DT:.V
MH'G#O;W=]^_>O]E[P8$Y7]!N;YU!NQ>;"]I=1'_%VU#<?8?BNGMO:KV"L[A2
MKF0G0L EB,V0"$OGA".[PW#V!+?)@@Y1.('YN900/I"'@\ O>_C'),.,E^#1
MD^3052O6:.O!,W@GRN*$@ (Q/(-<ERG>ARA1^0W&>."=%(#)MEOUG@,MW;<J
ME"QEH#I@%UP 8E!7WMG&KFT03EJJC-!](%JXPU2<=NH-52^TX4=:];L8E073
M!XQH9]K4XZ!+A>ZV0L0C;3Q AA<5+&2& :K*0EK&0.VWY^?/@W$\TH0Y%OHS
M$O807G0^C/09@DYX@=X,+=X<];IY@@C,F9#*N^_3@]2E62."9-)QU,I#;P86
M3I+SP8.2C)LK(5@VLXU%5E1U&8_X,7"<@_UH&NQ@<+L6Q;7X+QVF) F_6F.T
M@^9WVVH25?<;R@TG1%M/&A^8P[L]/Z'3J@,I<2O*"G:CP((!@?/U8O>.5,6W
M/W;X^KT/+O/$L1(A'M[7O/!8[CIS#J_638"PO=W\C8.U)748AE%*:PI@EM ;
MQA0NLALZB:.,X2G$5MI[N?=2Z65C[HYBYV.^G9X<!]_/#B\N#HZ#LX/__'9P
M?A%\_#/H!Z??SO:_],\/SH*+D^#BRT&P?_+UM'_\)_O#Y\'^E\.#S\'GP^/^
M\?YA_R@X^?SY</_@++0O#KX?'AT%IV?JIXNC/X.O_?_W(.C_O7]XU/]X=  /
M/O^V_\5^E;KU\/S\VX&Z1SV,GM7_>O+M^$(]/S@Y._Q#O>^(K_ET>+X/?PJM
M^S[U+_BV/P\/CC[!.[[V+[ZI+_P3GH#O^W3P\2(X/#Z_./OV]4!NQQ&?X;CH
MSO[Q)QCY?QSL7QRH?_7_A&N#\_TO!Y^^'1T\Y02'-N_/XO%_[[,G1QM?[;G_
M?O]C\/Y;L?>^?V>+?YT1XQ7DQ=EY\-T"9/FLYF)E)7V2$3\ I,S8,7=C!F&=
M>F\G+Y1G:]-\(@GX*"DIAJ6./SK1\]#P2"ES,"YZ0MW@I<@+X1G@[EN0T4H.
M(]5+ )\*GQ=\?_:>$\!SK2,)XLD=S3>E'M03SBO,$A,D(6H\O!CD$I49CX7G
M0031V[>[D%S9>;GK""-6C^J>^"]EE%3$_>S8"@.U9693!R)G9WVZX99K[=4,
M6XFP6"*\?E>/#RR^? T"9(V!PNZ;RMI0ZTDF;G%@-HC<VWU=3YEFNY-)C7*M
M)N)+]89R#&X22'!3"HA8K"*]E6CS2:5ZI[+M*T"IT&413:]0*.Z^^: 4IV91
M6UMR_$5WNUV\06H "M3:9OE-&H\N.3!B7%0DZYE03%9P".$N2NQK1VX:)2-=
MHZ*68*8K46V],.;V;4=_L#-)$11[UN!*EQL=(3>(0)5)7EV=[4C[0ZK+-ZNK
MN<M:N&I;5];A:7E0:\DHL)%FOD#X@[_0<7&R8'<;&'^I/3XEN;N[BC5+!3UK
MD(.3#*"<8.@PW\YB7$7%!+VL1YF'?[G-PZ^>A^^H97\9E=I O;#()TD:D@0N
MG!B4-!(.XCBKAZA1UD+@S1&CG0(270YR+6BQ2N2*?(G!C!"K,4,($?MB1-V3
M$F/QAX+"X ;:.T%TZR]T4XRH<)F5!\LE&^6M.H#JAE>FK$?RH8W[$RDU@[R.
M#8:N!A'J6@3K^M3&2F(YJ:/<M?7Z\D9TDMQ1B4YA OBI8\X8QV4EK*4H\FD7
MMVU2EXBO+;'>@3)VF$-1,(2H+;XDXQ=G@!28IC$QL,K  AWUY0MU(8DF?U;S
M4^8X?/5A)I2N[]A4:N=7\ TZN8B[+];@(FZRP>^03C4==D0-WN<.T SM3>R6
MXYZ\0:G% UR%&TH9H-<HH%S3"],\U.>G+H?-EK0?@YHDZRK'D,N"\9 Q[&QV
MO+H6_!=X;W\\3M*$2F!,C83[2@C]TTE-)L26R87KZK#-.*J=Q948ZCM7^4U\
MC=(BRU&KQ*->&(RA#/@*HN'T+*S&Q]]! <R8!P2)(A<WCU^)>2DFS=3PY8VC
M*3$X.W_3^%2Y&AH64+M1XYFN1B8Y?E,B+Z_2I9A#KK!^/ALF4^CZ1Q!MF(.4
MB9CY-PEQ YO(/]\> >]IZ8)RUQ$\[ 5@)/?:1Z^8"N1:I'_,BJ0<)::[#Y5A
MGB85,+I#*P< S9=.T@AGW9:&5OK.=MC<;4'3][E_L=_G=Y>SB?8*:[RJ0-[J
M"F+M+*II!D%.JV[XE,N<]0PVT'+BL,63!#ITM(#PE%C0X.YM)6?J]8VEPVF?
MVZT@ZEN,BRL[Q33&]!INC"^9V#QWG(NT6W__!R QU,MO./,X9_@(-W=Y%0&@
MQ))YT'/@F#6?.=F%#9'2]CC*9X,J9,#U"AZ"S4BLL,$FU,3U5/U5:-@B2^A@
MGE K5.)2AT0P/F:F_/\"FF;X.7YS#FP'$C(X1IH]36:^LM,/+QNK$\/6")Y6
MWW5X<G&'J],Z&Z@W@&#*U)(,8R-P$048&85A0 "W,TLOY?QYOE0.'!WN:*0$
M(G W1/A:I<WHX*%]-"LJ_9L>-2@IJ:$MIA6_.H(@%6\<F,-YUWEP4)$U[8Q>
M\L5+MW/G]*8'O-]G;*\GO=[5$B;,]PV.H^M 4#%&Z\F=U(R45=(FH=5=/HCK
M9M'6[EV:6]U?A]V[2<.W'ASM9%GU+ \1[3B=Z 20))!EZLS'?X&[5M+QL?&B
M*)-8H>[66@[LG[&:$I'];#R6I!^A/+D>?4;KUHJ!&&NBK:<5OH0W--3KU<*^
M'L6,.I?'M0-!"P29<FU\:$85\@?4'$V3H2'J$#L /_ R0;NQ2 B&WGJA.GM@
M;,-T0'GBK'J6CY]-\^&/N#(LP9;!@\_K-6WFKBLJ!A($[A.IM'((R[.Y^0/&
M^=G2*^(TOH;I_@,Z6!%*"U"MM&JL?[W]D;6*G57,D3N'V5NCV9WC)AD89J0L
M,)9M.U^#V/'TL$#4N(,+DD3W_V6<&IH+8@>=/S(QE!,RC&OA(C0D,$@_5I8F
M=</#WD4#_IE34H4[R;W;LGGY'$M "NZT.M E4Z![J-6.;3\_;#=7]% RG.-1
M:/QMQW_3[B<7:5K^@,@=[S:&(>*+T!/&5\'1J-6!)J65+G(T*E9M%C/:([Q?
M:A)9_8'PAZZC)"6D 3Z]4J#LVIX) D[1%!F(/QT*D'!R @9./$'G<@P@ E42
MI;V%.,O46;)<Z_^*F9A7VRS,D^R&?(*FZUULT0WR^JRL_>T0* 1,[7Q]GS0?
MX$0IV9G5(Z,@,1G]3*UUS S V+R:%][>/I\Z;^J(GZ+'N^7;FI9J ]VUKGGK
M'TC-?(N_\CX+"A92 =;";RX59@]S.N9G;2S0;L&_-+=3([8F30]KJONX_7*'
MZXD4-#]YA6 !QGVX@0 J3IEO@XX8FI*69V3Z6 !QY^8J%Y9L+$GJ>3(9RFZT
M5K,(E%55 .\>H E+;2HTHJ@]@-8,6:78#%;,+5(G/ %.>>P'$_..A$P,%M0\
M;#BGE(P[H$X/?\HQDCLHF@WJF4;( _+7U/4\JJ4"-B36;U6KE_G3*!U3XW0*
M4><Q^C?L>1ODT!3SX6&C/<UPT_K@8?M,9)\]T+T:!]=Z]S]FHTOQ']V!<_[$
MD@L@,D@7Q6E"F42*ORN?+6[$?>YY,>1;QS/E?,5VODQ#?XO/6ELP+F6<946<
M3 8 ]@_8&27F"CFB0U$8_2#CGP*$N#* \@GD\@#+/"FC$01=E,N0S\IFEJVU
M?Q;6><#=AZ4V9=1.<A#72]XA.M+$A%B4_G"/3Y.D0!=^F$7>2/'TN^=O7O]"
MS??48/]BG0WV+S?78-\"+^Q]H4<--:P$:S\N1BZ6^MS0M%?C3]A3[9 %!#L2
ML>0X$&?*V.YM%&G5>B?5;]AL,H_4#2,;TMN_Y)9]N<XM^VI]6[;#MEOT/9V*
M'?O&'#@'?!(E @\S:&2.1P P><MA/8!^I.YQMML&U>IS__+5VY>O&KU%UKJ\
MJO]M./UO>-]_O_COEZ]>M_UQ3_WQS:([WRZZ\_V".U_O+KCS]=ZB.QL0*_:=
M+Q?=N6@27B^:A->+)J'9TV7?N6@2WBR:A#<\"8<N3 _!CF/U:!9?YE7"1J:V
M#FSOS6- D+4A%1'V>7/,/TFK_T_/+]T-ZZ/SB!UQEKM9C%UE@$F:6U.Q<"^S
M#7\))1F"UZI4'528^4&BV';F:Y2ZHO*.&?7G:/028(M)3-T3I&I+;8@S?%1V
M:8L@IU.SZ[2<*%<B@4FY@!?49@%RMX#2BVF5@10"6\M^JU<N//UG)Y^/@V.<
MF]I@VG$Y&'R+%@)#8>C(@+@,I:AE;S<8 I/P*"H(8XPJTQ+A]9KJJCT8P4(9
MQ,,+&0\,4>WA.;1$A*:GUP[;I,#*1WSG)9NPGKE9X_2^MZ;W% <=I8LF^-#+
MFKY0P@8+12S/5&F1.A.BLK+:3,I1L)LU:T;//ZU<K^!\3GWV%J^\9]7-PBXY
M^Z(9R+!=J!_*63D%?).F"&T<)M@JKU[;L0O?N!=N45$\SIP(9ET$/>F(NJ31
MO.N0; U8X%QS.U!%JV\M> :7[.WZ[H)2LLX[3&3M.$I20G1=I#SE4*YEI]U^
M%T&)XL#[D74<H87:'C\:J3(RE%A9Z^?S&8<Z#QV:Y>&K?;5H^+5Z7PR4MFXR
M,2;,)D,@@4Z+:9D;= INM4:^Y(XK]V&^Y,C%8K*,["G4\$T:-<D8+,O$--=B
MNKKS^5K)X,G']"5_?QV74PS=M;B<KS<7)3F?3:<IHYVKG?$I*8=I#NT2P1%^
M:P?\F5^Q7.+UMEQB(TVKS6/\@,_MHBWPRP4G4.JP$7#HY]VM(TTS?L"\Q5GC
M#E)J&3*]2Q9_BPWE8QA!7%.UL^U>RQZ_>+[[4ID0.]=);Z<OV3149)V?N/-1
M[NN@-+$^%E/HT$:K$TL]2DV(D,3\$;"!X64-:>EI"IB#6PM_$M[DO(G8A#C.
M]@AY91CN:,$*?.@^&U,75823SK6X!]<\\XNU.=%] G88RF&,32H]Z\Y2WZJU
MS?GP*A[-E+'S\OG>RV!',\I*/7KI4UVH,__V;SW3!J,+_#S#G,2F6G7Q:"GI
MXW^ 1?=[JVP=CUGV]LOGNV\7*&>^.ES3N_;>_+QWO=CK\J[\EE0JS=<M2GGJ
MC5+F09JSB+J*G0)32%U>Z]J.=*Y;[Q9O* W!0AO#:?^!'JFD4(XC5((!*("I
M/EX6;$?]:+#ZVRF8,>(F1<.M5,R]!O;;))JW]3N$1B#FQ#:%PI"+=^$&Y?($
M9U$5!:=Y(1%*N/P<,KO@R,]EHL2SGU-UF]-;^#SH2W9U-AWQY/E/IU-I'.OF
M+Y^,G1*DJD^J"L*<64M"CL?55/]LOC?1JC$>M>A&QZ,/NMK&'6V+G^OMJ&E1
M0E]]VNU=GKT7RO1HYC"LOS52&(3F_N;EWHO=11F5MW=VH_IJKP[53O_[H=>)
M\EE<MX?WJCVH<=^@"'Z3_]YR*BX.SKX>'O<O#D^.GS8?P$+ AK>?5X$ W'W[
M9:7+W_57NWQ_M<L/%NR"=VN+*[QYOKM!3M(+J[?VDTU2L[DD\?V$$@XT=)D8
MV*:]ZY:N#ZR,[?#<P8M2CWIA^4!.Y2I#1_-"Q4H=8]?C-"DB6[VWP9??*D$#
MVZ*>>@D"+FD\X[HRC'\>2.66[DX$ *D&$>@(6_<MJ&P;$I#J 25WH R!$?;/
M>^>AB($'!N9Z/ /.P+Q@*DZNR9EE59(&DC#09*5Z=*8,'0?%S^'ZNMB[2>Q%
MZ@F6!J4GU%BY./NYFGB=%VD9>YGGT 1OEK*.B%3:/J]I;*5KJN!$Z$4;8%:W
MW7>OE8=CH+7\H.6>P2!L_89&,S#!  >Y92;865;'($^,#:-/K?7B:9Y8E:=V
MDRDT>2AE1?7;V.Y7S9TR55A>\@@RS/\G$Q<#I'?W4/KC4^=[KU?2H'NO&QIT
MX>5O_-8I*=SWZU2X&^03.F"0C7%@J=Y'JW7K@%>2H!630QI:C*1TFG[NKIA;
M)#$"E:*L&L2(,@7(-80,"M(.VJUIG:3P$T2*(6G6DJBPX  A/\X M]SV9>K9
M0T8^R8%YFN.$ZE^@):LYM,+@C_",#/^EUB*Z9!J)23P9X#_=]@_44)IUZ*Z&
MC+$^[B"\7ZW^$./V'=XJ=FS=KQ] J%.AT,V1ZIT5UP2+-'<V(!P4+.52.CU<
M[=76A^_96FNEAS0G<<^P'/@_@2P/0$S>>=D+YG%42*J\]G%UT /L<@3-%PD:
M_[IVC;;-TB3F2:;S@%EW<VXD?@O9-"'I<\ RGWJ$AL(+C3))H^=TJ>@Z(BV_
M0JBEPUP8OIC^'P?'%T\[W&)-S_HH%M]N- ;1GT[S)"/ +Q">&M+E<4) O-G6
M-&P<B/N!G<['9M8?6!2[-AD>]?PE11%?YT,B.*:S708GQ2#YJJR.LWP>I<H4
M^)=H,OT0[!?Q*(' QE09Y+.,2'D/_QX&1Z?!3I5?QFCSVLU^A)W0J(%8A]N@
MI)RD8'N2A*R_QPI70:"!)-4_U: ]9:F05V=29;S:IO2X,+BKP2<N7Z6Z3N V
MGU96T0>9L^!S@$\QB)6I-3;EC'4$'>JDU;S%V.Y&-(F0'V3>9/*]G <RH8/$
M>:A5$UMXE5^2WPBS9*'LM%'">+O*W!DC%0ED\6::[[' )&BA%BK%$HGX4I+R
MOAEE9@^L-/9-"@X?R@>&1#PA)2^UKM=Q#2<A&D($4IW!,&"H >5N049Y2.T>
M-'I8>?A1?>Q1$BM7ZA(XGN,Z6+@X?/N&@AZJ+;#N4J8=JRVM"!(U[%[WS)12
M()+G4N*D.G4,8, CPC2KR(U\'@0'INY!=QH:B"? @U_56U&;_)U3;>/Q(RT+
M$4?IA#PA>IHIGZEJ"(!:X; 1#(P"&R?LP9IYS1S@)V'ZMN*.TD4.R,45IJO)
ML: Q#)&9FSUPV1/F@YX'AXC7@/-05H -J.EF1@:G!'I[K-B$!,MQIPGH!*Q(
MDC%VA!FQ_QB[0%EEHF1R1&'?GF3%QS&A_[<<BH3*%FK$J^I7M-W&R6C&WRYT
M[,EDF@)K^@YU></IZSD13:EK8NEUB7 3HWQ8J4,2RQQ::,5I=./6PV=E%4>C
MT*5VFVDP;2Z?4@]2F@O0 X=*M^436OND=+\%R6*I^7Z<$NAL2M"(+J(M 8NI
MX5\E4[7FU0TBM_GVV%.-QUKV_OHZOM]N- 1Z9IWIC9,;W+NMA&U@A/ZC/O,Z
M,05.[;9%K?*Q5$LMDM#"(J)K;Q&OT@@4!,=)*BET^9PM0$0]!%N<W/WE5'!D
M4/]LH'.H@#**4P\ )RZ?75XA%K60M"Q20K9 =_#]0:@K^5/_4RE_PXD(F]R[
MQK)1&PQK.[%*B:\3 #$U$TV^WE(X%!C8<K5-H:R!<PM)"J6JBYD"<P;],\%$
M;4>H%B8L S13R+*&J"C;48@M0BV:@$ S4BH3=$E-O_'OY\$P OFC0WBC0 T.
M[*!4FG#EOA\)@>L.9F6"C2CULF:Q5+6):BDQ@[PD5B_ CKL06@N7W37/[>"]
MLD^Q@!IRE3-J%5.ZQU2A;36)I4G6!\2@-,D&L4.4>3Q+IU$%._34F'U/EWCU
M]@O60K"UGB*CUDYH.,>HYOB()@3]9"L:KLE0)]F1OH9ND$USBSMGD6VN<;Z3
MBBB,T9]0PO4["PN AB(L6_4DEG*8\R,/0=.RASX!]/L6ANTV>V^#R/-.<;)E
MU"QQHV@OA@%Q;9,-  C5%) "5HIQ-$NK4%)9S>[4]B@/8IOM1Y6Z[=M4UV,?
M2%6Z5>G#;$^L,2F+3H1V6JLR(I%Z(:,U0!PD*LN(T075&H<,]84@T$F%X:@%
M[X\\(X#:%^:L&XE#1S4T,_7V32'+//9=_U.VO2U>J84,4;ZSN=54 $= HH*%
M%0-L7"2N @ME]X\6XA]'N8RX=JBE.$ZL7L7'9G6!;:(WGM")77UH/J;D&@Q*
M?0,."G.94?4DWV*%LW?RPFXRR690AX'G2STR1DP\3Q \*HT39;Y?UQ."R>D$
MDZPW>">@=\N>'[T5IBO35/NFU9&C]@3K[<0#UX2;R&D]33+>58\RE_=V2ZR[
M>C[OD4"Z+SI'U)[%>Y]2,N!VEG$:<F@#T3]:\$RL0C,N,F9U*XQ9"&WE$19P
MO<OK1:##6_U\._W\,Q2TS:J^*?<F;%H!(VJGB^VP'TMWV'ZI > !;!?(<]5N
MFK<R@+2G):U@E=G6D\DLXT :E4[F ZY0$P+<3H&RUC=Q8$HB6-OHP&W.PN"^
MH@-F/[+<<U.^MN&!F/KJ=P9@'XH1&/=9_"5P@F2[D*7#A,NFCV83EJ"F'25O
MSK^%Y6JJHG0IL7U/,ORR=B=S6>]?62M;P#N3/UZXJJ;OOTEHC);AC?J\(B^!
MD?52'3OZ6X%P9>-9&DR4J,DS8%-"R]T0TB-D/[%;JD<I\3&-D7;"X:4=S#&X
MG3+]:/8LFD[C*'4@PY\'0?O6&\1(6Q2/I+T:!>B/++])X]&ESI?>(0R &Z%[
M%$ R#/!!U./$_C[31UIDM'>*3*PPH@1YY=0Q:TMB-[PL6RO\U-3?(Y3(PWN4
MR-#5K^1H(F8"^+1U R,J ?\D$C^7*,<0UFR'P4!*8*X@Z(&;J(#"FSF5!#"Y
M-5D6TJ:7>R'@:]T=3N&%;X]+,93DZ7#7TUFVX%H@[@<5:28NJ"$&#>* R361
MH63]Y X4_H2#E>MND)^2RIJP!(?JJ"(6@?D 3!WA4;8.[3!7IRU"V:%AX4HS
M1L9?+6QDGX8=*6/0_Y2XGO6ZGR9"0JJ0@J==JY.N!CV7*JV87:#0($H0KET!
M0?F94@49!V7K)$V+-X"[12*;WAX8\N22D77Y#@^Q5!NR'$N<C#>-3+4UTW=6
MN5)_I5M:EG P%4&<EO$-+"LO<^AT"^5$OE=,;"S(I )6/N-QU%IVER)K;(7V
M+82VGV;IY_*:R0[Q+*J&KB+0F5G5Q!QK$E3BPZ'6:Z0.:QF-XQ]Q/-5%EE?S
M$KA$ I3I2JK9+>M6.27'"Z?*(%3;$5NHC77[;7_?H=$,C9$&3JDR[!C.NQ)C
M$ZM%F'.\Q=B&VP3FEBOT )0U%IA;,5*Y8"!L!:"M&XQB+)J6:9OR)$(M:$\:
MS=.*TV,0P<PU)3=BPQ@T@WHY&\"6J(BU1U,.H_M-D0(PH2,",RT9252:\^EY
M]A5#_;ZM +B- (@W2#AE\ ?(5QYQ#2FEM)VMY6L>70N]$=1[=..:HN,-W?6.
M[\IH%[[:'L?"=*H$/'D("UDBQ,PIG!C2\8+.-<H!<JP] 10V\!FTZ/"SDF-Q
M\4#]$U*L-F270;>2P5%&5O+123/L*TQ-!HC  BHHI*AK;HR2G$+#3'BN&8EU
M(, Q4$UM6B[,R(/8"3'7++S2-?'86)B(_>P&G3="PO1+%E*]6F<AU1H9;1HE
MN<K:0X=C,%_=T/L5$W?OMDF[;1/>(R@L;[-%8XMILH#F'8#/J>=Z$$V^!FTQ
M1NE.")MRSYQCC:'$RD,W6,(Q]=".Z!AW.G2<:?)+)2YH5;-CA1/T@A1YE@R#
M28PU3"'VC1197%%<!:8FAMKO0:D<6#"(B9I&QVF@=R09S$!F]B24/N)$ 'FV
M'#Z0CC<#"(4<S=#@8@\5E23T^<&,4I:*+0;R%H2M?AGSBW(V<DS]ZM5P8V 4
MYR(%GE-A-=?'J$F97N4\X.87U0"M?(-;==VI^'KY-\'GP-K/4@)*":#5+Y5,
M=[!S<T6?C*8%_:[&ZM$+T:P!^A&<)/*U(NF%I#4%4PCX14O<'O+MBQ.77?)"
M'N0J3%2,KA,3"T.K3>?N[0'F>F3.1/41K(W63.UC.CFE6.02J=-_-_G/1-.N
M^&Q.GL<B9@]/<J-UXB:$0K/:<VV<-=@M5'K%)]80>M)SU>)OJ]]?KX\30AEM
M&^2$^$2MM>S6?<**U<?=1N4Y$]*#;"/^<8I16I*17Y:K &O,Q%RGZ/A&TC^R
M,(H\X-J< KN1J$4XUO0PRJ][ANVCI33 MY[8Y8J# >T8')D?O+YO=[]$C3 I
M)+H''9BFD*(Q4FD/YWY@?FJ17"=J7\9.JQI\>&PU:U U"_JS8Y9]5DRBY^]$
M!F@0"^Z)93^TK.JBJ-HDL8J'M]O<TNU]R\UGU!@TGZ1L7(S*UT#H67SYQ]4N
M_[0 _^?-.@7UFTUZUV!::DG]\S,I#TMD1]21ARQOB) OG0MCYCHTL]7,/M1H
MR006-$&JQY>[/:(.<UDN=>Q>^=K@:(=<]U,A0,2"@'Y2JC\4EU"V#7@;-<'J
MI;5_'@3?!*G4RK9IP6*^U?K.L+7RR$\82?EEL+LC.Q5N(;<:*H4L_XDE(8O[
M1)".DA5B$!DT%X(6SG(+W\7Z;O+-\J8F]<V7\0DH7(Q@*O&(@Z\6T!23SC5V
MCF$P;-T?L&?+]DV+BYDM?@02/$"=$H&O-&K'0M\TU9]R1U*94+<SL6]DOTJ#
MW9I9Y]^V3FDHGH0YOG*2$&+3,$/@F=4 -_SQ0DA+C;_V,:(WZGH(,TJ=KK07
M-FIB\5B9 %;N[C;#GRE60CXV08+&)7PF@0^195595H^TPE@&#X+\<!/CV-T
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MJ12VVM^XD#'D7(!GJ@1H$0S74SQLT440UV42*W]_)2:3HC0V#W!J[=13J.'
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M'L%A V2+)AIG,6\:11HM_7=MLL=,W.,JA7JY+87:I UXCTO[4*HT++P0ULT
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M:YT%RO:L\+U6JD7H0A%HPJ2BE)7B$EYH6M%$""II=IR42!^:]6$."$K3\&!
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M]5BHA*D?:&)>8UZL3'QQO]NFL2]D"M&T-1,&4GB:1IF3UAU$95)2E8=ZEO#
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M+X*U']U^._KFP3,6$?L^,A$@_Q2J9S4Q><KN&B]D([R^_L64J6Z1.E09AR)
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MY^S]O_XVR$=S2.+_=E5-4O6/_Q]02P,$%     @ J$4L54.W0V=!#0  S#4
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M3'O*V.A>I$(4 '^+<6G&H7Q. %6J*5KR#=![!9N8R(SE&+F'T>B8F_&9&*5
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M+3(P,C(P.3$R+GAS9%!+ 0(4 Q0    ( *A%+%4SP-17"0<  /E(   5
M          "  >,$  !A9'!T+3(P,C(P.3$R7VQA8BYX;6Q02P$"% ,4
M" "H12Q5U8_+^/H$  !G*P  %0              @ $?#   861P="TR,#(R
M,#DQ,E]P<F4N>&UL4$L! A0#%     @ J$4L5>TRN'$S&   V]$  !0
M         ( !3!$  &%D<'0M.&M?,C R,C Y,3(N:'1M4$L! A0#%     @
MJ$4L59^:*!X73 $ B!T+ !$              ( !L2D  &%D<'0M97@Q,#%?
M-C(N:'1M4$L! A0#%     @ J$4L54.W0V=!#0  S#4  !$
M ( !]W4! &%D<'0M97@Y.3%?-#<N:'1M4$L%!@     &  8 A0$  &># 0
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
